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A adenosine
ABPI ankle brachial pressure index
AUC area under the curve
BNF British National Formulary
C cytidine
CEAC cost-effectiveness acceptability 
curve
CFUs colony-forming units
CI conidence interval
df degree of freedom
DNA deoxyribonucleic acid
EQ-5D European Quality Of Life-5 
Dimensions instrument
4LB four-layer bandage
G guanosine
GP general practitioner
HRQoL health-related quality of life
HTA Health Technology Assessment
ICER incremental cost-effectiveness 
ratio
IPW inverse probability weighting
IQC internal quality control
MCS mental component summary
MREC Main Research Ethics 
Committee
MRSA methicillin-resistant 
Staphylococcus aureus
NE north-east
NW north-west
PCR polymerase chain reaction
PCS physical component summary
PCT Primary Care Trust
PSS personal social services
QALY quality adjusted life-year
RCT randomised controlled trial
SAUC standardised area under the 
curve
SD standard deviation
SE south-east
SF-12 Short Form 12, Version 2, 
4-week recall
SSB short-stretch bandage
SW south-west
T thymidine
VAS visual analogue scale
VenUS I Venous Ulcer Study I
VenUS II Venous Ulcer Study II
/LVWRIDEEUHYLDWLRQV
All abbreviations that have been used in this report are listed here unless the abbreviation is well 
known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation used only in 
igures/tables/appendices, in which case the abbreviation is deined in the igure legend or in the 
notes at the end of the table.
YLLL
In memory of Victor Beeston, one of our valued consumer advisors on this trial, who died in 2006
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2EMHFWLYHV
The objectives of the trial were to compare the 
clinical effectiveness and cost-effectiveness of larval 
therapy with those of a standard debridement 
technique (hydrogel).
'HVLJQ
This was a pragmatic, three-arm, randomised 
controlled trial with an economic evaluation.
6HWWLQJ
The setting was in community nursing services, 
community leg ulcer clinics and hospital outpatient 
leg ulcer clinics in a range of urban and rural 
settings.
3DUWLFLSDQWV
Patients with venous or mixed venous/arterial 
ulcers (minimum ankle brachial pressure index 
of 0.6) where a minimum 25% of ulcer area was 
covered by slough and/or necrotic material.
,QWHUYHQWLRQV
The treatments comprised loose larval therapy and 
bagged larval therapy in comparison with hydrogel.
0DLQRXWFRPHPHDVXUHV
The primary end point was complete healing of 
the largest eligible (the reference) ulcer and the 
primary outcome was time to complete healing 
of the reference ulcer. Secondary outcomes were: 
time to debridement, treatment costs, health-
related quality of life (including ulcer-related pain), 
bacterial load, presence of methicillin-resistant 
Staphylococcus aureus (MRSA) and staff and patient 
attitudes to and beliefs about larval therapy.
5HVXOWV
Between July 2004 and May 2007 the trial recruited 
267 people aged 20–94 years at trial entry. There 
were more female than male participants (59.2% 
compared with 40.8%) and most ulcers (75.7%) 
were classiied by the nurses as having an area 
greater than 5 cm2. Using the log rank test, there 
was no evidence of a difference between the three 
treatment arms in the time to healing of venous leg 
ulcers (p = 0.62). Using a Cox proportional hazards 
model to adjust for stratiication and prespeciied 
prognostic factors (centre, baseline ulcer area, ulcer 
duration and type of ulcer) there was no evidence 
of a difference between bagged and loose larvae in 
terms of healing [chi-squared test statistic 0.194, 
degrees of freedom (df) = 1, p = 0.66]. When results 
for loose and bagged larvae were pooled and 
compared with hydrogel there was no evidence of a 
difference in time to healing. The hazard ratio for 
healing was 1.13 [95% conidence interval (CI) 0.76 
to 1.68], which indicated a slightly increased risk of 
healing for the larvae group although this was not 
statistically signiicant (p = 0.54). The difference 
in time to debridement between loose and bagged 
larvae was not signiicant when compared in the 
Cox proportional hazards model (p = 0.22). The 
hazard of debriding at any time for both loose and 
bagged larvae was approximately twice that for 
hydrogel (hazard ratio for loose larvae relative to 
hydrogel was 2.56 (95% CI 1.76 to 3.71) and 2.06 
(95% CI 1.39 to 3.03) for bagged larvae relative to 
hydrogel).
There was no statistically signiicant difference 
between the larvae and hydrogel with respect 
to scores on the Physical Component Summary 
(p = 0.81) and Mental Component Summary 
(p = 0.97) scores of the Short Form-12 health-
related quality of life assessment. There was no 
evidence of a difference between larvae and 
hydrogel in terms of bacterial load over time 
(p = 0.75). When swab data were analysed up to 
the point of debridement only, there was also 
no evidence of a difference between the larvae 
and hydrogel groups (p = 0.86). Only 6.7% of 
participants had MRSA detected, using molecular 
([HFXWLYHVXPPDU\
([HFXWLYHVXPPDU\
[
techniques, in their ulcers at baseline. There was no 
statistically signiicant difference between the larval 
and hydrogel therapy groups in the proportions 
of people who experienced eradication of MRSA 
by the end of the debridement treatment phase 
(p = 0.34) although this analysis has low statistical 
power because of the small numbers. People 
treated with larval therapy reported signiicantly 
more pain (p < 0.001) in the previous 24 hours 
when asked at the removal of the irst debridement 
treatment compared with patients in the hydrogel 
arm; mean pain scores for both loose and bagged 
larvae were approximately twice those of the 
hydrogel participants.
Our base-case economic evaluation suggested a 
large decision uncertainty associated with the cost-
effectiveness of larval therapy when compared with 
hydrogel with a 50% probability of larval therapy 
being cost-effective. The nature of the uncertainty 
associated with our estimates of difference in costs 
and health beneit suggests that larval therapy and 
hydrogel are likely to have similar costs and effects 
in the treatment of sloughy leg ulcers.
&RQFOXVLRQV
Larval therapy signiicantly reduced the time to 
debridement of sloughy and/or necrotic chronic 
venous and mixed venous/arterial leg ulcers 
compared with hydrogel. However, larval therapy 
did not increase the rate of healing of the ulcers 
and was associated with signiicantly more ulcer 
pain. It was impossible on the basis of this evidence 
to distinguish between larval therapy and hydrogel 
in terms of cost-effectiveness.
,PSOLFDWLRQVIRUKHDOWKFDUH
There is no evidence from this trial that larval 
therapy should be used routinely on sloughy or 
necrotic leg ulcers with the aim of speeding healing 
or reducing bacterial load.
If debridement per se is a treatment goal, e.g. 
before skin grafting or other surgery, then larval 
therapy should be considered; however, it is 
associated with signiicantly more pain than 
hydrogel.
5HFRPPHQGDWLRQV
IRUIXWXUHUHVHDUFK
In the context of sloughy or necrotic venous and 
mixed aetiology leg ulcers, The Venous Ulcer 
Study II (VenUS II) did not ind that use of an 
active debridement treatment resulted in more 
rapid wound healing. Further robust exploration of 
the relationship between debridement and healing 
is required, including in wounds of different 
aetiologies, to inform clinical wound-care practice, 
where debridement is commonly undertaken.
Relatively little is known about the outcomes 
that matter most to people with chronic wounds. 
Further research is required to explore of the value 
of debridement to patients and clinicians.
There are several wound debridement methods 
available. When making debridement treatment 
choices, decision-makers are faced with a more 
complex decision than that represented by a 
single trial. To ensure the most cost-effective 
treatments are used, decision analytic modelling 
of all alternative debridement treatments should 
be undertaken. Modelling should aim to resolve 
decision uncertainty where debridement is the 
treatment goal and where treatments aim to 
promote ulcer healing.
7ULDOUHJLVWUDWLRQ
This trial is registered as ISRCTN55114812.
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/HJXOFHUV
Venous leg ulcers have been deined as non-healing 
wounds occurring on the lower limb [mid-calf to 
one inch (2.5 cm) below the malleolus] of people 
who do not have signiicant arterial insuficiency 
in the affected limb.1 Clinically signiicant arterial 
disease is usually ruled out by an ankle brachial 
pressure index (ABPI) equal to or greater than 0.8 
whilst the signs and symptoms of venous disease 
include lipodermatosclerosis, ankle lare, oedema 
and eczema.2 Venous ulcers are typically moist, 
shallow, irregular in shape and found in the gaiter 
area of the leg.2 Leg ulcers frequently have a mixed 
aetiology which may involve both venous and 
arterial insuficiency. These ulcers are normally 
identiied as having an ABPI of between 0.6–0.8, 
but other clinical factors are also important.2 
Such ulcers may develop in patients with a history 
of venous insuficiency who, over time develop 
arterial problems.3,4 Depending on the extent of 
arterial insuficiency, the usual treatments (i.e. high 
compression) may not be suitable for such ulcers,2 
and healing rates are reportedly slower than those 
of uncomplicated venous ulcers.5 Cornwell et al.6 
examined 100 patients with leg ulcers (193 legs; 
117 active ulcers) and found ischaemia in the 
absence of venous insuficiency in 9% of patients 
and ischaemia combined with venous disease in 
22% of patients. The proportion of people with 
ischaemic disease may increase with an ageing 
population.
Venous leg ulcers are one of the most common 
types of chronic wound in the UK, with an 
estimated point prevalence of 0.16%.7 The 
prevalence of venous leg ulcers increases with 
age and the annual UK prevalence in those over 
65 years is estimated at 1.7%.1 Venous leg ulcers 
develop as the result of underlying venous disease 
and usually take months to heal. They can be 
painful, malodorous and have been shown to 
severely impact on patients’ mobility and quality of 
life.8–10 In severe cases, ulceration can lead to limb 
amputation.11
Leg ulcers are also costly. A trial comparing 
two alternative bandage treatments for venous 
ulceration estimated the mean annual cost of 
treating a leg ulcer patient as £1300 at 2001 
prices.12 In 2004, the Healthcare Commission 
estimated annual National Health Service (NHS) 
leg ulcer treatment costs of £300–600 million yet 
these igures may not relect recent increases in 
the cost of dressings used to treat chronic wounds. 
The NHS (England) spend on wound management 
prescribing increased by 8.5% between 2004 and 
2005 and the Wound Dressings section of the 
British National Formulary (BNF) is in the Top 20 
in cost terms; accounting for 5 million community 
prescriptions in England during 2006 at a cost of 
£122 million.13 However, the main cost-drivers in 
the UK remain the staff time required to manage 
and treat leg ulcers. The majority of leg ulcer 
patients are treated in the community,14 and often 
make up a large proportion of community nursing 
caseloads.15 Community nursing time, particularly 
that associated with frequent home visits, drives 
these high costs. The increasing proportion of 
elderly people in the population is likely to lead to 
an increase in the absolute numbers of leg ulcers 
and consequently costs.
7UHDWLQJYHQRXVOHJXOFHUV
The treatment of venous leg ulcers aims to 
improve venous return in the leg and provide a 
wound environment that supports healing, whilst 
managing symptoms such as exudate. Although 
there are many types of wound dressings available 
and used in the management of venous leg ulcers, 
there is little evidence to suggest that any dressing 
type is more effective in terms of promoting 
healing.16 By contrast, there is evidence that 
graduated, multicomponent, high-compression 
(ankle sub-bandage pressures of 25–35 mmHg) 
bandaging, which aids venous return, is an 
effective treatment for venous leg ulcers,12,17,18 
and is advocated in major UK guidelines.2,19 
Compression bandaging can be applied as single 
layers of bandage, stockings and increasingly, as 
multicomponent bandage ‘systems’ – the most 
commonly used being the four-layer bandage 
(4LB) and the short stretch bandage (SSB). The 
Health Technology Assessment (HTA) -funded 
Venous Ulcer Study (VenUS) I trial12 directly 
compared the 4LB and the SSB and found that the 
&KDSWHU
%DFNJURXQG
%DFNJURXQG

4LB was more clinically effective and cost-effective 
than the SSB in terms of time to ulcer healing and 
value for money. This inding has been reinforced 
by a recent individual data patient meta-analysis 
of ive trials which conirmed that the 4LB is 
signiicantly more effective than the short stretch 
system in terms of time to healing.20
Wound management is a complex process that aims 
to promote wound healing and manage symptoms 
(such as pain and exudate) whilst meeting patients’ 
needs. An important aspect of this management 
is thought to be preparation of the wound 
bed for healing by the removal of devitalised 
tissue from the ulcer surface; a process called 
‘debridement’.21,22
:RXQGGHEULGHPHQW
Whereas acute wounds such as surgical incisions 
usually heal quickly because the edges are 
sutured together (known as ‘healing by primary 
intention’), chronic skin ulcers heal from the 
bottom up (secondary intention) and frequently 
contain dead tissue including sloughed material 
and exudate. For centuries it has been believed 
that removing this slough and dead tissue 
(debridement) is beneicial to wound healing and 
reduces the likelihood of infection.23 However, 
although the removal of such tissue is considered 
important, previous systematic reviews and clinical 
guidelines highlight the lack of robust evidence 
demonstrating that debridement speeds healing 
or reduces the risk of infection in chronic wounds 
such as venous leg ulcers.2,19,24
Several different debridement techniques are used 
in practice; these can be broadly categorised as: 
autolytic, surgical/sharp, mechanical and enzymatic 
methods of debridement (Table 1). However, 
recently there has been renewed interest in a ifth 
category – biosurgery – involving the use of larval 
therapy as a debriding agent.25
Accounts from the sixteenth century describe 
how army physicians observed larvae as having a 
positive impact on the wounds of injured soldiers, 
which had become naturally infested.26 Records 
from the American Civil War suggest that ly larvae 
were applied as a therapy and in the 1930s sterile 
larvae were produced and used to treat wounds in 
the USA.27 After the explosion in antibiotic use the 
treatment became almost completely redundant. 
In the 1990s there was renewed interest in the 
use of larval therapy in wound care, this time in 
Europe,28 where there are currently two major 
suppliers of medical-grade larval therapy. The 
larvae produced for medicinal purposes are those 
of the Lucilia sericata (green-bottle) ly. This species 
selectively feeds on necrotic tissue leaving live 
tissue intact. Since the 1990s, larval therapy has 
been widely promoted in the nursing literature to 
treat different types of chronic wounds.28–31 Larval 
therapy is classed as a medicinal product in Europe 
and, although used in the NHS, it remains an 
unlicensed product in the UK. It has been reported 
that the most common indication for use of larval 
therapy is as a treatment for leg ulcers.32
3URSRVHGPHFKDQLVPVRI
DFWLRQIRUODUYDOWKHUDS\
It is suggested that larvae debride wounds more 
swiftly than wound dressings and avoid the 
problems of surgical and mechanical debridement 
(pain, requirement for anaesthesia and 
appropriately trained personnel). It has also been 
suggested that larvae may have an effect beyond 
debridement by having a direct effect on wound 
healing and bacterial load. Proponents of larval 
therapy list a number of potential mechanisms for 
these proposed effects including the following:
• debridement
 – secretion of proteolytic enzymes that 
liquefy necrotic tissue26,33
 – ingestion of necrotic tissue leaving healthy 
tissue untouched34
• antimicrobial activity
 – physical presence of the larvae increasing 
the natural production of wound exudate, 
which washes out the bacteria26
 – destruction of bacteria [including 
methicillin-resistant Staphylococcus aureus 
(MRSA)] in the larval alimentary tract by 
antibacterial substances35
 – larval secretions may have antibacterial 
properties 36–40
• healing
 – movement of the larvae stimulating the 
production of granulation tissue26,41
 – secretions from the larvae altering wound 
pH to one that is more conducive to wound 
healing42
 – larval secretions possibly containing 
substances that promote healing.43–46
In Europe, larval therapy is currently available 
in two formulations: loose, or ‘free-range’ larvae 
placed directly into the wound, and bagged larvae 
(where the larvae are contained in a meshed 
polyvinylalcohol bag). The bagged formulation was 
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7$%/( 6XPPDU\RIZRXQGGHEULGHPHQWWHFKQLTXHV
'HEULGHPHQWWHFKQLTXHV 0HWKRGV
$XWRO\WLF 8VHRIPRLVWGUHVVLQJVK\GURJHOVWRFUHDWHDVXLWDEOHHQYLURQPHQWWRIDFLOLWDWHGHEULGHPHQW
6XUJLFDOVKDUS 6ORXJKDQGRUQHFURWLFWLVVXHLVFXWDZD\IURPWKHZRXQG
0HFKDQLFDO 6ORXJKDQGRUQHFURWLFWLVVXHLVSK\VLFDOO\VHSDUDWHGIURPWKHZRXQGXVLQJDSSURDFKHVVXFK
DVKLJKSUHVVXUHLUULJDWLRQDQGZHWWRGU\GUHVVLQJVQRWFRPPRQLQ8.
(Q]\PDWLF 7RSLFDOH[RJHQRXVHQ]\PHVDUHDSSOLHGWRWKHZRXQGVXUIDFH
%LRVXUJHU\ /DUYDOWKHUDS\
developed to make larval therapy more acceptable 
to patients and more easily handled by nurses; 
however, two studies assessing patients’ views of 
bagged and loose larvae reported that patients 
showed no preference either way.47,48 Additionally, 
one small laboratory study reported that loose 
larvae were more likely to survive and grow faster 
than bagged larvae; this inding was interpreted 
as evidence that loose larvae will be more effective 
debriding agents.49 A second in vitro study 
conversely suggested that loose and bagged larvae 
demonstrated the same rates of debridement.50 
Steenvoorde et al.51 report the outcome of 69 
gangrenous or necrotic chronic wounds after 54 
wounds were treated with loose larvae and 15 were 
treated with bagged larvae. The authors, using 
a composite outcome measure of total beneits, 
reported that wounds progressed signiicantly 
better when treated with the loose larval therapy. 
However, this was a small, unblinded, non-
randomised study using multiple outcomes and 
is not robust evidence of the comparative clinical 
effectiveness of loose versus bagged larvae.
([LVWLQJHYLGHQFHIRUWKH
HIIHFWVRIODUYDOWKHUDS\RQ
GHEULGHPHQWDQGKHDOLQJ
1RQUDQGRPLVHGFRQWUROOHG
WULDOHYLGHQFH
Case series have reported good outcomes when 
treating chronic wounds (several different 
aetiologies),52 foot ulcers53 and leg ulcers54,55 with 
loose larvae in terms of rapid debridement and 
improved healing. Studies have also compared 
larval therapy with conventional treatments in 
an ad hoc way. In an unblinded study, Sherman56 
reported the results of 43 pressure ulcers treated 
with loose larvae compared with 49 treated with 
conventional therapy. The study concluded 
that loose larvae promoted rapid debridement, 
although the method of assessing debridement was 
not reported. Each of these case studies has serious 
methodological laws and is at risk of selection 
and assessment bias. As a result, their conclusions, 
although providing a foundation for further work, 
cannot be used as evidence that larval therapy 
speeds debridement or healing.
5DQGRPLVHGFRQWUROOHG
WULDOHYLGHQFH
A search of MEDLINE and the Cochrane Wounds 
Group Specialised Trials Register (28 February 
2008) identiied one published randomised 
controlled trial (RCT) of loose larval therapy 
involving only 12 patients, all with venous leg 
ulcers.57 This small trial found that venous leg 
ulcers treated with larval therapy debrided more 
quickly than those treated with hydrogel. The study 
did not follow participants until complete healing; 
therefore the extent to which larval therapy speeds 
venous ulcer healing remained unknown. The trial 
also reported that larval therapy was a cost-effective 
treatment; however, this analysis was limited.
A search of the Register of Current Controlled 
Trials and the National Research Register 
(throughout the trial and inally in May 2008) 
identiied two further completed trials and one 
ongoing trial investigating the impact of larval 
therapy on debridement and/or healing. One 
further trial (Dompmartin; Table 2) was identiied 
via a personal communication. No results could 
be obtained for the completed trial, see Table 2 for 
details.
([LVWLQJHYLGHQFH
IRUODUYDOWKHUDS\
DQWLPLFURELDODFWLRQ
Open wounds, such as venous leg ulcers, are at 
risk of infection from pathogenic micro-organisms, 
which can cause adverse events for the patient 
and may also delay wound healing. There is no 
clear deinition of bacterial load in the literature; 
however, the term is used here to describe the 
%DFNJURXQG

7$%/( 8QSXEOLVKHGUDQGRPLVHGFRQWUROOHGWULDOVRIODUYDOWKHUDS\
&RQWDFWQDPH 7LWOH 3URJUHVV 'HWDLOV
'HEULGHPHQWDQGKHDOLQJ
0D\ORU²
$UFKLYHUHFRUG
0
'HVORXJKLQJZRXQGVDUDQGRPLVHGFRQWUROOHG
WULDOFRPSDULQJODUYDOWKHUDS\DQGVWDQGDUG
DXWRO\WLFWHFKQLTXHV
&RPSOHWHG &RQWDFWHGVHFRQGWLPH
0DUFK(PDLO
UHWXUQHGXQGHOLYHUHG
'DYLHV²
,65&71
$VWXG\WRDVVHVVWKHHIÀFDF\RIPDJJRWVDVD
ZRXQGGHEULGHPHQWDJHQWIRUYHQRXVOHJXOFHUV
XQGHUJUDGXDWHGFRPSUHVVLRQEDQGDJHV
2QJRLQJ
$QWLFLSDWHGVWDUW
GDWHUHFRUGHGRQ
GDWDEDVHDV
'HFHPEHU
,QYHVWLJDWRUFRQWDFWHGWR
FRQÀUP5HFUXLWPHQWRI
SDUWLFLSDQWVSODQQHG
3ULPDU\RXWFRPHDUHD
GHEULGHG3ODQQHGHQGGDWH
-XQH
'RPSPDUWLQ 8VHDQGLQWHUHVWRIWKHPDJJRWWKHUDS\LQWKH
WUHDWPHQWRIÀEULQDQGRULQIHFWHGZRXQGV$
UDQGRPLVHGVWXG\6WXG\REMHFWLYHVHVWLPDWHWKH
HIÀFLHQF\RIWKHXVHRIOLYHPDJJRWVODUYDORU
PDJJRWWKHUDS\LQWKHWUHDWPHQWRISUHVVXUH
YHQRXVDQGDUWHULRYHQRXVXOFHUVFRPSDUHGZLWK
WKHFODVVLFWUHDWPHQWFRPPRQO\XVHGIRUWKLV
SDWKRORJ\$LPVWRUHFUXLWSDUWLFLSDQWV
2QJRLQJ ,QYHVWLJDWRUHPDLOHGWKDW
WZRWKLUGVRISDUWLFLSDQWV
KDYHEHHQUHFUXLWHG
$QWLPLFURELDODFWLRQ
/DFH\²
,65&71
$UDQGRPLVHGFRQWUROOHGWULDORIODUYDOWKHUDS\
YHUVXVVWDQGDUGFDUHLQWKHPDQDJHPHQWRI
QHFURWLFZRXQGVZLWKDQGZLWKRXWPHWKLFLOOLQ
UHVLVWDQW6WDSK\ORFRFFXVDXUHXV
&RPSOHWHG 3ULQFLSDOLQYHVWLJDWRUQRW
DYDLODEOH1RUHVSRQVHIURP
VHFRQGFRQWDFWSURYLGHG
RUIURP5HVHDUFKDQG
'HYHORSPHQWGHSDUWPHQW
(PDLOHG)HEUXDU\
DQGSURYLGHGDTXDOLWDWLYH
VWXG\
quantity of micro-organisms in a wound. It has 
been suggested that wounds containing at least 
1 × 106 colony-forming units (CFUs)/gram of 
tissue are slower to heal than wounds with a lower 
bacterial load,58–63 – it is important to note that 
the wounds in these papers included postsurgical 
pressure ulcers and burns. More recently authors 
in the ield have identiied a stage before 
wound infection that they have named ‘critical 
colonisation’, where, although a wound’s bacterial 
load would not qualify it as an infection, the load 
is high and may impact on healing.64 Others note 
that a relationship between bacterial load and 
healing mediated by levels of micro-organisms 
alone may be too simplistic,65 and that the type 
of bacterial species present in a wound66–68 and 
interactions between different species69 may also 
be important; although a deinitive body of work is 
lacking.
Existing research does not allow clear conclusions 
regarding a relationship between the bacteriology 
of chronic wounds and healing to be drawn.70 In 
addition to general work in the ield described 
above, more recent work has suggested either 
an association66,68,71 or no association72 between 
bacterial load and/or species and leg ulcer healing. 
All studies were prospective and involved the 
collection of bacterial samples using discs,72 
swabs66,71, or swabs and biopsies68 and healing 
assessment conducted at regular time points. 
Analyses assessed how differences in healing 
time varied in relation to wound bacteriology. 
However, future research in this area requires a 
more robust design to allow a causal relationship 
between micro-organisms and healing to be fully 
investigated. Any possible relationship between 
micro-organisms and healing could be confounded; 
that is to say that a wound better able to ight 
infection is also more likely to heal. From this 
viewpoint a reduction in bacterial load may be a 
symptom of healing rather than the cause.
A recent Cochrane review investigating the 
impact of systemic and topical antimicrobials 
on venous leg ulcer healing found that there is 
currently insuficient evidence to suggest that 
wound infection or colonisation was prognostic 
for healing.73 Two RCTs are highlighted as having 
investigated a possible association between wound 
status (infected or colonised) and healing; both 
were subgroup analyses and involved very small 
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numbers. Alinovi et al.74 reported a positive 
association between reduced bacterial load and 
healing rates whereas Huovinen et al.75 reported 
that S. aureus did not appear to delay healing. 
Other RCTs76 have also reported no relationship 
between bacteriology and healing, however, this 
body of work is far from conclusive about any 
potential relationship between the microbiology of 
chronic wounds and healing.
Moreover, chronic skin ulcers are prone to bacterial 
infection, including with MRSA, which has been 
isolated in community-dwelling people.77,78 For 
example, a recent study in a UK diabetic foot ulcer 
clinic recorded MRSA in 13% of ulcers (where 65% 
of ulcers were classed as clinically infected)79 and in 
France, the leg ulcers of 31% of patients admitted 
to hospital contained MRSA on admission.80 A high 
community prevalence of MRSA in chronic wounds 
raises the potential for cross-infection, for example 
during hospitalisation.
1RQUDQGRPLVHGFRQWUROOHG
WULDOHYLGHQFH
It has been proposed that whilst feeding, larvae 
also ingest and destroy bacteria and in doing so 
can alleviate symptoms associated with infection 
and also potentially reduce bacterial load.26 Again, 
there has been very little recent research on this 
proposed antimicrobial action. Initial reports 
regarding the antimicrobial activity of larval 
secretions were in vitro indings published in the 
1930s.27 More recently Thomas et al.39 reported 
that L. sericata larval secretions showed good 
antimicrobial activity against Streptococcus A and B 
and S. aureus in vitro, with some activity detected 
against Pseudomonas sp. and MRSA. A further in 
vitro study tested excretions/secretions from L. 
sericata larvae against MRSA and also reported 
antimicrobial activity.36 A recent in vitro study also 
reported that whole body extractions of larvae were 
active against wound isolates of Gram-positive and 
Gram-negative bacteria including Pseudomonas 
aeruginosa, Klebsiella pneumoniae and MRSA.37,38 
However, there is relatively little in vivo work. 
Steenvoorde and Jukema81 treated 16 wounds 
infected with Gram-positive and/or Gram-negative 
bacteria with loose (n = 3) and bagged (n = 13) 
larvae and monitored the impact on wound lora. 
They reported a greater reduction in Gram-positive 
than Gram-negative bacteria after larval treatment.
The potential action of larvae on MRSA is of 
great interest because it is dificult to treat, has 
detrimental effects on patient health and is 
extremely costly to the NHS. The in vitro work 
above is supported by limited in vivo evidence. 
A prospective case series used loose larvae to 
treated diabetic foot ulcers that had been colonised 
with MRSA for more than 3 weeks.82 In total, 
13 participants were recruited and treated with 
larval therapy. The study reports that MRSA was 
eliminated in all but one ulcer. However, this 
evidence is severely limited by the lack of a control 
group so it is impossible to say whether MRSA 
would have disappeared without larval therapy, 
or there may have been some false-positive MRSA 
detection in the initial analysis.
(YLGHQFHIURPUDQGRPLVHG
FRQWUROOHGWULDOV
As with the effectiveness of larval therapy on 
debridement and healing, although the existing 
research provides interesting data, more research is 
required to investigate the antimicrobial activity of 
larval therapy using RCTs. A search of MEDLINE, 
the Cochrane Wounds Group Specialised Trials 
Register and national and international research 
registers identiied only one completed relevant 
RCT. This has not been published (as of 1 May 
2008) and no results could be obtained for the 
completed trial (Table 2).
$FFHSWDELOLW\RI
ODUYDOWKHUDS\
In additional to clinical eficacy, to be an effective 
treatment larval therapy must be acceptable to 
both patients and nurses. Three studies have 
investigated the patient acceptability of larval 
therapy.47,48,83 As part of the development of this 
study we used a questionnaire to assess leg ulcer 
patients’ preferences for loose larvae (versus 
hydrogel) and bagged larvae (versus hydrogel) 
by measuring the improvement in healing time 
that the patients would require in order for them 
to prefer larval therapy over hydrogel.47 In total, 
41 patients completed a questionnaire (they were 
randomised to receive either a loose larvae or a 
bagged larvae questionnaire), with 25% stating they 
would never use larvae. On average, those patients 
who would consider larval therapy as a treatment 
option would do so even if the healing rate with 
larval therapy was equivalent to treatment with 
hydrogel. There was no difference in preference 
between loose and bagged larvae. Steenvoorde 
et al.48 treated the non-healing wounds of 41 
Dutch patients (further details not supplied) 
with larval therapy, noting that none refused the 
%DFNJURXQG

treatment. The patients were asked to complete a 
questionnaire regarding their treatment. Of the 
37 patients who returned the questionnaires, none 
reported adverse feelings about larval therapy and 
89% would have it again.
Kitching83 conducted in-depth interviews with 
six UK-based participants who had received 
larval therapy on a chronic wound or burn. The 
study reported that patients tended to feel initial 
repulsion towards the larval therapy but this 
changed to a more positive view after the treatment 
was received. Four of the six patients reported less 
pain when treated with the larval therapy. This 
study also discussed the importance of the treating 
nurse in helping patients make the decision to 
accept larval therapy; however, nurses’ perceptions 
of larval therapy have not previously been formally 
assessed.
6XPPDU\RIPDLQSRLQWV
Leg ulceration is a chronic and common condition 
that is highly prevalent in older people and 
impacts negatively on quality of life. Although 
there is good-quality evidence that compression 
bandaging that delivers sub-bandage pressures 
of 25–35 mmHg at the ankle helps to heal 
venous ulcers more than no compression, only 
approximately 50% of ulcers are healed by 16 
weeks with best treatment,12 therefore research 
to identify further effective interventions is 
warranted. Larval therapy, a traditional approach 
to wound management, is increasingly used on 
leg ulcers32 and has been postulated to stimulate 
healing, reduce bacterial load and infection and 
eradicate MRSA, yet the only clinical evidence 
available to support claims of the effects on healing 
came from a small RCT which did not follow 
patients to healing. Evidence to support effects on 
microbiology was largely from laboratory studies. 
We therefore undertook an RCT to evaluate the 
effects of loose and bagged larvae on leg ulcer 
debridement, healing, microbiology, costs, and 
also to investigate nurse and patient attitudes 
to larval therapy. We identiied the appropriate 
patient population for study as being people with 
leg ulceration of venous or mixed venous/arterial 
pathology; the latter because ulcers in the presence 
of some arterial insuficiency are likely to contain 
more slough and necrotic tissue than purely venous 
ulcers.
5HVHDUFKREMHFWLYHV
To compare the clinical effectiveness and cost-
effectiveness of larval therapy with a standard 
debridement technique (hydrogel) in terms of its 
effect on time to complete healing of leg ulcers, 
time to debridement of leg ulcers, cost of treatment 
and health-related quality of life (HRQoL).
3ULPDU\REMHFWLYH
• To compare the effects of larval therapy and 
hydrogel on the time to complete healing of 
venous and mixed venous/arterial leg ulcers.
6HFRQGDU\REMHFWLYHV
• To compare the cost-effectiveness of larval 
therapy with that of hydrogel.
• To compare the effects of larval therapy and 
of hydrogel on time to debridement of venous 
and mixed aetiology leg ulcers.
• To compare the effects of larval therapy and 
hydrogel on bacterial load and presence of 
MRSA.
• To assess staff and patient attitudes to and 
beliefs about larval therapy.
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7ULDOGHVLJQ
The Venous Ulcer Study II (VenUS II) was a 
pragmatic multicentre, randomised, controlled, 
open, ixed sample, parallel group trial with 
equal randomisation. Participants with sloughy or 
necrotic leg ulcers were allocated equally between 
three treatment groups: loose larvae, bagged larvae 
or hydrogel.
$SSURYDOVREWDLQHG
The study was approved by West Midlands 
Research Ethics Committee – details of site-speciic 
approvals are given in Appendix 1. Approval was 
also obtained from the relevant Research and 
Development departments (see Appendix 1). 
Larval therapy is classiied as a medicinal product, 
therefore clinical trial authorisation was obtained 
from the Medicines and Healthcare Products 
Regulatory Agency (22803/0001/001). The trial 
was registered at inception: ISRCTN55114812, 
National Research Register: N0484123692.
'XUDWLRQRIIROORZXS
All participants were followed up for a minimum 
of 6 months. Planned follow-up was 12 months; 
however, it became necessary to extend the 
recruitment phase into 6 months of the 12-month 
follow-up period. Participants recruited in the inal 
6 months of recruitment were therefore followed 
up for between 6 and 12 months.
7ULDOVLWHV
There were 22 UK sites and one in Europe 
(Hungary). Sites were recruited throughout the 
duration of the trial.
3DUWLFLSDQWHOLJLELOLW\
Eligible participants were people with leg ulcers 
that were deemed to be either of venous or mixed 
venous/arterial aetiology and which contained 
slough and/or necrotic material. People were 
eligible for recruitment from hospital wards, 
outpatient departments (e.g. dermatology, 
surgery), community leg ulcer clinics and 
community nurse caseloads. Patients in nursing 
and residential homes were eligible for inclusion 
if they were identiied as above. To identify 
potential participants, trial sites were encouraged 
to regularly screen all existing leg ulcer patients 
against the eligibility criteria (below) (Appendix 
3.1). Where people were ineligible the reason(s) for 
exclusion were recorded.
,QFOXVLRQFULWHULD
People for whom all of the following criteria 
applied:
• They had a sloughy and/or necrotic leg ulcer 
(slough and/or necrotic tissue assessed as 
covering at least 25% of the wound) of purely 
venous or mixed venous/arterial aetiology. 
The 25% cut-off point was determined by 
senior wound-care specialists who advised 
that larval therapy would not be regarded as 
an appropriate treatment for people with less 
slough coverage.
• They had an ABPI equal to or more than 
0.6 determined using standard technique as 
described by Vowden et al.84
• They received their leg ulcer care either from 
community nurse domiciliary visits or at leg 
ulcer clinics held in a hospital or community 
setting.
• They had an ulcer with an area of more than 
5 cm2 or an ulcer equal to or less than 5 cm2 
and the ulcer was not healing (‘not healing’ 
deined as no measurable change in area over 
month preceding assessment).
• They were aged 18 years or above.
• They were willing and able to give written 
informed consent.
People with diabetes mellitus whose blood sugar 
was well controlled (HbA1c equal to or less than 
10%) and who had venous or mixed aetiology 
ulcers were eligible to participate, as were people 
with rheumatoid arthritis whose ulcers were 
deemed to be venous in origin.
&KDSWHU
0HWKRGV
0HWKRGV

The trial reference ulcer was deined as the largest 
ulcer containing at least 25% slough and/or 
necrotic tissue. If the ulcer was small (area equal to 
or less than 5 cm2) it had to be both non-healing 
and contain at least 25% slough and/or necrotic 
tissue.
([FOXVLRQFULWHULD
People who:
• were currently in a trial evaluating other 
therapies for their leg ulcer
• had previously been entered into the trial
• were women of child-bearing potential
• were pregnant or lactating
• were allergic to hydrogel dressings or any of 
their components
• had grossly oedematous legs, which in 
the opinion of the recruiting health care 
professional were unsuitable for treatment with 
larval therapy and/or hydrogel
• were on anticoagulants (e.g. warfarin) and 
could not be admitted to a health care facility 
while receiving larval therapy (this exclusion 
became necessary during recruitment when 
the manufacturers of larval therapy added 
anticoagulation as a contraindication unless 
patients were closely monitored).
5HFUXLWPHQWLQWRWKHWULDO
All nurses participating in the study received 
training in all aspects of the trial including 
participant recruitment. Potential participants 
who met the inclusion criteria were given full 
trial details by a research nurse or their regular 
nurse during routine care (Appendix 2). Details 
were provided verbally and written information 
was given to the patient to take away. Patients 
were given a minimum of 24 hours to consider 
participation in the trial. Written consent was 
obtained from all patients who were willing to 
participate and their general practitioner (GP) was 
notiied of their involvement in VenUS II.
%DVHOLQHDVVHVVPHQW
Once participants had consented to trial 
participation several baseline measures were 
recorded by the nurse in the patient record form 
(Appendix 3.3).
8OFHUDUHD
Previously, ulcer area together with ulcer duration 
were identiied as the two main prognostic 
factors for healing venous leg ulcers treated with 
compression.85 Margolis et al.86 then dichotomised 
these continuous variables, and found that an area 
of 5 cm2 and a duration 6 months were the cut-off 
points that maximised the differences between 
patients whose ulcers healed and those whose 
ulcers did not. In VenUS II baseline ulcer surface 
area was assessed using acetate tracings of ulcer 
perimeters (taken using a wound grid marked with 
1 cm2 squares and marker pen). An assessment was 
then made by the recruiting nurse of whether the 
reference ulcer area was equal to or less than 5 cm2 
or greater than 5 cm2 for stratiication purposes. 
The actual area was calculated at the York Trials 
Unit at a later date using the MOUSEYES computer 
program.87
'XUDWLRQRIUHIHUHQFHXOFHU
Longer ulcer duration is associated with longer 
time to healing and is an important prognostic 
variable;9,47 we therefore recorded duration of 
reference ulcer at baseline based on participant 
report.
1XPEHURIXOFHUHSLVRGHV
RQOHJZLWKUHIHUHQFHXOFHU
Data from VenUS I12 suggested that a greater 
number of ulcer episodes is prognostic of a longer 
healing time; we therefore recorded the number 
of ulcer episodes on the leg of the reference ulcer, 
based on participant report.
6H[
The sex of participants was recorded to allow 
comparison with the existing information on the 
population of people with ulcers in which women 
outnumber men.88
'DWHRIELUWK
Date of birth was recorded at recruitment so that 
age at recruitment could be calculated. Increased 
age has been associated with slower healing rates in 
one study.89
8OFHUSRVLWLRQDQGLPDJH
For monitoring purposes a record of the position 
of all ulcers on the trial leg including the reference 
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ulcer was made. Digital photographs were also 
taken of all leg ulcers present at recruitment, 
including the reference ulcer.
+HDOWKUHODWHGTXDOLW\RIOLIH
Participants were given a quality-of-life 
questionnaire booklet to complete immediately 
after recruitment. The questionnaire comprised the 
Short Form 12-item Health Survey (SF-12, Version 
2, 4-week recall)90 and the European Quality Of 
Life-5 Dimensions (EQ-5D) instrument.91
8OFHUPLFURELRORJ\
A swab was taken at baseline (described below) so 
that bacterial load in the ulcer could be assessed 
and the presence of MRSA ascertained.
2WKHU
VenUS I reported that ulcer area, ulcer duration, 
number of ulcer episodes, ankle mobility (classiied 
as full range of ankle motion, reduced range of 
ankle motion or ixed ankle), and body weight 
were prognostic for healing. These data were all 
collected at baseline, also recorded was an ulcer 
type variable (ABPI greater than 0.8 and treated 
with high compression; ABPI greater than 0.8 
and not treated with high compression, and ABPI 
0.6–0.8). We also assessed ulcer-related pain over 
the previous 24 hours using a visual analogue scale 
(VAS) (no pain to worst pain imaginable). The 
minimum value on the scale was 0 mm and the 
maximum was 150 mm.
5DQGRPLVDWLRQ
Randomisation was carried out with stratiication 
by centre and ulcer area (≤ 5 cm2 or > 5 cm2) using 
varying block sizes of three and six. Participants 
were randomised equally between three arms: loose 
larvae, bagged larvae, or hydrogel. To maintain 
allocation concealment the generation of the 
randomisation sequence and subsequent treatment 
allocation were performed by an independent, 
secure, remote (telephone) randomisation 
service (York Trials Unit). The computerised 
randomisation system was checked periodically 
during the trial following standard operating 
procedures.
6DPSOHVL]H
The original sample size calculation was based on 
a comparison of three groups of 200 each using 
survival analysis to assess time to healing of the 
reference ulcer (primary outcome). This would 
have given us 89% power to detect a reduction 
in median healing time from 20 weeks to 14 
weeks, whilst allowing for 15% attrition. Under-
recruitment led us to apply for an 18-month 
extension for recruitment with a revised overall 
target of 370 participants (90% power to detect a 
reduction in median healing time from 20 to 12.7 
weeks whilst allowing for 15% loss to follow-up), or 
270 participants to detect the same difference with 
80% power.
7ULDOLQWHUYHQWLRQV
VenUS II was divided into two phases. Phase 1 was 
a debridement phase during which participants 
received either larval therapy or hydrogel up 
to debridement (or up to cessation of the trial 
debridement treatment before debridement had 
occurred – classiied as ‘withdrawal from trial 
treatment’). Participants randomised to larval 
therapy did not receive compression during Phase 
1 because compression potentially suffocates the 
larvae. Instead, patients receiving larvae wore 
a layer of orthopaedic wool and a simple, light 
crepe bandage as described in the manufacturers’ 
speciications. Participants in the hydrogel group 
continued with their normal bandage regimen. If 
more than one application of larvae was required, 
the participants’ usual trial bandages were applied 
between larval treatments. All nurses involved in 
the trial were trained in larval therapy application 
(hydrogel being a standard treatment).
Phase 2 comprised treatment of the wound 
(postdebridement or withdrawal from trial 
debridement treatment) with a standard knitted 
viscose dressing with or without compression 
(use of which was determined by ABPI and 
participant tolerance). Where compression was not 
contraindicated the protocol advocated the use of 
the 4LB.12
/RRVHODUYDHJURXS3KDVH
Participants received sterile larvae (L. sericata), 
(Zoobiotic, Bridgend Wales, UK). The number of 
pots of larvae to be used at a single application was 
0HWKRGV

determined by referring to a ‘calculator’ supplied 
by the manufacturer (Appendix 4.1). The calculator 
assesses ulcer size and percentage of ulcer covered 
with slough. The required number of larvae was 
then ordered from the manufacturer (Table 3). At 
the time of the trial it was not possible to order 
larvae for a Monday delivery.
Larvae were retained in the wound by securing 
a net mesh dressing with Sleek tape (Smith 
and Nephew, Hull, UK) onto strips of either 
hydrocolloid dressing or zinc paste bandage 
applied around the ulcer. Where wounds were 
dry and/or necrotic, the wound was kept moist by 
application of a saline-moistened gauze pad over 
the net mesh retention dressing. Larvae could be 
applied to an ulcer previously treated with Purilon 
hydrogel (because it does not contain propylene 
glycol which is toxic to larvae); however, the use of 
other dressings, including other hydrogels, between 
larval treatments was prohibited by the protocol.
Loose larvae were left on the ulcer for 3–4 days, 
although nurses could check the participant and 
larvae during this period (i.e. to rehydrate). The 
removal of larvae was a straightforward process. 
Once the mesh was removed the majority of 
larvae would fall out of the wound or move away 
from it and were caught in a suitable receptacle 
or retrieved with a forceps or a gloved hand. Any 
larvae remaining were gently removed manually 
or irrigated out of the wound with a jet of saline. 
Larvae were disposed of in accordance with the 
local guidelines for each site. Once the larvae were 
removed the treating nurse assessed the amount 
of slough/necrotic tissue remaining on the wound 
and decided whether a further application of larval 
therapy was required.
Where further application was required, Purilon 
hydrogel and the participant’s usual bandage 
were applied and more larvae were ordered for 
reapplication as soon as possible. The timescales 
of treatment were recorded. Once debridement 
was deemed complete by the treating nurse, or a 
decision was made to cease trial treatment before 
debridement, participants moved into Phase 2.
%DJJHGODUYDH3KDVH
Participants received sterile larvae (L. sericata), 
(Biomonde, Barsbüttel, Germany) within a sealed 
dressing. The number of bags was calculated 
according to the manufacturer’s speciications 
(Appendix 4.2) and ordered from the manufacturer 
(Table 4). At the time of the trial larvae could not be 
delivered for application on a Monday.
Bagged larvae were applied directly to the ulcer 
without the need for hydrocolloid/zinc paste 
retention strips. The bag was kept in place by a 
simple retention bandage, e.g. crepe. Bagged 
larvae remained in the ulcer for 3–4 days, although 
the nurses could check on the larvae during 
this period (i.e. to rehydrate). When ready for 
removal, the bag was simply lifted from the wound 
and disposed of intact. Larvae were disposed of 
in accordance with the local guidelines for each 
centre. 
7$%/( 7LPHWDEOHIRUWKHRUGHULQJDSSOLFDWLRQDQGUHPRYDORIORRVHODUYDH
2UGHUODUYDOWKHUDS\ )ULGD\RU0RQGD\ 7XHVGD\RU:HGQHVGD\ 7KXUVGD\
$SSO\ODUYDOWKHUDS\ 7XHVGD\ :HGQHVGD\RU7KXUVGD\ )ULGD\
5HPRYHODUYDOWKHUDS\ )ULGD\6DWXUGD\ 6DWXUGD\6XQGD\RU0RQGD\ 0RQGD\RU7XHVGD\
,IPRUHODUYDHQHHGHG 3ODFHRUGHUIRUGHOLYHU\RQ
7XHVGD\
3ODFHRUGHUIRUGHOLYHU\RQ
7XHVGD\
3ODFHRUGHUIRUGHOLYHU\RQ
7XHVGD\RU:HGQHVGD\
7$%/( 7LPHWDEOHIRUWKHRUGHULQJDSSOLFDWLRQDQGUHPRYDORIEDJJHGODUYDH
2UGHUODUYDOWKHUDS\ )ULGD\RU0RQGD\ 7XHVGD\RU:HGQHVGD\ 7KXUVGD\
$SSO\ODUYDOWKHUDS\ 7XHVGD\ :HGQHVGD\RU7KXUVGD\ )ULGD\
5HPRYHODUYDOWKHUDS\ )ULGD\6DWXUGD\ 6DWXUGD\6XQGD\RU0RQGD\ 0RQGD\RU7XHVGD\
,IPRUHODUYDHQHHGHG 3ODFHRUGHUIRUGHOLYHU\RQ
7XHVGD\
3ODFHRUGHUIRUGHOLYHU\RQ
7XHVGD\
3ODFHRUGHUIRUGHOLYHU\RQ
:HGQHVGD\RU7KXUVGD\
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Where further application was required, Purilon 
hydrogel and the participant’s usual bandage 
were applied and more larvae were ordered for 
reapplication as soon as possible. The timescales 
of treatment were recorded. Once debridement 
was deemed complete by the treating nurse, or a 
decision was made to cease trial treatment before 
debridement, participants moved into Phase 2.
&RQWUROJURXS3KDVH
Participants in the control group received Purilon 
hydrogel dressing (Coloplast A/S, Humlebæk, 
Denmark) covered with a knitted viscose dressing. 
Nurses discontinued the hydrogel treatment when 
they regarded the ulcer as debrided and the date 
was recorded. Once debridement was deemed 
complete by the treating nurse, or a decision was 
made to cease trial treatment before debridement, 
participants moved into Phase 2.
&RPSUHVVLRQWKHUDS\²WKH¶WULDOEDQGDJH·
Participants received high or reduced compression 
depending on their ABPI and tolerance as 
described in Tables 5 and 6. Table 7, which 
contains general information about bandages 
and bandaging technique, was also supplied to 
trial nurses. Participants whose ABPI was equal 
to or more than 0.8 but who were unable or 
unwilling to tolerate compression were still eligible 
to participate in this trial and received reduced 
compression.
3DUWLFLSDQWVZLWKDQ$%3,HTXDO
WRRUPRUHWKDQDQGVXLWDEOH
IRUKLJKFRPSUHVVLRQ
Participants with a venous ulcer and an ABPI ≥ 0.8 
were offered compression in the form of the 4LB 
either throughout the trial (hydrogel) or when not 
receiving larval therapy (see Table 5). This trial 
design therefore answers the pragmatic question of 
whether the beneits of larval therapy outweigh the 
disadvantages of going without compression during 
larval therapy.
3DUWLFLSDQWVZLWKDQ$%3,HTXDOWRRU
PRUHWKDQEXWOHVVWKDQRUSHRSOH
QRWVXLWDEOHIRUKLJKFRPSUHVVLRQ
These participants were offered reduced 
compression in the form of a three-layer bandage 
comprising orthopaedic wool, crepe and a class 3A 
compression bandage (see Tables 6 and 7).
3DUWLFLSDQWIROORZXS
Appendix 5 shows a summary of the VenUS II trial.
)URPEDVHOLQHWRZLWKGUDZDO
IURPWULDOGHEULGHPHQW
WUHDWPHQW3KDVH
Every nurse visit was recorded by the treating 
nurse along with location and reason for visit 
(Appendix 3.4–3.6, depending on trial arm). 
Nurses also recorded the number of applications 
of trial treatment. Visit information relating to 
trial debridement treatment was recorded until 
the reference ulcer debrided (as assessed by the 
treating nurse) or the participant was recorded as 
no longer receiving the trial treatment (both events 
resulting in the participant moving to Phase 2). 
During Phase 1, when the debridement treatment 
was removed participants were asked to complete 
a VAS (as completed at baseline) to assess how 
painful their ulcer had been over the last 24 hours 
(no pain to worse pain imaginable, where a higher 
score was worse).
We advised nursing staff that larval therapy and 
hydrogel should continue either until debridement 
or for a minimum of 6 weeks if debridement had 
not been achieved. Previous studies indicate that 
the median number of applications of hydrogel 
needed to achieve debridement is 15.57
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The reasons for deciding to stop delivering 
(withdrawing from) the trial treatment were 
recorded as:
• deterioration in the ulcer evidenced by 
clinically signiicant increase in reference ulcer 
size observed over 2 consecutive weeks
• no change in ulcer size but a signiicant 
increase in slough and/or necrotic tissue
• allergic reaction to larval therapy or hydrogel
• participant hospitalised and trial treatment not 
adhered to
If a participant stopped receiving the trial 
treatment they moved into Phase 2 of the study 
and follow-up continued as per the protocol.
)URPUHIHUHQFHXOFHU
GHEULGHPHQWZLWKGUDZDOIURP
WULDOGHEULGHPHQWWUHDWPHQW
WRWULDOH[LW3KDVH
Following ulcer debridement the trial treatment 
speciied was a knitted viscose dressing and 
compression if appropriate (determined by ABPI 
and participant tolerance). Every nurse visit 
was recorded, along with location of visits and 
compression treatment received in the Dressing 
Log Booklet (Appendix 3.7, same for all three 
arms). If during Phase 2, a clinical decision was 
made to change the treatment for a participant 
who was still following the trial treatment protocol, 
a withdrawal-from-treatment form was completed 
with the reason for this change recorded and the 
new treatment noted.
7ULDOFRPSOHWLRQ
Participants exited the trial when:
• the participant had been in the trial for over 12 
months (6–12 months in some cases)
• the participant wished to exit the trial
• the participant’s doctor or nurse withdrew 
them from the trial
• the participant was lost to follow-up
• the participant had died
• other (details requested).
Participants whose reference ulcer healed ceased to 
have routine clinical data collected but were asked 
to continue completing HRQoL and resource-use 
questionnaires. If the reference ulcer was not the 
only leg ulcer the participant had, nurses were also 
asked to record if the participant became ulcer free.
0HDVXUHPHQW
DQGYHULÀFDWLRQRI
SULPDU\PHDVXUH
A variety of disease-speciic and generic outcome 
measures were employed to ascertain clinical 
effectiveness.
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3ULPDU\HQGSRLQW
The primary end point was deined as time to 
complete healing of the reference ulcer.
Ulcer healing was deined as complete epithelial 
cover in the absence of a scab (eschar). When 
nurses deemed the reference ulcer to be healed 
they were asked to seek independent veriication 
from a nurse not involved in the care of the patient 
one week after the visit at which they regarded the 
ulcer as healed. If the two nurses did not agree that 
healing had occurred, the participant continued in 
the trial until they agreed that the reference ulcer 
had healed. Upon healing a ‘reference ulcer healed 
form’ was completed (Appendix 3.2).
Remote, blinded assessment of healing from 
photographs was also conducted. Nurses took a 
digital photograph of the reference ulcer every 
week until 6 months after recruitment and then 
monthly until healing or exit (Appendix 6). Before 
taking the photograph the nurses were requested to 
clean the skin surrounding the leg ulcer to reduce 
the risk of treatment detection in the photographs 
(e.g. remnants of zinc paste). The nurses were also 
asked to take an image 1 week after healing was 
regarded by them as having occurred.
Two blinded assessors independently assessed all 
photographs for each participant to determine 
a date for healing. This assessment process was 
piloted by two additional nurses before being 
undertaken for the main analysis. At the pilot 
stage it was noted that the trial nurses and clinical 
blinded outcome assessors viewed an ulcer as 
healed in the presence of a very small amount of 
eschar or scab. A revised deinition for the blinded 
outcome assessment was agreed as:
Clinically, extensive epithelialisation is judged 
to have occurred (possibly under a very 
small amount of eschar/dry skin), no further 
primary wound contact dressing is judged to 
be required (maintenance treatment may be 
started).
The assessors discussed any discrepancies with 
referral to a third assessor for a inal decision if 
required. The primary outcome was calculated 
using the date of healing as decided by the blind 
assessors. However, if no photographs were 
available for a participant then the date of healing 
decided by the treating nurse was taken as the 
healed date.
0HDVXUHPHQW
DQGYHULÀFDWLRQRI
VHFRQGDU\RXWFRPHV
&ROOHFWLRQRIUHVRXUFHXVHGDWD
During Phase 1 information recorded (Appendix 
3.3–3.6) included reason for nurse visit and 
whether each visit was ulcer related; treatment 
received (used to calculate number of applications); 
the location of the visit and the compression system 
used.
During Phase 2 the Dressing Log Booklet 
(Appendix 3.7) recorded the reason for and the 
location of the visit and the compression system 
used.
Nurses were also asked to record details of 
participant hospitalisation, including the reason for 
the hospitalisation and length of stay (Appendix 
3.8).
At baseline and at 3-monthly intervals thereafter 
participants were posted a questionnaire asking 
about health and social-care resource use during 
the preceding three months (Appendix 3.9). 
The questionnaire was designed for participant 
completion and was returned to the trial ofice 
using a reply-paid envelope. Participants indicated 
how many times in the previous month they had 
used health services (for example, seen a GP or 
nurse; or received hospital care) and any health 
service use that was ulcer related. The collection of 
self-reported resource-use data was continued until 
trial completion.
7LPHWRGHEULGHPHQW
Debridement was deined as a ‘cosmetically clean 
wound’. Nurses recorded whether a wound had 
debrided at the end of Phase 1; however, the main 
debridement outcome was assessed by remote, 
blinded outcome assessors from photographs of the 
reference ulcer using the deinition: ‘a cosmetically 
clean wound requiring no further treatment for 
debridement’. If no photographs were available for 
a participant then the date of debridement healing 
decided by the treating nurse was taken.
%DFWHULDOORDG
Data were collected using microbiological swabs 
taken at baseline and after each Phase 1 treatment 
up to debridement or for a maximum of 1 month 
(if the ulcer debrided within 1 month then weekly) 
0HWKRGV
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and then monthly until healing or trial completion. 
A protocol for obtaining the swabs was provided 
for nurses. (Appendix 7) We used swabs, rather 
than biopsies, for sample collection. It was felt that 
the specialist skills required to take biopsies and 
the discomfort of this process for the participant 
(especially given the number of samples being 
taken) could not be justiied based on existing data 
regarding the comparative quality of bacterial load 
data from each source.
Samples (dry swabs), identiied by study number, 
participant’s date of birth and date taken, were 
sent by First Class post at ambient temperature to 
Micropathology Ltd, Coventry, UK. Upon receipt, 
samples were stored at – 70°C.
Bacterial load was assessed by measuring the 
amount of bacterial DNA present in wound 
samples. This molecular approach was able 
to provide a broad measure of bacterial load 
deemed suitable for this simple microbiological 
substudy. This approach was selected over other 
analytical methods that require specimen integrity, 
i.e. plating/culturing because of the logistical 
dificulties involved in processing a large numbers 
of viable samples from multiple centres across the 
UK. Because molecular analysis did not require 
sample preservation – swabs could be sent to 
a central location, stored and then analysed in 
batches. This batch analysis system and fact that 
bacterial load could be measured using a single 
assay, rather than requiring multiple cultures for 
subspecies growth, also meant that the molecular 
approach was much less resource intensive than 
qualitative analysis.
Bacterial DNA was released from swabs using 
a protocol adapted from Schabereiter-Gurtner 
et al.92 Swabs were processed in batches that 
included negative and positive swabs to control for 
contamination and extraction eficacy (see ‘Quality 
control’). Swabs were broken off into labelled 
2-ml sample tubes containing 500 µl XB buffer 
(150 mM sodium ethylenediamine tetraacetic acid, 
225 mM NaCl, pH 8.5), 60 µl lysozyme (100 mg/
ml) and 25 µl lysostaphin (1 mg/ml). The swabs 
were incubated at 37°C for 30 minutes and then 
subjected to three cycles of freezing (– 70°C) and 
thawing (72°C). Following this, 220 µl aliquots of 
each bacterial suspension were removed into a 
fresh tube and processed for nucleic acid extraction 
using the QIAamp DNA Blood Biorobot MDx kit 
combined with the Qiagen MDx Biorobot (Qiagen, 
Valencia, CA, USA) so that nucleic acids from 200 µl 
of sample were eluted into 200 µl TE buffer (10 mM 
Tris–HCl, 1 mM ethylenediamine tetraacetic acid, 
pH 8.0). The remainder of each sample containing 
the original swab was stored at – 70°C.
Nucleic acids from each swab were subjected to 
real-time quantitative polymerase chain reaction 
(PCR) using the following universal 16S ribosomal 
RNA gene primers: forward, 5′-AGA GTT TGA 
TCA TGG CTC AG-3′,93 reverse, 5′-ACC GCG GCT 
GCT GGC AC-3′.94 The reaction mixture consisted 
of ReadyMix Taq PCR reaction mix (12 µl; Sigma-
Aldrich, Poole, UK), combined primers (1 µl, 5 µM), 
MgCl
2
 (1.5 µl, 25 mM), Evagreen luorescent dye 
(1 µl; Biotium, Hayward, CA, USA) and template 
(10 µl, extracted nucleic acids). Real-time PCR was 
performed in a Rotorgene 3000 (Corbett Research 
UK Ltd, St Neots, UK) under the following 
parameters: 95°C for 40 seconds, followed by 30 
cycles of 97°C for 20 seconds, 55°C for 20 seconds, 
and 72°C for 20 seconds (acquiring to the Sybr 
channel).
The bacterial load (10x copies/ml) was calculated 
by comparison of extracted DNA levels with a 
standard curve, which was generated for each assay 
using 10-fold dilutions of DNA extracted from a 
culture of S. aureus that had been quantiied by 
viable and particle-counting methods. Unknowns 
were calculated by interpolation and results were 
expressed as 16s ribosomal RNA gene copies per 
ml. The lowest limit of detection of the assay was 
103 copies/ml.
Positive and negative extraction controls were 
included in each batch of swabs processed. Positive 
controls were prepared by absorbing 500 µl of a 
4-hour broth culture of S. aureus onto sterile swabs, 
which were stored at – 70°C until required. Negative 
controls were sterile swabs only. Extraction controls 
were processed using the same protocols as live 
samples and the extracted nucleic acids was 
analysed as described previously.
Positive extraction control swabs were expected 
to provide bacterial load results of at least 1 × 104 
S. aureus genome equivalents/ml and negative 
control swabs were expected to have a bacterial 
load of less than 1 × 103 S. aureus genome 
equivalents for results from that batch of swabs to 
be accepted.
Each quantitative PCR assay also included a quality 
control sample that consisted of extracted nucleic 
acids of a known bacterial load [internal quality 
control (IQC)]. This IQC sample had to provide a 
result varying no more than 0.5 of a log from the 
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predicted value for the results of that PCR assay to 
be accepted.
056$DVVD\
All baseline swabs were tested for MRSA. Those 
participants with a positive baseline swab then 
had all further weekly/monthly swabs analysed for 
the presence of MRSA. Participants with negative 
swabs at baseline had one further swab analysed at 
2 months to see if MRSA was detectable at the time 
when debridement treatment would have ceased in 
most cases.
MRSA was detected using a single-round PCR 
assay speciic for the 3′-terminal region of the 
Staphylococcal Chromosomal Cassette containing 
the mecA gene responsible for methicillin resistance 
(SCCmec) when speciically inserted into the S. 
aureus genome at orfX.
Nucleic acids were obtained from swabs as 
described for the bacterial load swabs and 
subjected to single-round PCR using the following 
primers: forward rjmec 5′-TAT GAT ATG CTT CTC 
C-3′ and reverse orfX 5′-AAC GTT TAG GCC CAT 
ACA CCA-3′.95 The reaction mixture consisted 
of PCR buffer (5 µl; Labmaster, Sevenoaks, UK), 
dNTPs (5 µl; Web Scientiic, Crewe, UK), combined 
primers (1.5 µl, 5 µM), water (18.5 µl; Sigma-
Aldrich, Poole, UK), MgCl
2
 (1 µl, 25 mM; Sigma-
Aldrich), and Immolase DNA polymerase (0.5 µl, 
Bioline, London, UK). The cycling parameters 
were 95°C for 20 seconds, followed by 45 cycles of 
97°C for 20 seconds, 57°C for 20 seconds, and 72°C 
for 20 seconds. PCR products were detected by 
ethidium bromide and agarose gel electrophoresis. 
Products were referenced to a positive control 
(MRSA, kindly provided by Prof. C. Dowson, 
University of Warwick, UK) and results were scored 
as either ‘detected’ or ‘not detected’. The minimum 
detection threshold for MRSA was ascertained to be 
equivalent to 1 × 103 CFUs/ml.
+HDOWKUHODWHGTXDOLW\RIOLIH
Generic instruments were used to measure 
participants’ perceptions of health outcome 
in this trial; these have previously been shown 
to be sensitive to changes in venous ulcer 
healing status.96 Generic instruments are also 
particularly useful for comparisons across groups 
of participants and have wide scope for use in 
economic evaluation. Their generic nature also 
makes them potentially responsive to side or 
unforeseen effects of treatment. The package of 
instruments was designed to be comprehensive yet 
brief and suitable and was administered at baseline 
and at 3, 6, 9 and 12 months’ follow-up.
Participants received the instruments by postal 
questionnaire to be completed either in the clinic 
waiting room or at home. The booklet included 
the EQ-5D and the SF-12. We used a layout of the 
SF-12 shown in previous work to yield improved 
response rates and quality.97
A systematic review investigating ways of increasing 
questionnaire response rates reported that 
response to postal questionnaires was doubled 
[odds ratio = 2.02; 95% conidence interval (CI) 
1.79 to 2.27] when a inancial reward was included 
with the questionnaire, versus no incentive.98 
The response rate increased further when the 
incentive was not conditional on response, versus 
upon return of questionnaire (odds ratio = 1.71; 
95% CI 1.29 to 2.26). Based on these data, we 
offered an incentive for participants to return their 
questionnaire. We notiied participants in their 
9-month questionnaires that once we received 
their inal questionnaire they would receive £5 in 
recognition of their commitment to our study and 
the time they spent completing questionnaires.
$GYHUVHHYHQWV
An adverse event can be deined as ‘any 
undesirable clinical occurrence in a subject, 
whether it is considered to be device related or 
not’.99 Although it is normal to monitor adverse 
events within an RCT, we had a mandatory 
responsibility to collect these data as part of VenUS 
II, given that it was a trial of an investigational 
medicinal product that is unlicensed in the UK. 
Both treatment-related and unrelated adverse 
effects were reported to the trial ofice on an 
adverse-event reporting form. The reporting 
clinician indicated whether, in their opinion, the 
event was related to trial treatment, or not. Events 
were also classed as serious or non-serious. Some 
events were always classiied as serious (death, 
life-threatening risk, hospitalisation, persistent or 
signiicant disability/incapacity). For other events 
the treating nurse made a clinical decision about 
the seriousness. Nurses were asked to report serious 
adverse events, such as admission to hospital, 
directly to the Trial Coordinator. Nurses were asked 
to report all adverse events on the adverse event 
form and state whether they considered them to 
be related to the trial treatment (possibly/probably/
deinitely or not). We established a list of possible 
treatment-related adverse events a priori, based 
on reports in the literature and the VenUS I trial. 
These are described as follows.
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3UHVVXUHGDPDJH
Excessively high levels of compression or the 
inappropriate application of compression can lead 
to pressure damage and in a small number of cases, 
leg or foot amputation,84 although frequently these 
adverse outcomes are not well described in research 
reports. Pressure damage presents on pressure 
areas (areas of small radius and/or little padding) 
such as the malleoli, Achilles tendon, or the front 
of the foot and is indicated by non-blanching 
erythema. Bands of high pressure on the leg can 
result in lines of skin damage along the lines of the 
bandage. Assessment of the skin of the leg after 
each bandage removal is a fundamental part of leg 
ulcer management.
0DFHUDWLRQH[FRULDWLRQDQGLQIHFWLRQ
Compression bandages may keep wound exudate 
in contact with the skin surrounding the ulcer, 
leading to maceration of the periulcer skin. 
Occlusion of the ulcer and the skin provides a 
moist environment, which may encourage fungal 
and bacterial infections of the periulcer skin or 
the ulcer itself. Maceration presents as swollen, 
white, soggy skin. Excoriation is the appearance of 
red, inlamed skin around the ulcer, thought to be 
caused by wound exudate which contains enzymes. 
Infection presents usually with a combination of 
any or all of inlammation, pain, odour, heat and 
purulent discharge.
8OFHUUHODWHGSDLQ
Research investigating the impact of a leg ulcer 
on HRQoL has demonstrated that pain is one of 
the most troublesome aspects of having a venous 
leg ulcer.100–104 Larval therapy may increase54,105 or 
decrease83 ulcer pain, or have no effect.52
8OFHUGHWHULRUDWLRQ
Assessment of ulcer healing progress is complex 
and includes assessment of the colour of the wound 
bed, e.g. a pink or red wound bed may indicate 
epithelialisation or granulation tissue, whereas 
yellow slough, or green/blue/black colours may 
indicate the presence of infection. Ulcer area was 
also assessed, although the trajectory of venous 
ulcer healing is not necessarily linear, and therefore 
assessment of progress can be dificult. If an ulcer 
has necrotic tissue edges then the autolysis of this 
dead matter, under compression, may lead to an 
apparent increase in the area of the ulcer. Ulcer 
deterioration included increase in ulcer area, 
malodour, apparent allergy and ulcer bleeding.
4XDOLWDWLYHVWXG\RI
QXUVHV·DQGSDWLHQWV·
SHUFHSWLRQVRIDQGDWWLWXGHV
WRZDUGVODUYDOWKHUDS\
A qualitative study was undertaken to look at 
the acceptability and experiences of participants 
and staff in relation to larval therapy. Purposive 
sampling was used to recruit patient and nurse 
participants who had and had not had experience 
of larval therapy.
Four groups were to be interviewed:
• up to eight people with venous or mixed 
venous/arterial leg ulcers who had experienced 
larval therapy (either bagged or loose larvae) 
(inal number of interviewees to be decided 
depending on saturation of themes)
• up to eight people with venous or mixed 
venous/arterial leg ulcers who had not 
experienced larval therapy (inal number 
of interviewees to be decided depending on 
saturation of themes)
• up to eight nurses currently caring for people 
with leg ulcers who had been involved in larval 
therapy previously (either bagged or loose 
larvae) (inal number of interviewees to be 
decided depending on saturation of themes)
• up to eight nurses currently caring for people 
with leg ulcers who had not been involved 
in larval therapy previously (inal number 
of interviewees to be decided depending on 
saturation of themes).
5HFUXLWPHQWWRWKH
TXDOLWDWLYHVWXG\
3DWLHQWV
Participants were recruited from three of the VenUS 
II trial centres, i.e. York, Bolton and Bradford 
(as these centres were readily accessible by the 
interviewer) using purposive sampling.106 Health 
professionals involved in the care of people having 
treatment for a leg ulcer either at home or at a 
leg ulcer clinic were asked to give a lealet about 
the study (Appendix 8) to potential interviewees. 
Potential participants considered whether they 
would like to be included and if they decided to 
participate and to give consent to be interviewed, 
an interview was scheduled at a convenient time 
and was conducted according to the Interview 
Schedule (Appendix 9).
'2,KWD +HDOWK7HFKQRORJ\$VVHVVPHQW9RO1R
4XHHQ·V3ULQWHUDQG&RQWUROOHURI+062$OOULJKWVUHVHUYHG

1XUVHV
Nurses working in Huddersield, York, 
Scarborough, Bolton and Bradford were recruited 
to the study (as these centres were readily accessible 
by the interviewer). The nurses worked either in 
the leg ulcer clinics or in the community. Nurses 
were given written and verbal information about 
the study at least 1 week before their recruitment 
into the study (Appendix 9). After giving written 
consent to take part in the study, nurses were 
interviewed at a time and in a location (usually 
their place of work) that was convenient.
Semi-structured interviews were conducted with 
each respondent to gain an insight into his/her 
health beliefs and views/experiences of larval 
therapy. The interviews aimed to yield naturalistic 
data concerning the experience of having larval 
therapy, attitudes, beliefs and the acceptability of 
receiving and giving the treatment. The interviews 
explored how these beliefs and attitudes were 
altered through experiencing the treatment 
(Appendix 9).
6WDWLVWLFDODQDO\VHV
All analyses were conducted on an intention-to-
treat basis, including all participants in the groups 
to which they were randomised, using two-sided 
signiicance tests at the 5% signiicance level. 
Analyses were conducted in SAS version 9.1 (SAS 
UK, Marlow, UK).
%DVHOLQHGDWD
All baseline data were summarised by treatment 
group. Baseline data were summarised 
descriptively. No formal statistical comparisons 
were undertaken.
3ULPDU\DQDO\VLV
Time to healing was derived as the number of 
days from randomisation until the date of healing 
as conirmed from the blinded photograph 
assessment (or the date recorded by the nurses if no 
photographs were available). Participants who did 
not heal were treated as censored and their date of 
trial exit, date of their last available assessment, or 
365 days/trial cessation, as appropriate was used to 
calculate their duration in the trial.
An initial analysis of time to healing of the 
reference ulcer compared the three treatment 
groups using a log-rank test. Kaplan–Meier 
survival curves were constructed and the median 
time to healing and corresponding 95% CI for 
each group were calculated. A Cox proportional 
hazards model was used to adjust the analysis for 
the randomisation stratiication factors (centre, 
baseline ulcer area) as well as duration, and ulcer 
type. Actual baseline area (as measured from 
the tracings) and duration of ulcer were used. A 
treatment contrast was included in the model to 
compare healing rates between loose and bagged 
larvae. It was decided a priori that if there was no 
evidence of any difference between the loose and 
bagged larval therapy then the hazard ratios and 
95% CI would be presented for larval treatment 
overall (loose and bagged combined) compared 
with hydrogel. This strategy was not detailed 
explicitly in the original study protocol but was 
stipulated in the analysis plan, which was written 
before any data analysis. If there was a statistically 
signiicant difference (p ≤ 0.05) in healing rates 
between loose and bagged larvae then the hazard 
ratio and 95% CI would be presented separately 
for each type of larval treatment compared with 
hydrogel. The assumption of proportional hazards 
was assessed graphically using log–log plots of 
the estimated survivor function and Schoenfeld 
residual plots. We also included interaction terms 
between each variable and log (time) in the Cox 
model. The results from the adjusted analysis are 
presented as the primary results.
As there were a number of centres that only 
recruited a small number of participants (fewer 
than 10), sensitivity analyses were conducted to 
assess the impact of different methods of handling 
these small centres. This was done by: combining 
small centres, stratifying by centre, and by 
excluding centre from the model.
6HFRQGDU\DQDO\VHV
7LPHWRGHEULGHPHQW
Time to debridement was derived as the number 
of days from randomisation until the date of 
debridement as conirmed from the blinded 
photograph assessment (or the date recorded 
by the nurses if no photographs were available). 
Participants who did not debride were treated as 
censored; the censoring date was date of healing 
or date of trial completion, date of their last 
available assessment, or 365 days/trial cessation, as 
appropriate.
The time to debridement was analysed in the 
same way as the primary outcome variable, with 
adjustment for the same covariates. The same 
0HWKRGV

treatment contrasts were used and results were 
presented as hazard ratio and 95% CI for larval 
therapy compared with hydrogel, or each larval 
treatment separately compared with hydrogel 
dependent on the analysis results comparing loose 
and bagged larvae.
+HDOWKUHODWHGTXDOLW\RIOLIH
The HRQoL was measured using the SF-12 
questionnaire at baseline and 3, 6, 9 and 12 
months. Descriptive statistics (mean; SD) for the 
Physical Component Summary (PCS) and Mental 
Component Summary (MCS) scores were calculated 
by treatment group and across all arms. The overall 
scores for the PCS and MCS were analysed in two 
ways. First, the area under the curve (AUC)107 over 
all assessments was calculated for each participant 
and then this was standardised to produce a 
standardised area under the curve (SAUC), which 
divides the AUC by the length of follow-up for 
each participant. The overall SAUC was compared 
between larvae and hydrogel groups using a 
Wilcoxon rank sum test. We also used a multilevel 
regression model (SAS proc mixed) which allows 
for repeated observations within each participant. 
The total score at each follow-up assessment (3, 6, 
9 and 12 months) was the outcome variable and 
the model included terms for treatment, time, 
baseline score, ulcer area, ulcer duration and ulcer 
type. The interaction between time and treatment 
arm was assessed for inclusion in the model. As the 
primary aim of the project was to compare larval 
therapy with hydrogel the primary comparison 
of this analysis was larval therapy compared with 
hydrogel.
%DFWHULDOORDG
Bacterial load data were log transformed (using 
logs to base 10) and summarised over time using 
descriptive statistics. A linear random coeficients 
model was itted to log bacterial count to compare 
changes in bacterial load over time between the 
larval therapy and hydrogel groups. Time of the 
ulcer swab (number of days from baseline) was 
treated as a continuous measure and a quadratic 
term for time (time2) was included to test if the 
effects of time were non-linear. Treatment (larvae 
or hydrogel), time, baseline ulcer area, ulcer 
duration and ulcer type were treated as ixed 
effects and participants (to allow for a different 
intercept for each participant) and participant–
time interactions [to allow for different effects of 
time (slopes) for each participant] were treated as 
random effects. The interaction between treatment 
and time (to test if changes in bacterial load over 
time differed between treatments) was also included 
in the model. Two analyses were performed: one 
assessed bacterial load until the end of the trial 
for each participant; and the other only analysed 
bacterial load data up to the end of Phase 1 (to 
debridement if the participant debrided during the 
trial, or to the end of the trial if the participant did 
not debride).
056$
All baseline swabs collected from the reference 
ulcer were tested for the presence of MRSA. This 
was a dichotomous outcome (presence or absence 
of infection). For MRSA-positive participants, 
the proportions of participants where MRSA was 
eradicated by the end of Phase 1 were compared 
between larvae and hydrogel groups using 
Fisher’s exact test. This analysis was repeated for 
the proportions of MRSA-negative participants 
who tested positive for MRSA at any follow-up 
assessment.
&RPSOHWHKHDOLQJRIDOOXOFHUV
The numbers of participants who healed 
completely by the end of their trial follow-up 
(i.e. all ulcers on both legs, not just the reference 
ulcer) were summarised by treatment group but no 
statistical analysis was performed.
$GYHUVHHYHQWV
The numbers of adverse events experienced by 
each participant were compared between treatment 
groups using a negative binomial model adjusting 
for the same covariates as the primary analyses 
(ulcer size, ulcer duration, type of ulcer). The 
number of participants experiencing an adverse 
event, the number of events recorded and their 
seriousness and suspected relationship to treatment 
were summarised for each treatment group.
8OFHUUHODWHGSDLQ
The score from the VAS assessed at the irst 
treatment removal visit (asking about ulcer pain 
over the previous 24 hours) was compared between 
treatment groups using linear regression, adjusting 
for baseline ulcer-related pain score, ulcer area, 
ulcer duration and ulcer type.
(FRQRPLFDQDO\VHV
A cost-effectiveness analysis and a cost–utility 
analysis were performed using patient-level 
data collected as part of VenUS II. Intention-to-
treat analyses compared incremental costs with 
incremental ulcer-free days (cost-effectiveness 
analysis) and incremental quality-adjusted life-time 
(cost–utility analysis).
'2,KWD +HDOWK7HFKQRORJ\$VVHVVPHQW9RO1R
4XHHQ·V3ULQWHUDQG&RQWUROOHURI+062$OOULJKWVUHVHUYHG

The perspective for the economic analysis was 
that of the UK NHS and Personal Social Services 
(PSS). Hence, beneits included clinical and health-
related beneits valued from the perspective of 
society, and costing included use of NHS and PSS 
resources required to achieve those beneits.108 The 
time horizon for the analysis was 12 months after 
recruitment, and consequently neither costs nor 
health beneits [quality-adjusted life-years (QALYs), 
ulcer-free days] were discounted. The analyses were 
conducted using STATA 10 (StataCorp 2007, College 
Station, TX, USA).
+HDOWKEHQHÀWV
0HDQWLPHWRKHDOLQJHVWLPDWLRQ
To meet the needs of decision-makers, the 
focus of economic evaluations alongside RCTs 
is on estimating mean costs and health beneits 
(QALYs and ulcer-free days) associated with 
health technologies. Unlike in clinical evaluations 
where the median is often preferred, in economic 
evaluations the mean is the only statistic that 
provides useful information on the expected 
health beneits and costs associated with health 
technologies.
In VenUS II, healing was the event of interest, 
however, as well as being healed, individuals could 
be censored or die. Nearly all statistical methods 
for survival analysis are based on the assumption 
that the reason for censoring is independent of 
the outcome – non-informative censoring. Yet, 
when the event of interest is not death – as is the 
case in VenUS II – participants who do die are 
usually censored even though we know that healing 
cannot occur after death. As only nine people were 
reported to have died during VenUS II follow-
up, it was decided not to consider death as an 
informative censoring event in the estimation 
of time to healing. Nonetheless, this issue may 
be explored in a future analysis using multistate 
models to estimate the transition probabilities of 
different events of interest (debridement, healing, 
amputation and/or death).109
If all participants were followed until the event of 
interest occurs (ulcer healing), mean time to event 
could be estimated by integrating the survival 
function over time. However, in VenUS II we 
know that censoring occurred as a result of loss to 
follow-up, death or study conclusion (participants 
were followed for a maximum of 1 year). In this 
case, conventional methods for the estimation of 
mean time to event (mean time to ulcer healing) 
are considered inappropriate. To estimate mean 
survival time over a speciic study period, two 
options have been explored in the literature: (1) 
the restricted mean approach; (2) the weighted 
ordinary least squares regression or inverse 
probability weighting (IPW) approach.110
In the last 5 years the IPW method has been 
proposed as a robust method to estimate mean 
cost and QALYs.111–113 Consequently, our base-case 
analysis was conducted using inverse probability 
weights in the estimation of mean time to 
healing, as well as mean costs and QALYs. In this 
approach only participants with observed time 
to healing data contribute with non-zero terms, 
but their contributions are inversely weighted by 
the respective probability of being observed. The 
weight is then zero if the participant is censored 
before or within an interval, corresponding to a 
missing observation. If the participant survives the 
interval or dies (heals), the weight is the inverse of 
the probability of not being censored at the end 
of the interval or at the time of death (healing) 
respectively.114 Consequently, individuals who 
are less likely to be observed are weighted most 
heavily. The censoring distribution was estimated 
through the Kaplan–Meier estimator and CIs were 
evaluated through non-parametric bootstrap.
As the IPW estimation procedure has not yet been 
applied to non-absorbent events such as healing, 
the restricted mean estimate was also computed 
to validate the current results.115 Mean time from 
randomisation to healing, restricted to an upper 
time limit, was calculated as the area under the 
survivor function from zero to the chosen inite 
time limit. The time point of restriction was 
evaluated in conformity to the statistical criterion 
proposed by Karrison,116 who suggests that 
information should be used until the standard 
error of the survival probability estimate does not 
exceed a certain lower limit; in the present analysis 
assumed as 10%.117 To account for stratiication 
variables and prognostic factors, the survival 
function was estimated using the same Cox model 
deined in the clinical analysis.
The results of the estimation procedures returned 
mean time to healing for each trial arm. If larval 
therapy reduced time to healing, the difference in 
time to healing between the larval and hydrogel 
groups would have been negative, which can make 
interpretation more dificult for the reader. To 
simplify the interpretation of the cost-effectiveness 
analysis, the effectiveness outcome was reported 
as gains in ulcer-free days, which assume the same 
absolute value as difference in time to healing but 
have the opposite sign.
0HWKRGV
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8WLOLW\VFRUHV
The health-state descriptor measure used was 
the EQ-5D, a widely recognised and validated 
descriptive system of HRQoL.91 HRQoL data were 
collected at baseline and 3, 6, 9 and 12 months. 
The EQ-5D questionnaire has ive questions, each 
relating to a different health dimension: mobility, 
self-care, ability to undertake usual activity, pain 
and anxiety/depression. Each question has three 
possible response levels: no problems, moderate 
problems and severe problems. Based on their 
combined answers to the EQ-5D questionnaire, 
participants can be classiied as being in one of 243 
possible health states. Each of these health states 
has an associated utility weight which denotes the 
impact this state will have on HRQoL. Responses 
to EQ-5D questionnaires were used to compute 
individual’s utility scores, which were used to 
calculate QALYs. Utility scores were calculated 
using an independent predeined algorithm 
obtained by the elicitation of societal preferences 
for the health dimensions in a random population 
sample through a time trade-off technique.118 
Hence, perfect health has a weight of 1, which 
decreases as health becomes impaired. Quarterly 
QALYs were calculated by applying individual’s 
utility weights to survival time using the AUC 
approach,107,119 which is deined by linearly 
interpolating the utility scores measured over time.
0HDQ4$/<HVWLPDWLRQ
Not all participants were followed up for a full 
year because of censoring. To account for the 
impact of censoring,120 and so avoid bias, mean 
QALYs over the 12 months follow-up period were 
again estimated using the IPW method.112,113,121 
The study time horizon was partitioned in 
homogeneous subintervals (quarterly intervals) 
and mean QALYs were estimated in each interval. 
To ensure comparability with the clinical analysis, 
linear regression was used to adjust QALYs by the 
same covariates and also baseline utility.119 QALYs 
were weighted by the inverse of the probability of 
an individual not being censored. If a participant 
died their utility values were recoded as 0. Mean 
total QALYs were then estimated as the sum of the 
estimated mean QALYs per period for each trial 
arm, considering the mean value of the rest of the 
covariates observed in the whole sample.
5HVRXUFHXVHDQGXQLWFRVWV
A cost for each trial participant was calculated as 
the product of resources used by their relevant 
unit cost. Resource-use data were collected in 
nurse questionnaires and self-reported participant 
questionnaires.
Analysis was carried out using 2006 costs in Pounds 
Sterling.
Three different elements were considered in the 
estimation of costs:
• trial debridement treatment
• health care provider time (visits to/from health 
care provider for leg-ulcer-related reasons)
• cost of compression therapy.
Other treatments, such as primary and secondary 
dressings or skin preparations, were assumed to be 
used equally across treatment arms: these resources 
were not included in the economic analyses.
7ULDOGHEULGHPHQWWUHDWPHQWVDSSOLHG
Ulcer debridement data used in the analysis were 
collected by the treating nurse at each visit. Where 
data on the number of larvae pots/bags required 
were missing (31% for bagged larvae and 54% 
of loose larvae), these were estimated from the 
existing data using linear regression and the area 
of the reference ulcer at baseline. When costing the 
number of larvae bags or pots for each participant 
we assumed the cheapest combination of bags or 
pots of larvae possible. Unit costs were obtained 
from the larvae suppliers (Table 8).
9LVLWVWRIURPKHDOWKFDUHSURYLGHUV
Data from two sources of information on visits to or 
from health care providers were available in VenUS 
II: nurse-reported and self-reported. Ulcer-related 
self-reported data were collected after healing of 
the reference ulcer while nurse-reported data were 
systematically collected only for the reference ulcer; 
however, some participants had multiple ulcers. To 
record ongoing resource use after healing of the 
reference ulcer, self-reported data were used in the 
base case, while the use of nurse-reported data was 
explored in a sensitivity analysis.
The cost per visit was calculated assuming different 
durations of home and clinic visits (Table 9). The 
self-reported data collected information about 
the visit setting (home or clinic); however, this was 
recorded for all nurse visits rather than for ulcer-
related visits only. Consequently, we assumed that 
the setting of ulcer-related visits from self-reported 
data would follow the same pattern as that reported 
for all nurse visits, where data were available. 
Hospital visits were costed on an outpatient visit.
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The costs of compression therapy were determined 
on a visit-by-visit basis. As no information on 
the size of the system brand was available, an 
arithmetic average cost for commercially available 
systems was used to cost the class recorded (High 
compression: 4LB, SSB, two-layer, three-layer 
high compression; Low compression: three layer 
reduced compression; light compression), assuming 
that the elements used to compose the compression 
system were as per protocol (Table 10). Where the 
use of more than one compression system was 
reported in a single visit, the more costly system 
was considered.
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Resource use data collected are also subject to 
censoring and estimating the mean total cost 
based on complete case analysis will underestimate 
the true expected costs. An IPW regression (as 
described above) was used to account for censoring, 
possible baseline imbalances and randomisation 
stratiication variables. Mean cost estimation 
was made by partitioning the study period into 
multiple time intervals (quarterly periods) and the 
IPW regression per period estimates were then 
summed to obtain total expected costs.
&RVWHIIHFWLYHQHVV
As in the clinical analysis, in the incremental 
cost-effectiveness analysis estimates of total cost 
and health beneit (ulcer-free days and QALYs) 
were reported for larval treatment (pooling data 
from the loose and bagged larvae groups) and 
hydrogel treatment. Nonetheless, for completeness 
descriptive measures on costs and health beneits 
were described for each of three trial arms.
To assess cost-effectiveness, we compared the 
mean difference in costs between trial arms with 
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the mean difference in number of ulcer-free days 
and QALYs. The results of economic evaluation 
studies can be graphically represented in what is 
known as a cost-effectiveness plane where results 
are characterised in one of four potential scenarios 
(Figure 1).
Alternative scenarios on the cost-effectiveness 
plane:
• If the results from the economic evaluation 
analyses of VenUS II fall in the north-west 
(NW) quadrant of the cost-effectiveness plane 
it implies that larval therapy is dominated 
by hydrogel, in other words, larval therapy is 
more expensive and is associated with fewer 
health beneits than hydrogel. In this case, the 
decision regarding adoption of larval therapy is 
straightforward and one should not adopt it.
• Similarly a straightforward decision can be 
made when the cost-effectiveness measure is 
positioned in the south-east (SE) quadrant. 
In this situation, larval therapy would be 
dominant, i.e. estimated to be less costly and 
more beneicial than hydrogel and should 
therefore be implemented.
0HWKRGV
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• In the NE or SW quadrants, decisions are 
more dificult to make. Here one must 
evaluate whether the increased cost of the new 
intervention is worth the increased beneit (NE 
scenario), or if the reduced beneit conferred 
by the new treatment is justiied by the reduced 
costs (SW).
To ascertain the cost-effectiveness of a health care 
intervention relative to another in the absence of 
dominance, one needs to conduct an incremental 
analysis of cost-effectiveness. The incremental cost-
effectiveness ratio (ICER) is the most commonly 
used cost-effectiveness measure and combines 
costs and health in a single measure to which a 
decision rule for cost-effectiveness can be applied. 
It combines costs and beneits in a ratio of the 
mean difference in cost between the alternative 
treatments being compared with the mean 
difference in health beneits such that:
ICER = (C1 – C0) / (B1 – B0)
where: C1 is the mean cost associated with the 
technology under evaluation (larvae); C0 is 
the mean cost associated with the technology 
of comparison (hydrogel); B1 is the mean 
health beneit associated with the technology 
under evaluation (larvae); and B0 is the mean 
health beneit associated with the technology of 
comparison (hydrogel).
The decision rule for cost-effectiveness on the basis 
of the ICER indicates that a treatment strategy can 
be considered cost-effective only if the decision-
maker’s willingness to pay for an additional unit 
of health beneit (QALYs, ulcer-free days) is 
greater (or equal) to the ICER. In this context, the 
decision-maker is responsible for establishing the 
willingness to pay.
8QFHUWDLQW\DVVHVVPHQW
The treatment decision is uncertain because 
the expected cost-effectiveness outcomes are 
assumed to be stochastic (in a Bayesian approach 
to parameter probability). Nevertheless, decision-
makers have to decide on the provision of services, 
even in the presence of uncertainty. It has been 
argued that, irrespective of whether the cost-
effectiveness estimate is statistically signiicant at 
conventional (arbitrary) levels, the expected cost-
effectiveness can be used to decide on the adoption 
of the new technology.124
Conidence intervals
Uncertainty around the decision to adopt the 
treatment under evaluation was assessed through a 
non-parametric bootstrap resampling technique.125 
This is a common methodology used to construct 
conidence intervals around the incremental 
costs and health beneits from sampled cost 
and effectiveness random variables.126–128 First, 
the bootstrap technique was used to sample 
(with replacement) from the observed cost and 
effectiveness pairs, maintaining the correlation 
structure. For each bootstrap resample, an IPW 
estimate of expected total costs, expected QALYs 
and expected time to healing was calculated, 
which allowed computation of cost-effectiveness 
and cost–utility outcome replicates. The 95% CIs 
for the differential costs and QALYs were then 
calculated using bias-corrected non-parametric 
bootstrapping.125
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Cost-effectiveness acceptability curves
To explore the decision uncertainty regarding 
the cost-effectiveness of larval therapy, cost-
effectiveness acceptability curves (CEAC) were 
estimated. The CEAC expresses the likelihood 
that the cost-effectiveness estimate relects a 
cost-effective intervention, based on the existing 
evidence.129 The CEAC summarises, for every value 
of willingness-to-pay thresholds, the evidence in 
favour of the intervention being cost-effective. In 
this case, given the trial data, the CEAC for larval 
therapy represents the probability of this therapy 
being cost-effective compared with hydrogel 
for a range of willingness-to-pay values for an 
ulcer-free day/QALY. This represents a Bayesian 
interpretation of cost-effectiveness uncertainty, 
although a full Bayesian analysis was not 
undertaken.
6HQVLWLYLW\DQDO\VLV
Total costs of treating venous leg ulcers are driven 
by nursing costs and hospitalisation costs.12 As 
information on nurse and hospital visits was also 
collected by nurses (as well as self report), the 
use of this information source to estimate total 
costs was explored in sensitivity analysis. Nurse-
reported costs of health care provider visits were 
calculated distinguishing the visit location. Clinic, 
home or GP surgery visit costs were estimated 
assuming differential visit duration, see Table 11. 
Ulcer-related hospitalisations were costed based on 
the duration of hospitalisation through a bed day 
cost. Nevertheless, if a participant was hospitalised 
for a non-ulcer-related reason and received ulcer 
treatment while in hospital, this ulcer-related cost 
was calculated considering only the hospital nurse 
time.
To explore the impact of using nurse-reported data 
on visits and hospitalisations, the cost-effectiveness 
of larval therapy was re-estimated using these data 
and including the cost of trial treatments, nurse 
visits and hospitalisations. Two scenarios were 
implemented:
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• Scenario 1: Ignoring amputation costs in the 
calculation of hospitalisation costs.
• Scenario 2: Considering amputation costs in 
the calculation of hospitalisation costs.
Amputation is an expensive procedure and a 
small number of events may change the total 
costs estimates. As information on amputation 
was not systematically collected, the inclusion 
of amputation costs was assessed in a sensitivity 
analysis, recalling that this analysis may be biased. 
As described in Table 11, amputation costs (scenario 
2) were considered as a one-off cost.
One-way sensitivity analysis was also carried out 
in an attempt to disentangle the inluence of the 
duration of nurse visits in total treatment cost. The 
base-case analysis (considering self-reported visits 
to/from health care providers) was reproduced 
for a range of sensible values of the following 
parameters:
• duration of nurse visits
• ratio of home versus clinic visit duration (to 
explore whether changing site of visit affects 
cost-effectiveness).
4XDOLWDWLYHGDWDDQDO\VLV
Interviews were recorded onto tapes and 
transcribed verbatim. Analysis of the interview 
had ive stages: reading the text and coding for 
descriptive labels; sorting for patterns within the 
data; identifying outliers or negative cases and 
revising theory accordingly; generalising and 
reining constructs and theories; more detailed 
relection and revision. Analysis was conducted with 
the assistance of the computer software package 
ATLAS.TI (Atlas.ti, Berlin, Germany). The data were 
analysed using an iterative, comparative approach 
to elicit similarities and differences across the data 
set.131
At the coding stage, reliability of coding was 
assessed by asking another researcher to 
independently code some of the raw data, 
using previously agreed coding criteria. This 
is close to the concept of inter-rater reliability 
which is familiar in quantitative research.131 The 
‘independent researcher’ had no connection with 
the study of larval therapy, but had wide experience 
of analysing and interpreting qualitative data. 
Codes had been derived by the primary analyst 
after close reading of the total data set to identify 
all the key issues, concepts and themes by which 
the data could be examined and referenced. 
Four patient and nurse interview transcripts 
(representing 10% of the data set) were randomly 
selected and subjected to examination by the 
independent researcher for adequacy of the coding 
framework and accuracy of coding. Subsequent 
discussion between the independent researcher and 
the primary analyst led to further reinement of the 
coding framework, which was then applied across 
the total data set.
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3DUWLFLSDWLQJFHQWUHV
The original proposal contained eight recruiting 
sites and planned to recruit participants over  
18 months with all participants being followed up 
for 12 months. As the trial progressed, recruitment 
fell below expected levels and further sites were 
recruited. Details regarding the recruitment 
duration of each site can be found in Appendix 1. 
An extension in time and funding was obtained 
from the funder and the recruitment period was 
extended to 35 months (June 2004 to May 2007). 
The recruitment period was also extended into  
6 months of the 12-month follow-up period.
,QFOXVLRQH[FOXVLRQFULWHULD
In the original protocol inpatients, patients with 
bilateral leg ulcers and patients with more than 
four leg ulcers were excluded from the trial. Low 
rates of recruitment at an early stage led us to 
request Main Research Ethics Committee (MREC) 
approval to remove these exclusions: inpatients 
were eligible for inclusion from August 2004; 
people with bilateral leg ulcers were eligible for 
inclusion from November 2004; and people with 
more than four leg ulcers were eligible for inclusion 
from November 2004.
During the trial the manufacturers of the loose 
larvae added a contraindication to the use of larvae 
for those receiving anticoagulants when they were 
not under constant medical supervision. As a result, 
this was added as an exclusion criterion (May 
2005).
6DPSOHVL]H
A recruitment rate that was substantially under 
target led us to apply to the funder for an 
extension to the recruitment period. To calculate 
the most appropriate duration for the extension 
we estimated the difference in median time to 
healing detectable with 90% power with different 
sample size scenarios (and allowing for a 15% loss 
to follow-up) (Table 12).
We requested an 18-month extension to 
recruitment with a revised recruitment target of 
370 participants (90% power to detect a reduction 
in median healing time from 20 to 12.7 weeks 
while allowing for 15% loss to follow-up), or 270 
participants to detect the same difference with 80% 
power.
'LJLWDOLPDJHV
The reference ulcer was originally photographed 
weekly throughout the study until healing. During 
the trial it became apparent that this requirement 
created an amount of work for nurses working 
on the trial that was dificult to justify and was 
probably reducing recruitment of new participants; 
furthermore, the requirement for weekly 
photographs was causing some inconvenience to 
participants. This was especially the case where 
participants were coming back to clinics speciically 
for a digital image to be taken or where nurses 
were travelling long distances to take images in 
participants’ homes. The trial statistician (Professor 
Martin Bland) undertook a simulation using data 
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from a previous study (VenUS I). He explored the 
effect that monthly rather than weekly follow-up 
would have had on the precision of the estimate 
of the treatment effect for the VenUS I trial and 
found that it would have almost no impact (but the 
beneit to this trial would be potentially greater 
recruitment because centres were less likely to reach 
capacity). MREC approval was gained to reduce 
the frequency of collection of digital images from 
weekly to monthly after 6 months of follow-up.
5HFUXLWPHQWLQWR
RWKHUWULDOV
Our initial protocol precluded participants in 
this trial from participating in other trials during 
follow-up. One of our main recruiting centres 
voiced strong concerns that they were unable to 
recruit clinic patients into other leg ulcer clinical 
trials because of the extended duration of follow-
up of patients in VenUS II. The trial statistician, 
Professor Bland, simulated the effect on the 
VenUS I end point estimate of 50% of participants 
being randomised into other trials and found no 
discernable impact on power so we obtained MREC 
approval for VenUS II participants, randomised 
more than 6 months previously, to be recruited to 
other trials while still being followed up for VenUS 
II
4XHVWLRQQDLUHUHVSRQVHUDWH
As discussed in Chapter 2, a systematic review 
investigating ways of increasing questionnaire 
response rates reported that the response rate to 
postal questionnaires was doubled (odds ratio = 
2.02; 95% CI 1.79 to 2.27) when a inancial reward 
was included with the questionnaire, compared 
with no incentive. Based on these data we obtained 
MREC approval to include £5 with the inal 
questionnaire sent to participants at 12 months; 
however, participants were only informed of this 
unconditional token of our appreciation in their 
9-month letter.
,QWHULPDQDO\VLV
Before the trial commenced we were concerned 
that it might be dificult to recruit suficient 
numbers of participants to a three-arm trial and 
we therefore sought mechanisms by which we 
might be able to close one arm to recruitment early 
without losing valuable information. We therefore 
planned to undertake an interim analysis after 200 
participants had been followed for 92 days at which 
point:
• If there was a treatment difference between 
the two larvae formulations in favour of loose 
larvae then we would continue with the three-
arm trial because bagged larvae may still be 
more acceptable or cost-effective than loose 
larvae. We calculated that, after 15% attrition, 
we would end up with approximately 160 
participants in each group. This would give us 
78% power to detect an absolute difference in 
proportions healed of 15% (from 50% to 65% 
ulcers healed at 16 weeks).
• If there was no discernible difference between 
the two larvae formulations then we would 
close the loose larval therapy arm down 
(because bagged larvae would always be likely 
to be more acceptable). If the loose larvae arm 
had closed at the interim analysis we would 
have changed the randomisation ratio. We had 
then planned to randomise 276 participants 
to the control arm and only a further 209 to 
the larval therapy arm giving a total of 276 
in larval therapy including the original 67 
participants receiving loose larvae (assuming 
15% attrition). This would have given us 90% 
power to detect an absolute difference in 
proportions healed of 15% between the two 
arms.
• If bagged larvae seemed slightly less effective 
we would have continued with the three arms;
• If bagged larvae seemed ineffective at the 
interim analysis we were to close the bagged 
larvae arm down. We would have changed 
the randomisation ratio at this point to 1 : 1 
(two arms). We would have randomised 243 
participants to each of the continuing arms; 
leaving 206 after 15% attrition. This would 
have given us 84% power to detect an absolute 
difference in proportions healed of 14% 
between the two arms.
These steps were agreed with the funder before 
inalising the research contract. However, after 
the start of the trial a number of arguments 
were presented against conducting an interim 
analysis. It was suggested that the analysis seemed 
unnecessarily complicated, ineficient and quite 
likely to mislead. In practice, if the results of an 
interim analysis had meant it was possible to close 
either larval therapy arm, we would have already 
recruited more than 200 participants (because 
of the time taken to do the analysis, consult 
stakeholders and make decisions). Additional 
'2,KWD +HDOWK7HFKQRORJ\$VVHVVPHQW9RO1R
4XHHQ·V3ULQWHUDQG&RQWUROOHURI+062$OOULJKWVUHVHUYHG

participants would also have been recruited in 
the 92 days while the 200th participant was being 
followed up. In practice, there would have been 
fewer than 250 participants per group after closure 
of one group. The standard error of a difference 
between two groups of 250 would be 87% of 
that for two groups of 189, hence the detectable 
difference for given power is 87% of that for three 
groups. So there would not be much difference and 
delays would make this closer to 100%. For these 
reasons, we sought and received approval from 
MREC and the funder to not conduct the interim 
analysis and we retained three treatment arms until 
trial closure.
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5HFUXLWPHQW
Recruitment began in July 2004 and ceased in 
May 2007. In total, 1712 participants with leg 
ulcers were screened as potential participants 
and of these, 267 (15.6%) were randomised. 
Over the course of the trial there was a total of 
22 participating centres in the UK plus one in 
Hungary. Recruitment was staggered with centres 
joining and leaving the trial over its course. 
Recruitment of at least one trial participant 
took place in 18 of the 22 sites (participants per 
centre ranged from 1 to 52; Figure 2). The rate of 
recruitment is shown in Figure 3. Further details of 
the recruiting sites are presented in Appendix 1.
Of the 267 participants, 94 received loose larvae, 
86 received bagged larvae and 87 received 
hydrogel. Figure 4 shows the low of participants 
through the trial.
%DVHOLQHGHPRJUDSKLFV
DQGFOLQLFDOFKDUDFWHULVWLFV
RISDUWLFLSDQWVE\
WUHDWPHQWDUP
The baseline characteristics of participants are 
summarised in Tables 13–16. Table 15 summarises 
the participants by the prespeciied prognostic 
factors. Most ulcers (75.7%) were classiied by 
the nurses as having an area greater than 5 cm2, 
although the actual areas measured from baseline 
tracings were used in the statistical analyses. There 
was some imbalance between the treatment groups 
with respect to ulcer duration (at least 6 months 
or more than 6 months) with fewer ‘older’ ulcers 
(more than 6 months) in the bagged larvae group 
(46.5%) compared with the loose larvae (64.9%) or 
hydrogel (59.8%) groups. Similarly, there was some 
imbalance in ulcer type; with more participants 
with an ABPI of 0.8 or more treated with high 
compression in the hydrogel group (70.1%) 
compared with the larvae groups (loose and bagged 
were similar at 53.2% and 53.5%).
As expected, there were more female than male 
participants (59.2% compared with 40.8%) and a 
greater proportion of men in the hydrogel group 
(50.6%) compared with the loose (38.3%) or 
bagged (33.7%) larvae groups. However, as there is 
no evidence that gender is a prognostic factor for 
ulcer healing, this imbalance is unlikely to affect 
healing outcomes and gender was not included in 
any analyses.
The mean age of participants was 74 years, 
with a range from 20.9 to 94.9 years. The mean 
participant weight was 81.1 kg and 50.9% of 
&KDSWHU
&OLQLFDOUHVXOWV
0
10
20
60
50
40
30
N
u
m
b
e
r 
o
f 
p
ar
ti
ci
p
an
ts
Le
ed
s
52
Br
ad
fo
rd
45
Bo
lto
n
40
H
ul
l
25
Al
tn
ag
el
vi
n
24
Yo
rk
24
Sc
ar
bo
ro
ug
h
15
Be
df
or
ds
hi
re
11
N
or
th
 E
ss
ex
6
N
or
th
 T
yn
es
id
e
5
C
um
br
ia
4
Bo
ur
ne
m
ou
th
4
Ea
st
bo
ur
ne
3
Bu
rt
on
3
St
oc
kp
or
t
2
C
or
nw
all
2
Be
lfa
st
1
B 
& 
D
1
),*85( 3DUWLFLSDQWUHFUXLWPHQWE\VLWHIRXUVLWHVLQFOXGLQJWKHVLWHLQ+XQJDU\GLGQRWUHFUXLW
&OLQLFDOUHVXOWV

0
100
200
700
600
500
400
300
N
u
m
b
e
r 
o
f 
p
ar
ti
ci
p
an
ts
Ap
r-
04
Ju
n-
04
Au
g-
04
Se
p-
04
N
ov
-0
4
Ja
n-
05
M
ar
-0
5
M
ay
-0
5
Ju
l-0
5
Se
p-
05
N
ov
-0
5
Ja
n-
06
M
ar
-0
6
M
ay
-0
6
Ju
l-0
6
Se
p-
06
N
ov
-0
6
Ja
n-
07
M
ar
-0
7
M
ay
-0
7
Recruited
Revised target
Original target
),*85( 7ULDOUHFUXLWPHQWUDWH
participants had no mobility problems. The 
mean ABPI of the reference limb (the leg with 
the reference ulcer) was 1.0 with a range from 0.6 
to 2.1 and 53.4% of participants had full ankle 
mobility. The mean ankle circumference was 25 cm, 
ranging from 18 to 51 cm. These factors were fairly 
well balanced between the three treatment groups.
With respect to the reference ulcer, ulcer duration 
was positively skewed; 50% of ulcers had been 
present for less than 7 months. The median 
duration of the current reference ulcer was 
7 months (range 1 to 372) overall; 9 months for the 
loose larvae group, 6 months for the bagged larvae 
group and 8 months for the hydrogel group. The 
median time since the irst ulcer was 25 months 
[range 1–720 months (i.e. 60 years)] and there was 
some imbalance with the hydrogel group having 
a median duration of 37.5 months compared with 
21 and 24 months for the loose and bagged larvae 
groups respectively. The number of ulcer episodes 
since the irst occurrence was similar between 
groups with an overall median of 1 (range 0 to 25) 
indicating that for at least 50% of participants this 
was their second episode of leg ulceration. The 
data for baseline ulcer area (as measured from 
the tracings) was also skewed with a median ulcer 
area of 13.2 cm2 (range 0.6–197.9 cm2). The ulcers 
in the bagged larvae group were slightly larger 
(median 17.3 cm2) compared with the loose larvae 
and hydrogel groups (both medians of 12.2 cm2). 
Although there was an observed baseline imbalance 
between treatment groups for ulcer duration and 
surface area, as these were identiied at the design 
stage as important prognostic factors for ulcer 
healing, these were prespeciied as factors to be 
included in the primary analyses.
7ULDOZLWKGUDZDO
IURPWUHDWPHQWDQG
WULDOFRPSOHWLRQ
The numbers withdrawing from trial treatment 
were similar in each group, with 41.4% of loose 
larvae, 41.9% of bagged larvae and 39.1% of 
hydrogel participants withdrawing from treatment, 
but only six (6.4%), three (3.5%) and four (4.6%) 
participants, respectively, withdrawing their 
consent to further follow-up assessments. A total of 
nine participants (four loose larvae, four bagged 
and one hydrogel) died during the trial.
The reasons given for trial completion are 
shown in Table 17. In total, 14.2% of participants 
requested trial withdrawal and 9.7% of participants 
were either withdrawn by their doctor or nurse 
or admitted to hospital. There were 45.3% of 
participants whose ulcers all healed completely 
during the trial (clinical data collection stopped but 
HRQoL data was still requested).
3ULPDU\RXWFRPH
XOFHUKHDOLQJ
The initial analysis of time to healing used a log-
rank test to compare the survivor functions of 
the three treatment groups (loose larvae, bagged 
larvae and hydrogel). There was no evidence of 
a difference between the three treatment groups 
in time to ulcer healing [log rank test statistic 
0.995, degrees of freedom (df) = 2, p = 0.62] (Table 
18). We then used a Cox proportional hazards 
model to adjust for stratiication and prespeciied 
prognostic factors [centre, baseline ulcer area, ulcer 
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Assessed for eligibility
n = 1712
Randomised
n = 267
Included in
primary analysis
n = 94
Included in
primary analysis
n = 86
Included in
primary analysis
n = 87
Allocated Bagged larvae
n = 86
Received bagged n = 82
Treatment not received:
Refused larvae n = 1
Hospital admission n = 1
Reason unknown n = 2
Allocated to Hydrogel
n = 87
Received gel n = 78
Treatment not received:
Never applied n = 2
Hospital admission n = 2
Trial withdrawal n = 1
Reason unknown n = 4
Excluded n = 1445
Reasons for exclusion:
Already been in larval trial n = 4
Pregnant/breastfeeding or women
of child-bearing potential n = 13
In other leg ulcer trial n = 3
Allergy to hydrogel n = 6
Diabetic with HbA1c not measured
in past 3 months or higher than 10%
n = 32
ABPI < 0.6 n = 129
Grossly oedematous legs n = 56
Ulcer < 5cm2 n = 205
Ulcer with < 25% slough n = 504
Will not consider LT n = 85
Unwilling or unable to give informed
consent n = 121
Under 18 n = 2
On an anti-coagulant n = 30
Multiple reasons n = 255
Allocated Loose larvae
n = 94
Received loose n = 88
Treatment not received:
Withdrew on day of
randomisation n = 1
Ulcer improved n = 1
Patient died n = 1
Reason unknown n = 3
Withdrew from treatment
n = 36
Ulcer area increased n = 1
Slough increased n = 19
Patient request n = 4
Withdrawal from treatment
and follow-up
assessments n = 3
Adverse treatment
reaction n = 9
Withdrew from treatment
n = 34
Ulcer area increased n = 2
Slough increased n = 16
Patient request n = 5
Withdrawal from treatment
and follow-up
assessments n = 4
Adverse treatment
reaction n = 7
Withdrew from treatment
n = 39
Ulcer area increased n = 2
Slough increased n = 19
Patient request n = 6
Withdrawal from treatment
and follow-up
assessments n = 6
Adverse treatment
reaction n = 5
Patient was dying n = 1
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duration and type of ulcer (ABPI ≥ 0.8 and high 
compression; ABPI ≥ 0.8 and low compression; 
ABPI 0.6 to 0.8)]. We compared the healing rates 
between the loose and bagged larvae arms in this 
model and found no evidence of a difference 
between them (chi-squared test statistic 0.194, 
df = 1, p = 0.66). Results are therefore presented 
for larvae overall (pooling data from the loose 
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and bagged arms) compared with hydrogel. The 
median times to healing were 236 days (95% CI 
147 to 292) for participants receiving larvae and 
245 days (95% CI 166, upper limit not estimable) 
for those receiving hydrogel (Table 19). Figures 5 
and 6 show the Kaplan–Meier survival curves for all 
three treatment groups and larvae compared with 
hydrogel respectively.
The adjusted analysis results are presented in 
Table 20. The hazard ratio was 1.13 (95% CI 0.76 
to 1.68), which indicated a slightly increased risk 
of healing for the larvae group although this 
was not statistically signiicant (p = 0.54). Plots 
of Martingale residuals were used to check the 
linearity assumption of terms in the model and 
these indicated that using the logarithm of both 
baseline ulcer area and duration provided a 
better it therefore the model presented includes 
the logged terms. However, using the log-
transformed data did not alter any conclusions. 
Both baseline ulcer area and ulcer duration were 
statistically signiicant predictors of time to healing 
(p < 0.0001) with larger ulcers and those of a longer 
duration having a reduced risk of healing. There 
was no evidence that healing rates differed between 
trial centres (p = 0.31).
The proportional hazards assumption was checked 
using log–log plots of the estimated survivor 
function and by including interaction terms 
between each variable and time in the model. 
Visual inspection of the survival function and log–
log plots indicated potential non-proportionality 
of hazards for the treatment groups; however, 
further investigation using statistical testing of the 
time–treatment interaction indicated no evidence 
of non-proportionality (p = 0.25) and this was 
conirmed by plotting scaled Schoenfeld residuals. 
The only variable which did appear to violate the 
proportional hazards assumption was ulcer type 
(ABPI ≥ 0.8 and high compression; ABPI ≥ 0.8 and 
low compression; ABPI 0.6–0.8). Two sensitivity 
analyses were performed which included removing 
ulcer type from the model, and stratifying by ulcer 
type. Neither altered the conclusions; the hazard 
ratio for larvae versus hydrogel from the stratiied 
model was 1.15 (95% CI 0.77 to 1.71). We also 
undertook sensitivity analyses to investigate the 
effect of centre, as several centres only recruited 
small numbers of participants. The sensitivity 
analyses included stratifying the model by centre, 
treating centre as a random effect in a frailty 
model and removing centre from the model. 
None of these approaches altered the conclusions 
about the treatment effect. We also repeated the 
time-to-healing analysis using the date of healing 
as recorded by the nurses on the patient record 
forms (as opposed to the date from the blinded 
assessment of photographs), and this did not alter 
any of the conclusions.
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Participants with multiple ulcers at randomisation 
remained in the trial after healing of the reference 
ulcer. At the end of follow-up, all ulcers of 124 
participants (46.4%) were completely healed; 
representing 48.9% (46/94) in the loose larvae 
group, 47.7% (41/86) in the bagged larvae group 
and 42.5% (37/87) of hydrogel participants.
8OFHUGHEULGHPHQW
There was a statistically signiicant difference in the 
time to debridement between the three treatment 
groups (log-rank test p < 0.0001) (Table 21), and 
also when the two larvae groups were combined 
and compared with hydrogel (Table 22; Figures 
7 and 8). The median time to debridement was 
shorter for the loose larvae (14 days, 95% CI 10 to 
17 days) compared with 28 days (95% CI 13 to 55 
days) for bagged larvae and 72 days (95% CI 56 
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to 131 days) for hydrogel. However, the difference 
in time to debridement between loose and bagged 
larvae was not signiicant when compared in 
the Cox proportional hazards model (p = 0.22). 
As larvae had a statistically signiicant effect on 
debridement, compared with hydrogel, the results 
from the Cox model are presented for each type of 
larvae separately.
Table 23 shows the results from the adjusted 
analysis of time to debridement after adjustment 
for the same factors used in the time to healing 
analysis. The hazard of debriding at any time in the 
loose and bagged larvae groups was approximately 
twice that of the hydrogel group with the hazard 
ratios for loose larvae compared with hydrogel 
being 2.56 (95% CI 1.76 to 3.71) and 2.06 (95% 
CI 1.39 to 3.03) for bagged larvae compared 
with hydrogel. The only other factor that was 
signiicantly related to time to debridement was 
baseline ulcer area (p = 0.02) with larger ulcers at 
baseline having a reduced risk of debriding. There 
was no evidence that debridement rates differed 
between trial centres (p = 0.17). Model assumptions 
were checked using the same methods as for the 
time-to-healing analysis and there was no evidence 
of any departures from the proportional hazards 
assumption for any of the factors in the model. 
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Sensitivity analyses investigating the effect of centre 
also did not alter any of the conclusions.
+HDOWKUHODWHGTXDOLW\RIOLIH
The SF-12 questionnaire was used to assess self-
reported HRQoL at baseline, and 3, 6, 9 and 
12 months. Descriptive statistics of the PCS and 
MCS scores are presented in Tables 24–26 and 
Figures 9 and 10. Descriptive statistics of the other 
component scores are presented in Table 27. Only 
the PCS and MCS have been analysed, all other 
components are presented descriptively. In all cases 
the minimum, and worst, score possible was 0 and 
the maximum was 100.
The mean PCS and MCS for the trial population 
at baseline were both lower than the mean values 
for the general US population. The median age 
of the VenUS II population was 76 years so we 
have compared the mean baseline scores of the 
participants with the US norm-based scores for 
individuals aged 75 and above.132 For the PCS the 
means (SD) were 33.3 (11.4) for the larvae group 
and 35.9 (11.5) for the hydrogel group, compared 
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with 37.9 (11.16) for the general US population. 
For the MCS the baseline means were 46.9 (12.3) 
for the larvae group and 47.2 (11.0) for the 
hydrogel group, compared with 50.4 (11.66) for 
the general US population. This implies that the 
trial population had a low overall quality of life 
in terms of physical and mental health compared 
with a similar age group in the USA. Figure 9 shows 
the mean PCS (and 95% CI) by larvae or hydrogel 
group, over time. This shows that there was little 
difference between the treatment groups at any 
time and no clear pattern of improvements over 
time.
For the MCS the mean scores for the larvae group 
increased slightly and then remained constant 
whereas the hydrogel group scores were more 
variable but differences over time for both groups 
were very small (Figure 10). Each of the PCS and 
MCS scores were compared between the larvae and 
hydrogel groups using two analysis methods. Firstly 
an overall measurement was computed for each 
participant; the SAUC, and compared between the 
groups using a Wilcoxon rank sum test (Table 26). 
There was no evidence of a difference between the 
treatment groups for PCS (median values of 0.4 
for larvae and – 0.5 for hydrogel indicating a small 
average deterioration in the hydrogel group but no 
evidence of a difference between groups; p = 0.25). 
The result for the MCS was similar (p = 0.95, with 
median values of – 0.8 for larvae and – 0.7 for 
hydrogel).
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We also itted a repeated measures multilevel 
regression model to the PCS and MCS scores. The 
values at 3, 6, 9 and 12 months were the outcome 
measures, and the baseline value, treatment 
group and time were included as ixed effects. 
The interaction between treatment and time was 
assessed for inclusion but was not signiicant in 
either model. Different covariance patterns were 
assessed for the repeated measurements within 
participants but the results were similar so an 
unstructured covariance matrix was used. For the 
PCS, there was no evidence of an overall difference 
between larvae and hydrogel (p = 0.75) and the 
mean PCS score (over all follow-up assessments) 
was 34.4 (95% CI 32.95 to 35.84) for larvae and 
34.0 (32.14 to 35.98) for hydrogel. Similar results 
were obtained for the MCS where there was also 
no evidence of a difference between larvae and 
hydrogel (p = 0.82). The mean MCS score (over all 
follow-up assessments) was 46.56 (95% CI 44.79 
to 48.34) for larvae and 46.88 (44.83 to 49.27) for 
hydrogel.
In terms of missing HRQoL data, of the 
participants that healed 25% (loose larvae), 25.6% 
(bagged larvae) and 15.8% (hydrogel) did not 
return forms subsequent to healing. In contrast, 
for those participants who did not heal 60.9% 
(loose larvae), 62.8% (bagged larvae) and 63.3% 
(hydrogel) had HRQoL forms missing at trial exit. 
Most participants with missing HRQoL data had 
all data missing after a particular assessment, and 
these numbers suggest that those participants 
with more severe ulcers or worse general health 
were less likely to return questionnaires. However, 
summary statistics of PCS and MCS scores by 
healing status (data not shown) showed similar 
scores at baseline for those participants who later 
healed or did not heal and these were similar 
to the mean values by group. Repeating the 
repeated measures modelling to compare healed 
and non-healed patients showed no evidence of 
any differences in overall PCS between healed 
and unhealed patients (p = 0.80) but that healing 
status had an effect on the MCS (p = 0.004) with 
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healed patients having a better mental health score 
(difference in means 4.30, 95% CI 1.42 to 7.18). We 
are planning to undertake further analyses using 
these data and data from the ongoing HTA-funded 
VenUS III trial to explore the impact of ulcer 
healing on patient quality of life.
0LFURELRORJ\
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Table 28 shows summary statistics of the baseline 
bacterial count (logs to base 10) and the within-
participant change over time (baseline to inal) 
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for three different groups of participants: (1) all 
participants (to last available swab); (2) only those 
participants who debrided (to last available swab 
during the debridement treatment phase); (3) 
participants who did not debride (change from 
baseline to last available swab). The average log 
bacterial count at baseline was 6.5 (approximately 
3.1 × 106 copies/ml) and the three treatment 
groups were similar. The summaries of the within-
participant change from baseline show that on 
average, most participants, regardless of whether 
or not they debrided, had very little change in the 
bacterial load of their ulcer over time with median 
log differences in the range of – 0.5 to 0.2 copies/
ml.
To investigate whether there were any differences 
between the larvae and hydrogel treatments in 
reducing the bacterial load of the ulcer, a repeated 
measures analysis (linear random coeficients 
model) was used. Two models were used; one 
analysed data from all available swabs for each 
participant; the other used only swab data up to 
the point of debridement for those participants 
who debrided and to the end of the trial for any 
participants who did not debride. The results 
for the model using all data and for the model 
using only data up to debridement are in Table 29. 
When using all swab data there was no evidence 
of a difference in bacterial load over time between 
larvae and hydrogel [p = 0.75, estimate of the mean 
log bacterial count (standard error) for larvae was 
6.59 copies/ml (0.06) and for hydrogel it was 6.64 
copies/ml (0.08)]. Time had a signiicant effect 
(p = 0.01) indicating that overall ulcer bacterial 
load decreased over time, but the interaction 
between treatment and time was not signiicant 
(p = 0.63) indicating that decreases in bacterial load 
over time did not differ between the larvae and 
hydrogel groups.
When analysing only swab data up to the point 
of debridement, there was also no evidence of a 
difference between the larvae and hydrogel groups 
[p = 0.86, estimate of the mean log bacterial 
count (standard error) for larvae was 6.72 copies/
ml (0.07) and for hydrogel it was 6.73 copies/ml 
(0.09)]. Furthermore, there was no evidence of a 
time effect and bacterial load appeared to remain 
constant over time (p = 0.91), and again there was 
no evidence that the effect of time differed between 
the larvae and hydrogel groups (p = 0.65).
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Overall only 18 out of 267 participants (6.7%) had 
MRSA detected in their baseline ulcer swab, of 
whom seven were in the loose larvae group, ive in 
the bagged larvae group and six in the hydrogel 
group (Table 30). MRSA was absent from swabs 
taken at the end of the debridement phase [to 
debridement if they debrided, or the end of the 
trial period if they did not debride (one loose and 
one hydrogel)] in 100% (5/5) of participants in the 
bagged larvae group, 57.1% (4/7) of participants 
in the loose larvae group and 50% (3/6) of the 
hydrogel participants. Three participants in the 
loose larvae group but none in the other groups 
had a recurrence of MRSA after debridement.
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We compared the proportions of participants with 
MRSA detected at baseline who were free from 
MRSA by the end of the debridement treatment 
(Phase 1) – there was no evidence of a difference 
between the larvae and hydrogel groups (75% or 
9/12) compared with the hydrogel group (50% or 
3/6), Fisher’s exact test p = 0.34). This analysis was 
repeated for the proportion of participants testing 
negative for MRSA who were found to have MRSA 
at one or more follow-up assessments and again 
there was no evidence of a difference between 
the larvae and hydrogel groups (7.1% or 12/168) 
compared with 2.5% (2/81), Fisher’s exact test 
p = 0.16.
8OFHUUHODWHGSDLQ
Using the SF-12 we collected data about general, 
bodily pain, at 3-monthly intervals. We also 
collected data about ulcer-related pain and 
enquired about the intensity of pain experienced 
over the previous 24 hours both at baseline 
and when the debridement treatment was irst 
removed. Participants indicated the intensity of 
pain they had experienced on a VAS, the scale of 
which ranged from no pain (0 mm) to worst pain 
imaginable (150 mm), midpoint 75 mm. Mean 24-
hour ulcer-related pain scores at the irst dressing 
removal during the debridement treatment were 
twice as high in the larvae group compared with 
the hydrogel group (Table 31). The difference in 
the ulcer-related pain score over the previous 24 
hours was compared between larvae and hydrogel 
after adjusting for baseline pain score, log ulcer 
duration and log ulcer area (Table 32). There was 
signiicantly more pain experienced by both larvae 
groups (p < 0.001) compared with hydrogel, with a 
difference in pain score for loose larvae compared 
with hydrogel of 46.74 (95% CI 32.44 to 61.04) and 
for bagged larvae compared with hydrogel of 38.58 
(95% CI 23.46 to 53.70).
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Adverse event data were collected by the treating 
nursing staff. Nurses classiied events as non-
serious or serious and treatment-related or non-
treatment-related. In total, 131 participants had 
340 adverse events. Of these 13.8% were classed as 
serious. More participants receiving larval therapy 
experienced one or more adverse events compared 
with hydrogel participants (51.7% compared with 
43.7%) However, this difference was not statistically 
signiicant [chi-squared test statistic 1.50 (1 df), 
p = 0.22]. We also compared the total number of 
events experienced by each participant (larvae 
versus hydrogel) using a negative binomial model, 
adjusting for the prognostic factors used in the 
randomisation (ulcer type, baseline ulcer area 
and duration) and again there was no evidence of 
a difference [chi-squared test statistic 2.65 (1 df), 
p = 0.10]. Details of all adverse events reported are 
shown in Table 33.
6XPPDU\RIFOLQLFDOÀQGLQJV
• Median times to healing were 236 days (95% 
CI 147 to 292 days) for larval therapy and 245 
days (95% CI 166, not estimable) for hydrogel 
therapy. In an adjusted analysis there was no 
evidence of a difference between larval and 
hydrogel therapy in the time to healing of 
venous and mixed venous/arterial leg ulcers 
(p = 0.54) or between loose and bagged larvae 
(p = 0.66).
• Larval therapy debrided ulcers signiicantly 
faster than hydrogel (p < 0.0001). Loose larvae 
debrided most quickly with a median time 
to debridement of 14 days (95% CI 10 to 17 
days) compared with 28 days (95% CI 13 to 55 
days) for bagged larvae and 72 days (95% CI 
56 to 131 days) for hydrogel. However, in an 
adjusted analysis the difference between loose 
and bagged larvae in debridement times was 
not statistically signiicant (p = 0.22).
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• Initial ulcer area and ulcer duration were both 
statistically signiicant predictors of time to 
healing, but only area was signiicantly related 
to time to debridement.
• There was no statistically signiicant difference 
between the larval and hydrogel groups 
with respect to scores on the PCS (p = 0.81) 
and MCS (p = 0.97) of the SF-12 HRQoL 
assessment. Other SF-12 components showed 
similar results between treatment groups and 
little change within treatment groups over 
time.
• Only 6.7% of participants had MRSA detected 
in their ulcers at baseline. There was no 
statistically signiicant difference between 
larval and hydrogel therapy in the proportions 
with MRSA eradicated by the end of the 
debridement phase (p = 0.34) although the 
numbers were very small. There was also no 
statistically signiicant difference between 
treatments in the reduction of bacterial load 
during debridement treatment.
• Recipients of larval therapy reported 
signiicantly more pain (p < 0.001) in the 
previous 24 hours at the removal of the 
irst debridement treatment compared 
with hydrogel recipients. Mean pain scores 
(measured using a VAS scale) for each of loose 
and bagged larvae being around twice those of 
the hydrogel participants.
• Slightly more larval therapy recipients reported 
one or more adverse events, but the numbers 
of events classed as serious and the overall 
numbers of events were similar between 
treatment groups.
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A total of 267 people were recruited into VenUS II: 94 were allocated to receive loose larvae, 
86 to receive bagged larvae and 87 to receive 
hydrogel. There were eight participants for whom 
we were unable to report any resource use data 
(recorded as missing values throughout).
5HVRXUFHXVHDQGFRVWV
7ULDOGHEULGHPHQWWUHDWPHQW
The number and duration of trial debridement 
treatments are described in Table 34. Participants 
receiving larval therapy obtained their irst 
treatment application approximately 3 days later 
than participants allocated to hydrogel (because 
of the need for ordering and delivery). Those 
allocated to one of the larval therapy arms had, on 
average, 1.45 trial treatment applications before 
the debridement treatment was discontinued 
(i.e. participant was moved to Phase 2) or data 
were censored. Participants in the hydrogel arm 
received, on average, 9.2 applications of Phase 1 
treatment before being moved onto Phase 2 or data 
were censored.
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Nineteen participants never received the trial 
debridement therapy (see Figure 4). Data regarding 
nurse visits were missing for 14 participants, 
while ive people received a treatment other than 
the trial treatment (one in the loose larvae arm 
and four in the hydrogel arm). The duration of 
Phase 1 (debridement) treatment was, on average, 
30 days longer in the hydrogel arm (mean days of 
treatment 43 days) than the larval therapy arms 
(mean days of treatment 12 to 13 days).
The average estimated cost of the trial 
debridement treatment, per application was: loose 
larvae £71.70 (SD £13.40; minimum to maximum 
£51.50 to £132.50); bagged larvae £111.90 (SD 
33.6; minimum to maximum £80.10 to £218.50) 
and hydrogel £1.50 (SD 0).
9LVLWVWRIURPKHDOWK
FDUHSURYLGHUV
Visits to and from health care providers were 
recorded by participants and used for the base-
case analysis. These self-reported data suggested 
that the number of consultations with health care 
(FRQRPLFDQDO\VHV
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professionals was similar in each trial arm (Table 35) 
with the majority of nurse and hospital visits being 
related to ulcer treatment.
The proportion of visits that took place at home 
was similar between all arms (63% for the loose 
larvae arm and 64% for bagged larvae arm; 67% 
for hydrogel). A summary of the unadjusted ulcer-
related costs of health care provider visits for each 
of the trial treatments is presented in Table 36.
&RPSUHVVLRQWKHUDS\
The use of high-compression bandaging through 
the trial was similar across all arms (Table 37).
7RWDOFRVWV
The cost of nurse visits was the major driver of total 
costs. In the base-case analysis, patient-reported 
data on ulcer-related visits to and from health care 
providers were combined with trial debridement 
treatment costs and compression therapy. Quarterly 
estimates are presented in Table 38.
To account for the censored nature of cost data, 
mean differences in ulcer-related costs between 
treatments were estimated using inverse probability 
weighted regression estimates of time to survival. 
The results of the base-case analysis show that 
larval therapy costs, on average, £96.70 more 
per participant per year (95% bias corrected 
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CI –£491.90 to £685.80) (Table 39). This difference 
was not statistically signiicant.
+HDOWKEHQHÀWV
0HDQWLPHWRKHDOLQJ
The difference in estimated mean time to healing 
(over 12 months) favoured larval therapy. On 
average, participants treated with larval therapy 
healed 2.42 days before those in the hydrogel 
arm. However, this difference was not statistically 
signiicant (95% bias corrected CI of the difference 
was from – 40.95 days to 31.91 days) (see Table 40). 
Estimation through the restricted mean approach 
(see Chapter 2) returned 2.74 additional ulcer-
free days for larval therapy users, conirming the 
appropriateness of the IPW regression.
8WLOLW\DQG4$/<V
Quarterly utility scores per participant by trial arm 
are presented in Table 41 and unadjusted average 
QALYs per group are described in Table 42. The 
results show that, after adjustment for original 
imbalances in utility scores at baseline, stratiication 
covariates and after accounting for the censored 
nature of data, individuals in the larval therapy 
arms had, on average, a better quality of life 
than individuals in the hydrogel arm [the annual 
difference in QALYs was 0.011 (95% CI – 0.067 to 
0.071), see Table 43].
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&RVWHIIHFWLYHQHVV
DQGXQFHUWDLQW\
Our base-case analysis showed that participants 
randomised to receive larval therapy for 
debridement had slightly greater health beneits 
at 12 months but also incurred higher costs than 
hydrogel users, though none of these differences 
were statistically signiicant. In these circumstances 
we use a decision rule to assess whether the 
treatments are cost-effective; we do this by 
combining our estimates of differential costs and 
health beneits as a ratio, the ICER. That is the 
ratio of the mean difference in cost between the 
alternative treatments and the mean difference in 
health beneits between the alternative treatments. 
The ICER associated with larval therapy use was 
estimated at £8826 per QALY gained and £40 
per ulcer-free day. The point estimates of cost 
and effect differences were small relative to their 
standard error, indicating that the uncertainty 
around the decision to adopt larval therapy is high.
To investigate the uncertainty of the mean 
difference in costs and health beneits between trial 
arms we used the incremental cost-effectiveness 
plane, where we graphically plotted the results of 
4000 replicates of the non-parametric bootstrap 
of the mean difference in cost and health beneits 
(QALYs, ulcer-free days).
As Figure 11 shows, the cost and effectiveness pair 
replicates fall in all the quadrants of the plane in a 
fairly symmetrical way, suggesting that differential 
costs and health beneits can go in any possible 
direction. This suggests that there is considerable 
uncertainty associated with the mean differential 
cost and mean differential effectiveness between 
the larval therapy and hydrogel arms. In turn, 
this implies that there is considerable uncertainty 
associated with the cost-effectiveness of larval 
therapy when compared with hydrogel.
Although in 24% of the simulations our point 
estimates of cost–utility suggested a better 
(FRQRPLFDQDO\VHV
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performance of the comparator treatment (larval 
therapy was dominated, NW quadrant), in a non-
negligible proportion of cases (27%) the results 
favoured larval use for debridement (larval therapy 
dominated, SE quadrant).
The CEAC (Figure 12) indicates that the probability 
of larval therapy being cost-effective when 
compared with hydrogel is almost constant at 50% 
for a range of willingness-to-pay values. This result 
is a direct consequence of the distribution of the 
cost-effectiveness cloud, where the joint density for 
costs and effects is almost evenly spread through 
the four quadrants of the cost-effectiveness plane 
(Figure 11); suggesting that larval therapy and 
hydrogel have similar costs and effects in the 
treatment of sloughy leg ulcers. As expected, the 
decision uncertainty evaluated at a willingness-
to-pay value equal to the ICER indicates that 
when compared with hydrogel, larval therapy has 
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approximately a 50% probability of being cost-
effective in the treatment of sloughy leg ulcers.
6HQVLWLYLW\DQDO\VHV
Sensitivity analyses were conducted focusing on 
resource-use estimates and cost parameters. Firstly, 
the use of nurse-reported data on nurse visits and 
hospitalisations was evaluated. The number of 
visits (calculated from data collected by nurses) was 
slightly lower than that recorded by patients, but 
again was similar for all arms. This difference may 
be related to the fact that nurses did not collect 
data after healing (Table 44). The use of nurse-
reported data allowed us to distinguish between 
hospital visits and inpatient stays and cost them 
appropriately.
Amputation was identiied as inluential for 
adjusted cost differences between arms, and 
consequently two scenarios were evaluated, one not 
considering costs associated with amputations and 
the other including amputation costs.
6FHQDULRQXUVHUHSRUWHG
GDWDH[FOXGLQJDPSXWDWLRQ
Unadjusted costs estimated using nurse-reported 
visit data indicated that bagged larvae were more 
costly (Table 45). Conversely, patient-reported costs 
data indicated that loose larvae were more costly. 
The adjusted analysis of costs estimated smaller 
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costs for larvae users (– £31.30); however, this 
was not statistically signiicant (Table 46). As only 
costs are subjected to sensitivity analysis, the cost-
effectiveness/utility was based on the health beneits 
estimates of the base-case analysis (Tables 40 and 
43). The decision to adopt larval therapy was 
associated with considerable uncertainty (Figures 13 
and 14).
6FHQDULRQXUVHUHSRUWHGGDWD
LQFOXGLQJDPSXWDWLRQFRVWV
The cost estimates for this scenario show that 
unadjusted total costs incurred by participants in 
the hydrogel group are higher than for the larval 
therapy groups (Table 47). Adjusted cost estimates 
(Table 46, scenario 2) conirm this result, suggesting 
that the use of larval therapy may reduce costs by 
£227 per patient per year. The CEAC and cost-
effectiveness plane show that the probability of 
larval therapy being cost-effective varies between 
55% and 75% for a willingness-to-pay range 
between 0 and £30,000 (Figures 15 and 16). The 
scenarios further explained the uncertainty 
surrounding the decision of adopting larval 
therapy. Although the number of participants who 
had an amputation is very low (three participants), 
the high costs incurred shifted the estimate of 
cost difference. As information on this event was 
not collected systematically but only through 
‘reason for hospitalisation’ data, we might be 
underestimating the event rate and consequently 
biasing the cost estimates. Nevertheless, 
amputation is revealed to be an important cost 
driver for leg ulcer participants.
2QHZD\VHQVLWLYLW\DQDO\VLV
As identiied across other studies in wound care, 
both the setting and the duration of nurse visits 
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are important in the evaluation of cost differences. 
A one-way sensitivity analysis was conducted to 
evaluate the inluence of nurse visit costs on the 
cost difference. To this end, duration of nurse visits 
was increased/reduced by up to 13 minutes, i.e. 
the maximum reduction evaluated was 13 minutes 
and the maximum increase was 13 minutes from 
base-case values. As a consequence, a 5-minute 
reduction in clinic visit duration from the base-case 
analysis resulted in values of 31 minutes for a home 
visit and 17 minutes for a clinic visit (see Table 9 in 
Chapter 2).
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The sensitivity analysis shows that homogeneously 
reducing visit duration increases the cost difference 
(Figure 17). A 5-minute reduction in each visit 
increases the cost difference to £132 [bias corrected 
95% CI (£– 408.90 to £652.10)]. While the 
differences were not statistically signiicant, the 
uncertainty surrounding the cost difference reduces 
as the visit duration reduces.
The ratio of clinic to nurse home visit duration was 
subjected to sensitivity analysis. In the base-case 
analysis this ratio was 40 : 22, and in the sensitivity 
analysis it varied between 30 : 22 and 60 : 22.
As the duration of home visits increases in relation 
to clinic visits, the cost difference reduces and the 
uncertainty increases, i.e. conidence intervals are 
wider (Figure 18). None of the scenarios considered 
in the sensitivity analysis revealed a statistically 
signiicant difference in costs at conventional levels 
of signiicance.
6XPPDU\RIFRVW
HIIHFWLYHQHVVGDWD
• The estimated mean cost per application (£) 
of trial debridement treatments was higher for 
larvae than hydrogel. Both the use of high-
compression bandaging and the number of 
visits to and from health care professionals 
were similar across all groups.
• Nurse visits were the major cost driver. The 
adjusted annual cost difference between larval 
(FRQRPLFDQDO\VHV

therapy and hydrogel was estimated as £96.70 
(larvae more expensive), but this difference was 
not statistically signiicant (95% bias corrected 
CI varied from £–491.90 to £685.80)
• On average, participants treated with larval 
therapy healed 2.42 days before those in 
the hydrogel arm and had more QALYs 
(annual difference was 0.011). However, these 
differences were not statistically signiicant 
(95% bias corrected CI – 40.95 to 31.91 gains 
in healed days and – 0.067 to 0.071 QALYs 
gained).
• The ICER associated with larval therapy use 
was estimated at £8826 per QALY gained 
and £40 per ulcer-free day. The nature of the 
uncertainty associated with our estimates of 
mean costs and health beneit suggests that 
larval therapy and hydrogel are likely to have 
similar costs and effects in the treatment of 
sloughy leg ulcers.
• Using nurse-reported data as an alternative 
information source for resource use returned 
smaller but non-signiicant adjusted costs 
for larval therapy compared with hydrogel 
(– £31.30). When amputation costs were 
included, this cost difference decreased to 
– £227. While larvae are dominant in these 
scenarios, these results are associated with high 
levels of uncertainty.
• One-way sensitivity analyses did not show any 
effect of altering the duration of nurse visits on 
the overall conclusions of the cost-effectiveness 
and cost–utility assessments.
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3DWLHQWLQWHUYLHZHHV
Participants were recruited from three clinical 
sites involved in VenUS II. Purposive sampling 
was used to ensure representation from patients 
who received their leg ulcer treatment in different 
clinical settings (at home and in clinics), to ensure 
inclusion of people of minority ethnic origin and 
of people who both had and had not experienced 
larval therapy as treatment for their leg ulcer.
In total, 18 participants were recruited to this 
qualitative study. Fourteen participants with leg 
ulcers were recruited into the study from those 
attending vascular clinics; one attached to a 
hospital (Bradford) and one in a community setting 
(Bolton) during April and July 2007. On arrival for 
their appointment at the clinic in Bolton, potential 
participants were informed about the study by the 
clinic nurse, and provided with an information 
sheet. A member of the research team (J.D.) was 
on hand to give a full explanation of the study and 
answer any questions or concerns. Participants 
who consented to take part in the study were then 
interviewed after their clinical consultation had 
taken place by the nurse researcher (D.M.). At 
the Bradford clinic, patients were given written 
information and a verbal explanation of the study 
(using the services of interpreters where necessary) 
at least one week in advance of the interviewer 
attending the clinic. Subsequently, interpreters 
assisted in gaining the consent of, and conducting 
interviews with two participants (P12 and P14).
A further four patients, who were receiving 
treatment for leg ulcers in their own homes 
were recruited through referral from a team of 
community nurses (based in York) in March and 
June 2007. These patients were told about the 
study by the community nurse involved in their 
care, and those who wished to hear more agreed 
to being contacted by the researcher (D.M.), who 
provided them with a full verbal explanation and 
written information about the study, before their 
deciding whether they wished to participate. One 
patient referred by a nurse declined to take part in 
the study, because he said he doubted its value.
3DWLHQWSDUWLFLSDQW
FKDUDFWHULVWLFV
Details of the study participants are given in Tables 
48 and 49, based on their previous experience of 
larval therapy. In summary, 12 study participants 
were male, with ages ranging from 29 to 93 
years (median age 64 years). The ages of the six 
female participants ranged from 62 to 76 years 
(median age 69.5 years). Fifteen participants were 
White British, one (male) was Asian (Pakistani), 
one (male) was Iraqi and one (female) was Black 
Caribbean. Duration of participants’ current ulcer 
ranged from 1 month to 108 months (median 36 
months; mean 44 months).
Five of the 18 participants had experience of 
being treated with larval therapy. Of these ive 
participants, three were male and two were 
female; one female participant had experienced 
loose larvae, and one bagged larvae; two male 
participants had experienced bagged larvae and 
one loose larvae. Of the 13 participants who had 
never been treated with larval therapy, 10 were 
male and three were female.
3DWLHQWH[SHULHQFHVRI
OLYLQJZLWKDOHJXOFHU
Many of the participants described lives that were 
disrupted or diminished because of their leg ulcers, 
which they associated with pain, restricted mobility, 
weight gain, odour, disturbed sleep (their own 
and their partners’), loss of physical and economic 
independence, reliance on medication, social 
embarrassment and low mood.
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3DLQ
While some participants said they were able to 
‘shrug off ’ or tolerate pain from their ulcers, others 
described excruciating pain which kept them awake 
at night, or led them to depend on medication to 
enable them to sleep.
Varying levels of pain were attributed to the stage 
of healing of their ulcer, to external factors, such as 
hot weather, and to the application of compression 
bandaging.
they don’t hurt me, I’m one of those people who can 
suffer pain I think. (P17)
you get quite depressed, the pain is obnoxious, 
absolutely obnoxious. (P10)
you’re just going to sleep and then it ‘whoa, what the 
hell?, and it wakes you up. It’s only the ulcer telling 
you ‘I’m here’, isn’t it? The pain of it wakes you 
up… (P7)
it’s a lot better, at the beginning I was taking a lot of 
pain killers, but I don’t take any now. (P18)
I was having to keep the leg outside the covers 
because the heat was making it worse. (P18)
the pain sometimes goes, like after a day or two on 
your tablets it will subside and it’ll be okay, but then 
you come to get it redressed and you know you are 
going to get pain after the redressing of the bandages. 
(P11)
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0RELOLW\
The majority of the participants interviewed 
attributed lack of mobility to comorbidities such 
as osteoarthritis (resulting in stiff knees and hips) 
rather than to pain from their ulcer. However, the 
two youngest male respondents (P5 and P14) said 
that their leg ulcers restricted how far and for how 
long they could walk, which had a negative effect 
on their ability to work.
Although some participants were determined that 
they would not let their ulcer ‘slow them down’, 
others highlighted some of the physical and 
psychological consequences of immobility because 
of their ulcer pain. Reduced mobility was perceived 
as linked to social isolation and a dependence on 
others (P16). The importance of being able to drive 
to keep up social contact with his family and friends 
was stressed by P15.
I don’t let it slow me down, I mean I struggle 
with my walking anyway because I am waiting for 
an operation on my left hip…so my movement is 
relatively slow and limited. (P2)
I was avoiding walking, you know, I need to do more 
walking to get back some level of physical itness and 
get rid of that… [pats his stomach] (P1)
I can’t walk, I can’t really walk more than 100 
metres without feeling, well not severe, but average 
pain and I have to stop. (P5)
I can move and walk for one hour, two hours, but 
more than that, no…it hurts me a lot and sometimes 
makes me fed up with life. (P14)
it means that I can’t walk, I can’t go out, I can’t go 
into [name] or on the bus to [name] where I used 
to…so I do miss going out, yes I do…walking down 
to the post ofice to get my pension… but I haven’t 
been able to, so my daughter-in-law does a lot for 
me… (P16)
I can drive, once I get into my car, not far, but I can 
drive, yes… (P15)
6RFLDOHPEDUUDVVPHQW
Having to wear special clothes or shoes to 
accommodate compression bandaging was 
associated with social stigma by three (male) 
respondents. Asked about the effect of his leg ulcer 
on his life, P11 responded that it was:
Terrible…when I am in the bandages, the 
compression bandages…this is the only pair of shoes 
I can get in. I take 12s or 13s anyway, so when I’ve 
got the compression bandages, these are the only pair 
of 14s I’ve seen in my life, and I have had to take the 
laces out, so it means unless I go out in these shoes, I 
don’t go out for a meal or anything. (P11)
P6 felt similarly socially curtailed because of 
dificulties in inding shoes to it:
because you can’t get your shoes on when they put all 
these bandages on, you can’t get your shoes on and 
you can’t get dressed up or anything to go out… (P6)
P3 described attracting unwanted glances due to 
his wearing shorts rather than full length trousers 
for comfort with his compression bandages.
if you can get over the embarrassment because you 
are walking around with a bandage on your leg, I 
could wear the pants and then my legs get very hot 
which is bad for them, so I tend to wear shorts, so 
people are always looking at me. (P3)
The pervasive odour emanating from leg ulcers 
was regarded as a further potential source of social 
embarrassment:
it’s like rotten cabbage…it’s like a stinky cabbage…
when it’s really on its bad side, it does not smell very 
nice. (P6)
1XLVDQFHIDFWRU
Having a leg ulcer was perceived as time-
consuming (P3), activity restricting (P5, P6, P7, 
P11, P12, P14, P16) and a general nuisance 
(P10, P13, P15, P18) because of having to attend 
regular clinic appointments, spending time (and 
sometimes money) in consultations with doctors 
and nurses, and running into dificulties pertaining 
to care of the ulcer when travelling away from 
home.
it is time-consuming, it does restrict you to go 
anywhere, you’ve got to allow time for it. (P3)
within a fortnight I saw a specialist, if you pay, you’ll 
get in that much earlier… (P15)
when I went to see the Dermatologist at the hospital, 
she did suggest the pressure bandage…but that 
created its own problems, particularly as we go away 
4XDOLWDWLYHVWXG\UHVXOWV

in our motor home and each time we were going 
away, I was having to contact local surgeries in the 
area we were travelling to… (P18)
¶(YHU\WKLQJXQGHUWKH
VXQ·OHJXOFHUWUHDWPHQWV
RWKHUWKDQODUYDOWKHUDS\
FLWHGE\SDUWLFLSDQWV
The majority of participants reported having tried 
more than one type of treatment for their ulcer (see 
Table 50), in the form of compression bandaging, 
gels and dressings, creams and ointments. One 
participant, P15, said he had been treated with 
gentian violet and potassium permanganate on the 
respective recommendations of a doctor abroad 
and one in the UK. P9 simply said that she had 
tried ‘everything under the sun’.
Participants’ descriptions of the treatments they 
received for their leg ulcers were couched in terms 
that suggested little or no real involvement on their 
part in the decision-making process about choice of 
treatment.
they tried honey at irst but it was too painful…
they’re using like an iodine ointment now, which 
seems to be doing the trick…it started healing, so they 
said, well, let’s carry on… (P1)
While some participants appeared to have 
complete faith in professional expertise, others 
voiced concern about the effectiveness or side 
effects of the various treatments used on them, or 
about the ways in which they were administered.
he is not sure of what they are actually using, but 
they are doing their best they can for him and he is 
grateful for the help that he is getting, he says what 
ever they feel is appropriate that they are using, 
dressings and bandages and so on. 
(P12 via interpreter)
then they suggested the up and coming thing is 
the honey treatment…and I were getting shocking 
nights, they were burning and I kept complaining 
about it, my leg was terribly raw and they said, ‘well, 
it could be it’s doing it’s job, so I said ‘Okay’, and I 
ploughed on… (P15)
each time the bandage was being put on, by different 
people, sometimes it was too tight, sometimes it was 
not tight enough… (P18)
P15 expressed concern about the lack of 
consistency of approach to the application of 
treatments by members of community nursing 
teams:
the trouble is, you never see the same person every 
day, or every visit, I suppose I’ve got about ive or six 
different nurses that will come and attend to my leg, 
and none of them do it the same way…they all do it 
slightly differently... (P15)
P7 was more pointed in his criticism of ‘district 
nurses’ (community nurses) and drew an 
unfavourable comparison between them and the 
nurses working in the vascular clinic.
I thought, I want to be getting to that ulcer centre at 
[name], they look after you here…they look after you 
better than the district nurses…I mean they assess 
you…and they know what they are doing. I have 
great faith in these people. (P7)
3DWLHQWDWWLWXGHVWRDQG
H[SHULHQFHVRIODUYDO
WKHUDS\RYHUYLHZ
A brief overview of data relating to acceptability 
of larval therapy, preferences for loose or bagged 
larvae, and participants’ previous experience of 
handling maggots is presented here, followed by a 
more detailed analysis of the qualitative interview 
data.
$FFHSWDELOLW\RIODUYDOWKHUDS\
The majority of the participants interviewed stated 
that they would be prepared to have larval therapy 
as a treatment for their leg ulcer. Five out of the 18 
participants had tried larval therapy, and a further 
10 participants said that they would be willing to 
try it.
Two respondents (P13 and P16; both female and 
aged 76 years) stated categorically that they would 
not ind larval therapy acceptable under any 
circumstances. However, interestingly, one of these 
participants, (P16) revised her opinion during the 
course of the interview when she learnt that larvae 
were obtainable in ‘bagged’ form; this prompted 
her to say that she might be prepared to consider 
having larval therapy.
One respondent (P8) was equivocal about whether 
or not he would accept larval therapy. He said he 
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would need to be convinced of its effectiveness 
before he could make a decision. Figure 19 
summarises participants’ responses to the question 
posed during interview concerning acceptability of 
larval therapy.
Of the 15 respondents who said that they would be 
prepared to accept, or had accepted, larval therapy 
as treatment, 13 said that they would be prepared 
to accept either loose or bagged larvae. Of the two 
remaining participants, one said he was unsure 
about whether he would prefer to have loose or 
bagged larvae, stating that he would wish to know 
more about the effectiveness of the different types 
and to be shown them before he could express 
a preference, while P18 had been recruited to 
VenUS II and had been randomised to receive 
loose larvae. Given a choice, she said she ‘might 
have preferred’ to have had bagged larvae, but she 
emphasised that this was not a strong preference as 
she ‘didn’t mind having the loose’.
3ULRUH[SHULHQFHRI
ODUYDHJHQHUDOO\
Male participants were more likely than female 
participants to have handled ‘maggots’. Of the 12 
male participants, seven had handled maggots, 
in connection with ishing as a hobby as a child, 
two of whom (P5 and P11) mentioned that they 
Uncertain
n = 1
(6%)
No
n = 2
(11%)
Yes
n = 15
(83%)
Would you be willing to receive larval therapy
as treatment for your leg ulcer?
),*85( 3DWLHQWZLOOLQJQHVVWRWU\ODUYDOWKHUDS\
4XDOLWDWLYHVWXG\UHVXOWV

had held or ‘rolled maggots’ in their mouths when 
ishing. Neither of the male participants who were 
born outside the UK (P12 and P14) had had any 
experience of handling maggots as a child.
None of the female participants mentioned that 
they had handled larvae. P9 said she had seen 
them as a child ‘in a tin’ belonging to her brother 
when he had been going ishing. P16 could not 
recollect if she had actually ever seen larvae, 
though she remembered that her son had used 
them when he went ishing when he was young.
Of the ive participants who had received larval 
therapy (three male and two female), two of 
the males (P11 and P17) said that they had had 
experience of handling maggots, while the other 
three participants (one male and two females) (P15, 
P9, P18) had not.
$WWLWXGHVWRODUYDOWKHUDS\
GHWDLOHGÀQGLQJVIURP
SDUWLFLSDQWLQWHUYLHZV
A range of factors, either alone or in combination, 
appeared to inluence participants’ views and 
decision-making about the acceptability of larval 
therapy. The majority of participants who had 
already accepted, or who said they would be willing 
to try, larval therapy (n = 15) displayed:
• a strong desire to try any treatment that might 
ameliorate or hold out the hope of a cure for 
their leg ulcer
• prior knowledge of, or contact with, ‘maggots’
• an open-minded approach towards new or 
‘alternative’ therapies
• positive health beliefs about the effectiveness of 
larval therapy
• an absence of, or willingness to overcome, any 
feelings of squeamishness about ‘creepy-crawlies’ 
on the part of the participant or their family 
members.
Participants who appeared less willing (P8), or 
unwilling, (P13, P16) to accept larval therapy 
exhibited squeamishness or strong feelings of 
aversion to the idea of larval therapy; had had 
little, or no, prior knowledge or contact with 
‘maggots’; were sceptical about whether larval 
therapy would be beneicial, or believed that 
it could cause harm; and were supported in 
their views by their family members (with the 
exception of P16, whose son, she said, had actively 
encouraged her to try larval therapy).
)DFWRUVDVVRFLDWHGZLWK
DZLOOLQJQHVVWRDFFHSW
ODUYDOWKHUDS\
¶,·OOWU\DQ\WKLQJ·
Participants’ willingness to try any kind of 
treatment that might hold hope for the 
amelioration or cure of their ulcer was 
encapsulated in the phrase ‘I’ll try anything’, which 
was recurrent in a majority of their accounts of 
living with their leg ulcer. For these people, larval 
therapy was viewed as a last resort, a treatment to 
try when everything else had failed to rid them of 
their ulcer and its associated pain.
basically, I would do anything that would do my leg 
good. (P1)
when you get into a strait with leg ulcers they are 
painful and you can’t ind a cure for them, you’ll do 
anything. (P6)
we just felt it was worth trying anything, because I 
didn’t feel I was getting anywhere very much really, 
and you know, it was worth trying various things 
and seeing if that helped. (P18)
3ULRUNQRZOHGJHRIRU
FRQWDFWZLWK¶PDJJRWV·
Television, newspapers, books about the First World 
War, magazines, nurses, friends and fellow patients 
at the leg ulcer clinic that they attended, were all 
quoted by participants as sources of knowledge 
about larval therapy, which contributed to them 
developing positive views of how it might be 
beneicial in treating their ulcer.
I’ve seen on the television they’ve used them – was 
it about Florence Nightingale, and it eats only dead 
tissue, not live tissue. It’s not like it’s going to bore 
into your leg and inish up at your heart or your 
head or somewhere, no, it only eats dead tissue. (P2)
they found this in 1916 with the chaps laid in 
trenches for days…they were full of maggots, but the 
wound was clean… (P17)
P7 recounted an article in a magazine reporting 
the case of a young girl whose foot was apparently 
saved by the application of larval therapy:
she reckoned that she would have to have her foot off, 
but they put the maggots on and the maggots must 
have ate all the badness or whatever… (P7)
About half the participants who said they would 
be willing to accept larval therapy had handled 
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maggots, usually as a child when they had gone 
ishing. P7 said he had handled them when 
working on a farm:
I’m not frightened of maggots, I can pick a big 
handful in my hand and it wouldn’t bother me one 
bit, the maggots wouldn’t bother me at all. (P7)
P5 and P11 mentioned ‘rolling’ maggots in their 
mouths during ishing trips, while P6 said he had 
bred them speciically for ishing when he had 
observed them closely:
I used to breed maggots myself for ishing and they 
only eat bad stuff. If you put good stuff there they 
won’t touch it… (P6)
Two participants (P12 and P14), born in Pakistan 
and Iraq respectively, constituted ‘negative cases’133 
in that they were willing to try larval therapy, 
although they had never seen or handled maggots, 
or heard of them being used to treat wounds. Their 
expressed willingness to accept larval therapy 
appeared to be based largely in their trust in the 
expertise of health care professionals to do their 
best for them:
they are doctors, they know more than me…so I listen 
to them whatever they say… (P14)
he is saying that if they [health care professionals] 
felt that it would beneit him and would improve his 
health, his ulcer, he wouldn’t have a problem with it, 
no… (P12 via an interpreter)
$QRSHQPLQGHGDSSURDFKWR
QHZRU¶DOWHUQDWLYH·WKHUDSLHV
Participants who were readily accepting of larval 
therapy appeared to have an interest in, and were 
open to, trying new health care technologies, to 
adopt a proactive approach to seeking treatment 
options, and to be prepared to take the risk of 
having new treatments for which there was no 
established evidence base. When asked if she would 
be interested in taking part in a trial of treatments 
for leg ulcers, P10 agreed to participate, even 
before she knew the details of the trial.
at Christmas, when this [her ulcer] was really going 
bad [name] said ‘why don’t you come on one of our 
trials?’ So I said, well, I have nothing to lose, so they 
picked this one, the ultrasound. (P10)
for the majority of people, it is an unknown quantity. 
(P17)
stick them on, by all means! (P7)
P11 was the instigator of his receiving larval 
therapy after hearing about it from the media. 
Disappointed by the lack of interest that he 
encountered initially in his GP and other health 
care professionals, he persevered and inally got 
the treatment he wanted:
They didn’t suggest it. I told them I wanted it…I’d 
heard on radio, television programmes about it so I 
tried at the GP, but they didn’t seem interested in it...
and I tried the clinic I was going to at [name] and 
they didn’t do ‘owt...and when I came to [name] …
the doctor agreed there… (P11)
P18 also tried larval therapy as a result of 
information found in the media. Her husband 
had seen an advert in the local paper about larval 
therapy, and suggested to her that it was ‘worth a 
try’. P18 mentioned that she had used the Internet 
to search for treatments for leg ulcers, especially 
when she irst developed her ulcer, and that she 
was willing to try ‘alternative’ or complementary 
therapies as well as more established treatments.
I’ve tried homeopathic and acupuncture and I go to 
an osteopath, yeah, I tend to look down that route to 
see what there is, rather than down the traditional 
route… (P18)
P1 expressed a general interest in alternative 
approaches to health care, particularly those 
that have been used in the past, but which have 
not always received support from the medical 
profession.
I ind it interesting that medicine in general is going 
back to methods that we used 150 years ago…leeches 
used for the anticoagulant and so many herbal 
remedies that are actually the source of the drugs they 
give in tablet form. I’m just pleased that the medical 
professions are getting a more open mind than it had 
50 years ago, apparently. (P1)
3RVLWLYHEHOLHIVDERXWWKH
HIIHFWLYHQHVVRIODUYDOWKHUDS\
Participants who were willing to accept larval 
therapy appeared to hold strong beliefs that 
‘maggots’ would work as well as, or better than, 
other treatments, such as surgical debridement. 
4XDOLWDWLYHVWXG\UHVXOWV

These beliefs were grounded in their own 
experience of observing or handling maggots, 
anecdotes and media coverage.
P3 had seen a television programme about the use 
of maggots, which had made a strong impression 
on him that they could be extremely effective in 
removing dead or infected tissue and from an 
article that he had read, he assumed they were safe.
years ago I had an accident and I got my leg partly 
run over…there was dead tissue, and they had to cut 
it away…but maggots would probably have got rid 
of that just as easily as the knife…because to get to 
the dead tissue, they had to cut into the good tissue… 
(P3)
when it was explained that they only eat the dead 
tissue and don’t go into the live tissue, there’s no 
problem. (P3)
P5 was the only participant willing to have larval 
therapy who raised signiicant concerns about the 
possibility that they might harm him in some way, 
for example, by causing infection.
I would be open to using maggots, why not?....if it’s 
clean and by putting maggots a wound cannot cause 
any infection…if it can’t cause me any infection, it 
can only be good…if I’ve got proof that it can’t cause 
me any harm… (P5)
$EVHQFHRIRUZLOOLQJQHVVWRRYHUFRPH
IHHOLQJVRIVTXHDPLVKQHVVRQWKHSDUW
RIWKHSDUWLFLSDQWRUWKHLUIDPLO\
All but two of the male participants who were 
predisposed to accepting larval therapy remarked 
that they did not experience any feelings of 
squeamishness or distaste in relation to larvae, 
perhaps because most of them had handled 
maggots at some stage in their lives.
I’ve had them in my hands and everything, I’ve put 
them in my mouth… (P5)
P1 had not been ‘keen’ on handling maggots as a 
child, but said he would be prepared to have larval 
therapy if he thought it would be beneicial for his 
ulcer; (P2) said his feelings were not strong enough 
to deter him from having treatment:
I’m not very keen, you know, sticking worms on the 
end of a hook to go ishing…I’m not sort of one of the 
celebrities in the jungle types, you know stick my head 
in a bag of them! (P1)
I mean, it makes you feel a little squeamish, but no, 
it’s ine, I wouldn’t object. (P2)
None of the female participants interviewed had 
ever handled maggots but of those willing to have 
larval therapy, only one (P4) expressed feelings of 
distaste, related to the thought of maggots ‘eating 
your lesh away’. However, she too believed she 
would be able to overcome these feelings if she 
could be sure that her leg ulcer would be helped by 
larval therapy.
In several cases, the attitudes and feelings of family 
members appeared to play a potentially supportive 
role in participants’ decision-making about whether 
to have larval therapy; in other cases, the fact that 
they were unlikely to object seemed to be taken 
into account in participants’ decision-making. P18 
pointed out that her husband had been the one to 
tell her about larval therapy in the irst instance, 
and that he was ‘quite happy with the idea’ (P18), 
while P2 said his wife was as interested in it as he 
was. Participant 15 had already made the decision 
to accept larval therapy when he was interviewed. 
His wife was present at the interview also, and 
described her initial reaction to the suggestion of 
larval therapy as ‘Yuuuuk’! Nevertheless, she said 
she was willing to try anything to help her husband, 
and referred to the decision they made for him to 
have larval therapy as a joint one. P15’s wife then 
described how she had watched as the loose larvae 
were applied and removed by the community 
nurses in their home.
P6 thought his wife would not object to his having 
larval therapy because both he and her father had 
bred maggots for ishing:
I don’t think she would bother because she used to go 
ishing and I was breeding my own maggots, so she 
wouldn’t bother, and her dad used to go ishing. (P6)
)DFWRUVDVVRFLDWHGZLWKD
UHOXFWDQFHRUXQZLOOLQJQHVV
WRDFFHSWODUYDOWKHUDS\
Factors associated with reluctance or unwillingness 
to accept larval therapy were evident in the 
accounts of three participants (P8, P13 and P16). 
These included: feelings of squeamishness or 
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strong feelings of aversion to larval therapy; little 
or no previous contact with maggots; scepticism 
about the beneits of larval therapy; negative views 
of larval therapy shared by family members.
The accounts of the three participants, derived 
from their interviews, are presented here in the 
form of case studies or summary descriptions106 to 
illustrate how the interplay of these factors could 
lead the participants to say that they would be 
likely to reject larval therapy as a form of treatment 
for their leg ulcer (Boxes 1–3). During the course of 
her interview, P16 appeared to revise her attitudes 
towards larval therapy, as she learnt more about it, 
and as she relected on a discussion she had had 
with her son just before the interview. P8 implied 
that he might be willing to accept larval therapy 
if there was strong enough evidence to support its 
effectiveness in healing ulcers, and if its application 
could be effected in a manner that did not distress 
his wife or cause any domestic upset. P13 seemed 
adamant that she would never consider larval 
therapy an acceptable form of treatment.
3DWLHQWV·H[SHULHQFHV
RIODUYDOWKHUDS\DVD
WUHDWPHQWIRUOHJXOFHUV
GHWDLOHGÀQGLQJVIURP
SDUWLFLSDQWLQWHUYLHZV
Three male (P11, P15 and P17) and two female 
(P9 and P18) participants recruited to the study 
experienced larval therapy as a treatment for their 
leg ulcer. Three of the ive (P9, P11 and P17) had 
experienced bagged larvae and two (P15 and P18) 
had experienced loose larvae.
Participants frequently adopted a narrative style 
to recount details concerning their experiences 
of ‘having maggots’, and used vivid words and 
phrases that conveyed a strong message of what 
the experience meant to the individuals concerned. 
These experiences will be discussed under the 
subheadings below in an attempt to portray those 
aspects which appeared to be of most signiicance 
to the participants and, where appropriate, 
their exact words will be reproduced at length in 
quotation.
3DUWLFLSDQWZDV\HDUVROGDQGKDGKDGKLVXOFHUIRUDSHULRGRI\HDUV+HDWWULEXWHGLWVFDXVHWRDQRFFDVLRQZKHQ
KHFDXJKWKLVOHJRQDEHQFKDQGEURNHWKHVNLQ&RPSUHVVLRQEDQGDJLQJZDVKLVPDLQVWD\WUHDWPHQW
3VDLGWKDWKHKDGQRWJRQHÀVKLQJRUKDQGOHGPDJJRWVLQKLV\RXWK
 ,VXSSRVHWKHFORVHVW,·YHFRPHWRDQ\WKLQJLVSLFNLQJXSDZRUPRFFDVLRQDOO\
+HGHVFULEHGKLVGLVWDVWHIRU¶FUHHS\FUDZOLHV·DVDIDPLO\WUDLWWKDWKHKDGLQKHULWHGIURPKLVPRWKHUDQGVKDUHGZLWKKLV
ZLIH
 ,WKLQNSUREDEO\WKHLQLWLDOVWDUWLQJSRLQWZDVSUREDEO\ZLWKP\PRWKHUVKHGLGQ·WOLNHZKDWVKHFDOOHGFUHHS\FUDZOLHV«
PDJJRWVZRUPVDQGWKLQJVOLNHWKDW,·YHQHYHUSDUWLFXODUO\HQMR\HGWKHP0\PRWKHUZDVYHU\PXFKDJDLQVWDQ\WKLQJWKDW
ZULJJOHG0\ZLIHKDVEHHQWKHVDPHZH·YHEHHQPDUULHGRGG\HDUVDQGFUHHS\FUDZOLHVVHQGKHUUHDOO\ZREEO\,WKLQN
EHLQJKRQHVW,·YHDOZD\VKDGWKLV«
3SXWIRUZDUGWKUHHUHDVRQVDVH[SODQDWLRQVIRUKLVUHOXFWDQFHWRDFFHSWODUYDOWKHUDS\)LUVWKHVXJJHVWHGWKDWWKH
WUHDWPHQWZRXOGEHLQDSSURSULDWHIRUWKHW\SHRIXOFHUKHKDGVHFRQGKHVDLGWKHRGGVRIKLVXOFHUEHLQJKHDOHGZRXOG
KDYHWREHKLJKWRFRQYLQFHKLPDQGWKLUGKHVDLGKHNQHZWKDWKLVZLIHZRXOGQRWWROHUDWHPDJJRWVLQWKHKRXVH
 ,DVVRFLDWHPDJJRWVDQGZRXQGVZKHUH\RX·YHJRWDVRUWRIFUDWHUDQGDWWKHPRPHQW,·YHQRFUDWHU«LIWKH\WXUQHGURXQG
DQGVDLGZRXOG\RXKDYHLWRQ\RXUOHJQRZ,·GVD\QR,I,KDGWKHZRXQGDQGWKH\VDLGWKHFKDQFHVDUH,·GVD\QR6R
LWZRXOGKDYHWREHDWOHDVWVXFFHVVUDWH
 WKHELJSUREOHPDV,VD\LVJHWWLQJLWRYHUWRP\ZLIH,W·VQRWMXVWWKHTXHVWLRQRI¶,GRQ·WZDQWWRWRXFKWKHP,GRQ·WZDQWWR
VHHWKHP·,W·VDTXHVWLRQRI¶,GRQ·WZDQWPDJJRWVLQWKHKRXVH·DQG,WKLQNLIVKHWXUQHGDURXQGDQGVDLGLI\RXGRWKDW\RX·OO
KDYHWRJRLQWRDKRWHORUVRPHWKLQJXQWLOLW·VVRUWHG«WKHQ,ZRXOGVD\QR
3VXPPHGXSKLVIHHOLQJVDERXWODUYDOWKHUDS\DWWKHHQGRIWKHLQWHUYLHZ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6HWWLQJZKHUHSDWLHQWV
UHFHLYHGODUYDOWKHUDS\
Four of the ive patients experienced larval 
therapy in their own homes, applied by nurses who 
were members of the community nursing team, 
generally well-known to participants, who referred 
to them by their irst name and spoke highly of 
them and their dedicated approach to care.
P11 was the only participant in hospital on account 
of his leg ulcer when the larvae were applied, 
and his experience was in marked contrast to the 
others. He complained that he had been made 
to feel like a ‘peep show’ during his stay in hospital 
as nurses whom he did not know came to take a 
quick ‘peep’ at the larvae when they were being 
rehydrated, their use being something of a novelty 
on the ward.
A major potential drawback of receiving larval 
therapy in a community setting was highlighted by 
one the two participants who suffered intense pain 
soon after the larvae were applied. P18 described 
seeking advice, in vain, during a pain-illed and 
sleepless night, and how she had had to wait for 
the nurse to return the following day to have the 
larvae removed and the pain relieved.
I mean, I couldn’t take them off myself, I had to wait 
until the next day, if it had been happening during 
the day, I would have contacted the Sister and asked 
her to come round, but because it happened overnight 
I couldn’t do anything about it, and I didn’t get any 
sleep, I was just sitting watching the clock go round 
until the time that she was due to come, and just 
kept taking the painkillers…I rang [the out of hours 
service] at about half past three in the morning, and 
left a message and he [the emergency doctor] rang me 
back but you see, a lot of people don’t know anything 
about the larval therapy, so when I told him about 
it, it was something he had not come across before, 
and all he could suggest was keep taking the 
painkillers… (P18)
3HUFHLYHGFRPSHWHQFHRIVWDII
Participants who received larval therapy in their 
home were pleased with the experience and 
praised the nurses who applied it. The manner 
in which the nurse broached the topic of using 
larval therapy was perceived as important by P17, 
who was pleased that the nurse had ‘asked’ his 
permission to use it, so that he felt drawn in to the 
decision-making process, though in fact he happily 
deferred to her expertise saying that he would try 
anything she recommended: ‘whatever you want, I’ll 
try’ (P17).
By contrast, P11 judged his experience of receiving 
larvae in hospital as a disappointment; his stay 
coincided with a Bank Holiday, the Tissue Viability 
Nurse was apparently unavailable, and he was 
critical of the nurses who had applied the larvae to 
his ulcer.
I was just a bit disappointed that they were actually 
put on by someone who really hadn’t done it before 
and wasn’t one of the Tissue Viability Nurses…it 
were people who had to read the instructions on the 
packet…and they were like feeling their way, and 
to me, something like that is a specialist thing and 
someone like a main person from, a district nurse 
type, I think should have been [there], and then 
as they got on, the seniority got less and less…they 
weren’t at the top of their game on that front… (P11)
([SHFWDWLRQVYHUVXVH[SHULHQFH
3DLQ
Descriptions of pain, unanticipated and intense, 
dominated the accounts of the two female 
participants (P9 and P18). The male participants 
(P15 and P17) had not expected to feel any 
pain, and neither did they report any, just a little 
‘irritability’ just before the larvae were removed 
(P15).
it didn’t affect me during the day and it didn’t affect 
me at night. No, the last day you get a bit irritable, 
you wanted them off, because you knew they were 
coming off, but other than that, no… (P15)
P11 observed little change in the level of pain 
he experienced while the larvae were in situ – he 
described the pain as no more or less than usual 
with his leg ulcer. P9 and P18 both appeared 
shocked by the intensity of the pain they suffered 
within a short period of the larval therapy being 
applied; P18 had not expected to feel any pain; 
P9 had anticipated that she might feel a low level 
of pain while the larvae were ‘crawling around and 
cleaning up the slough’. Both participants believed 
that they had a high pain threshold, but both 
sought to have the larvae removed earlier than 
planned because they found the pain unbearable. 
P9 said she had experienced constant pain ‘from the 
moment they [the larvae] went on’ and was concerned 
because the pain exacerbated her angina:
I really wasn’t so bothered about the pain of the 
maggots, I was more bothered about the angina…
because every attack I have makes it [her heart] 
weaker, and I couldn’t afford that you know... (P9)
4XDOLWDWLYHVWXG\UHVXOWV
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P18’s pain was attributed to a reaction to the 
larval enzymes by the nurse who had applied the 
therapy, an explanation repeated by P18 during 
her interview:
I seemed to have a reaction, I couldn’t sleep at 
all…I went to bed for about an hour, and I was in so 
much pain, I just sat in the chair all night…it was 
like shooting pains really, coming up my leg, almost 
like knives going into it…it was the sort of pain 
where I just didn’t know what to do with myself… 
(P18)
when I spoke to Sister about it afterwards, she said 
that there are a few people that get a reaction to the 
enzymes from the larvae, not the larvae itself, but 
from the enzymes, and I may have been one of the 
people that did… (P18)
Although she did not make any connection between 
the pain she experienced and vascular impairment, 
P18 did refer to a forthcoming operation in the 
near future:
he [a Vascular Surgeon] said that I really need an 
operation on my vein, on the vein in my leg, because 
without that operation I will probably keep getting 
ulcers. (P18)
$SSHDUDQFHRIODUYDH¶WKH
WKRXJKWLVZRUVHWKDQWKHDFW·
Two participants (P15 and P18) commented on 
how they were pleasantly surprised when they irst 
saw the larvae. The ‘maggots’ appeared much 
smaller than they had expected, like ‘wisps of hair’ 
or an ‘eyelash’, which made the process of having 
them applied much more pleasant, and less 
disturbing.
I think a lot of people, as well as myself, tend to think 
of maggots as the sort ishermen use, you know, these 
big fat things that you see wriggling around, and I 
think if I had had those on my leg, perhaps I would 
not have been so happy about it, but [name] had 
told me they are very thin, they are sort of almost like 
an eyelash, and I think because of the size of them, 
they weren’t these fat maggots that most people know 
about, I think that made a difference. (P18)
P15 described the maggots as ‘little wisps of hair so 
small you can hardly see them…’
Asked if they had watched the larvae being 
removed, they replied that they had, P15 saying 
that ‘they had grown…yes, they jolly well had grown’ 
and P18 remarking that while they had grown, it 
was not as upsetting to look at them as she had 
thought it might be: ‘the thought is worse than the act’.
As P15 pointed out, ‘you are not obliged to watch [the 
larvae being removed] you can leave it to the nurses’, 
which is what P15’s wife did when she was in the 
room when the nurse removed some of ‘the hundred 
plus’ that she had put on, and some rolled onto the 
carpet.
3HUFHLYHGHIIHFWLYHQHVVRIODUYDOWKHUDS\
With the exception of P11, participants felt that 
the larval therapy had done a good job of cleaning 
slough from their ulcer, but they also thought that 
their ulcers had deteriorated again, sometimes 
quite quickly. Effectiveness was initially measured 
by how clean the ulcer looked on removal of the 
maggots – participants looked to see if there was a 
visible improvement.
I was happy with the maggot treatment and I felt 
at the end of the time, my leg was feeling quite 
clean, but at the moment, if you took that bandage 
off now, there is a big …[indicates size and depth 
of ulcer with his ingers]…we have had it down as 
low as that…[indicates depth again] and now it’s 
gone back to that [indicates size again], the area 
is not healing…it’s growing, yeah, you can see it 
growing… (P15)
P15’s strong belief in ‘maggots’ as an effective 
therapy did not seem to be shaken by the fact 
that his ulcer remained unhealed, or the fact that 
apparently, according to his wife, the nursing staff 
had commented that they could see little change 
after applying the larvae.
but they said they didn’t do you any good…  
(P15’s wife)
well, they said they didn’t do me any good…I just 
felt my leg was cleaner, not as clean as it was way 
back, but cleaner than it is now…I have no problems 
with the maggots treatment, if that is the ideal way of 
curing an ulcer, go ahead full steam… (P15)
P17 reported that in his case, the larvae had 
eficiently removed all the dead lesh, to leave a 
clean wound:
they eat all the dead, dead everything, dead lesh, 
skin, everything that is dead they clear away, and 
you are left with a clean wound… (P17)
The two female participants (P9 and P18) who 
had their larvae removed ‘early’ due to pain, 
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reported improvements in their ulcer, that seemed 
to indicate a belief in the power of larval therapy 
to achieve a beneicial effect in even a very short 
period of time. Despite the pain that they had 
suffered, and the fact that their therapy was 
terminated after a brief application, they seemed 
satisied with the results:
I truly believe in them. I think they are wonderful…I 
believe in them thoroughly but the only trouble is I 
couldn’t keep them on a third night, but they did do 
a marvellous job, they did clear a lot of the slough 
away, but with me having angina, I’m afraid 
it was too painful…I couldn’t have stood it any 
longer…they had done their job by then, and then it 
deteriorated again… (P9)
P18 relied on the judgment of the nurse for her 
opinion that her ulcer had been improved by the 
application of the larvae, though she herself was 
disappointed that she had not been able to tolerate 
them for a second day, because she assumed there 
would have been an even better effect:
she said it did look cleaner after they took them away, 
so she said she could see the difference, because she 
had obviously seen the ulcer the day before when she 
was putting it on, so she said it had cleaned them up, 
yeah… (P18)
P11 was unsure about the effect of the larval 
therapy on his ulcer. He had described his ulcer 
as having a ‘terrible’ effect on his daily life, due to 
constant pain, disturbed sleep and feelings of social 
isolation. He had sought to have larval therapy as 
a treatment after hearing about it in the media. 
He appeared to have high expectations of its 
effectiveness. Until his admission to hospital, his 
ulcer had been treated mainly with compression 
bandaging. Once in hospital, larvae (bagged) had 
been applied to a large, necrotic, ulcerated area on 
his right leg. He revealed that he had not wanted 
to look at his ulcer when the larvae were removed 
for fear there had been little improvement. Neither 
did he seem willing to trust the judgment of the 
nursing staff, whose competence he had questioned 
elsewhere in his interview.
I had necrotic parts of the ulcer, so they had the 
larvae treatment on them, but it seems that…when 
they covered the ulcers, it [the bagged larvae] wasn’t 
big enough, it was only big enough to go round the 
necrotic area. But I had it done, and it was taken off 
every day and rearranged and rehydrated and put 
back and redressed, but every time, people used to 
say, ‘Oh, yes, that’s a bit better, but you don’t know 
whether they are just saying that, I really didn’t want 
to look to be honest…not because of the maggots, 
I wasn’t bothered about those. I just thought that 
perhaps if I looked at it and found out that it wasn’t 
improving as much as I’d want it to improve I’d be 
upset about it. (P11)
Only one participant (P18) commented that they 
thought loose maggots might be more effective 
than bagged ones. As a trial participant, P18 had 
been randomised to receive loose larvae, though, 
given a choice, she said she might have opted for 
bagged. However, she did speculate that perhaps 
the loose maggots might be able to work more 
effectively as they would not be constrained:
I didn’t mind having them loose, but I think in a 
way there was this feeling of them being a bit more 
contained, rather than having sight of it, but then I 
thought maybe if they are in a bag, maybe they aren’t 
doing their job so well, so I suppose there are two 
ways of looking at it. (P18)
5HÁHFWLRQVRQWKHH[SHULHQFH
RIKDYLQJODUYDOWKHUDS\
Asked about their understanding of how larval 
therapy works, two of the male participants 
referred to larvae eating dead cells, and then 
eating each other. None of the participants seemed 
particularly well informed at a detailed level about 
how the larvae actually functioned; mostly, they 
referred to bits of information they had picked up 
from newspaper or magazine articles, or books they 
had read.
apparently, they devour the cells do they not, I think 
[name of nurse] said one eats the other one, and one 
eats the other one, and one eats the other one that’s 
eaten the bad skin… (P15)
I knew alright about them, from reading books. 
(P17)
Only participant (P18) referred to larval enzymes, 
in relation to the reaction she experienced at the 
outset of her treatment, the causal explanation 
offered by the nurse:
she said that there are a few people who get a 
reaction to the enzymes from the larvae, not the 
larvae itself, but from the enzymes… (P18)
Participants believed that the views of people in 
general about larval therapy would be characterised 
by ‘fear of the unknown’ (P17) and distaste because of 
4XDOLWDWLYHVWXG\UHVXOWV
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possible connotations of uncleanliness, leading to a 
degree of social stigma about having larval therapy:
for the majority of people, it is an unknown 
quantity…I am convinced that it’s people’s fear of 
them rather than anything else, you see the mere 
mention of maggots puts them off… (P15)
P9 referred to people talking about maggots in 
a hushed tone, or preferring to refer to them 
euphemistically as ‘that new treatment’. P18 
contrasted her attitudes towards larval therapy 
with those of her friends: ‘I know some people when I 
mentioned it to them seemed quite shocked at the idea, but 
it didn’t bother me…’ (P18)
With one exception (P11), participants seemed to 
retain their prior positive attitudes towards larval 
therapy, whether they had a ‘good’ or ‘negative’ 
experience of using them. Where the experience 
was deemed ‘good’, by the participant, their 
views of the beneicial effects were reinforced. 
Participants who seemed to have reported a 
‘negative’ experience (P9 and P18), because of the 
pain they felt, still believed that they had beneitted 
from the treatment during the short time that they 
experienced it.
I would have maggots again tomorrow if necessary. 
(P17)
I just think if they are the right thing for ulcers, then 
so be it…if they are going to help people… (P15)
I don’t regret being in the trial, even though there 
was a reaction… (P18)
I’ve had maggots which I thought were a wonderful, 
wonderful thing. I believe in them thoroughly… (P9)
P11, who had had bagged larvae applied to his 
large necrotic ulcer in hospital, was the only 
participant who appeared disillusioned by his 
experience. Holding high expectations at the 
outset, he appeared disappointed in the small 
improvement he discerned in his ulcer. P11 
implied that he thought the ulcer might have 
improved more markedly if more larvae had 
been applied: ‘I probably could have done with two 
bags bigger than what was there, or another bag…’ 
(P11). During his stay in hospital, P11 felt that 
the treatment had been mismanaged for a variety 
of reasons; in particular, he had been unhappy 
that the treatment was not applied by the Tissue 
Viability Nurse Specialist, as he had hoped.
6XPPDU\RIPDLQ
ÀQGLQJVIURPSDWLHQWV·
LQWHUYLHZGDWD
• The patient interview data revealed that the 
majority of participants were willing to try 
larval therapy either in bagged or loose form.
• Of the ive participants who had experienced 
larval therapy, the four who had received it 
from community nurses were satisied with 
the experience and believed they had seen an 
improvement in their ulcer.
• Only one participant (P11) had received larval 
therapy in hospital, and was disappointed 
with the experience and found little sign of 
improvement in his ulcer.
1XUVHLQWHUYLHZHHV
Nurse participants (n = 22; Tables 51 and 52) were 
purposely selected to include some working in the 
community and some working in clinics, to relect 
a broad age range, and to relect nurses both with 
and without experience of using larval therapy for 
leg ulcers. The total number of nurse participants 
(n = 22) included two nurses working in a site not 
involved in the main study, who agreed to pilot 
the Nurse Interview Schedule. These nurses are 
identiied as N(P)1 and N(P)2.
Four of the nurse participants (N17, N18, N19 
and N20) were selected from a group of clinicians 
attending an academic course at the University of 
York. These were nurses with extensive experience 
of caring for patients with leg ulcers, who held 
senior clinical or combined clinical and academic 
posts.
Six participants (N1–N6) were based in Vascular 
Clinics in sites involved in VenUS II, one attached 
to the Outpatients’ department of a hospital 
and the other in a community setting. Eleven 
participants (N7–N17 and N19) worked primarily 
in a community setting, while N18 worked in 
a hospital setting, and N20 was moving from a 
clinical to an academic role.
Although we had hoped to include a number of 
nurses of minority ethnic origin in the study, we 
found that the majority of nurses working in the 
sites where recruitment took place were White 
British, with the result that only two nurses from 
minority ethnic groups were recruited; N4 was 
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Black Caribbean and N16 was South East Asian in 
origin.
1XUVHSDUWLFLSDQWFKDUDFWHULVWLFV
All nurse participants were female and their ages 
ranged from 30 years to 62 years; the median age 
was 45 years (Tables 51 and 52). Participating nurses 
had between 1 and 27 years’ experience of caring 
for people with leg ulcers (median was 9.8 years, 
mean was 11.3 years). Three participants (N8, N12 
and N16) had no experience and three participants 
(N15, N18 and N20) had used larvae on only 
one or two occasions. Those nurses without any 
experience of using larval therapy were community 
nurses; all of the clinic nurses had experience of 
using larval therapy. Sixteen nurse participants had 
more extensive experience of using larval therapy. 
Of the 19 nurses who had used larval therapy, 17 
(89%) had used loose larvae, 13 had used bagged 
larvae (68%) and 11 nurses had used both (58%).
$WWLWXGHVEHOLHIVDQG
DFFHSWDELOLW\RIODUYDO
WKHUDS\ÀQGLQJVIURP
QXUVHLQWHUYLHZV
Of the 22 nurse participants interviewed in the 
qualitative study, all but three (N8, N12, N16) 
had experience of using larval therapy. Nurses 
varied in the number of times they had used larval 
therapy, depending on individual factors, for 
example, relative seniority in the nursing team 
and the setting in which they worked. Within the 
community nursing team, it tended to be senior 
nurses or those with a particular interest in larval 
therapy who had most experience; experience 
of larval use was more evenly spread amongst 
clinic-based nurses, some of whom said they were 
using it as often as ‘a couple of times per week’ (N2). 
Three nurses, (N15, N18 and N20) had limited 
experience, having used larvae on only one or two 
occasions.
3HUFHLYHGXWLOLW\EHQHÀWVDQG
HIIHFWLYHQHVVRIODUYDOWKHUDS\
Nurse participants were unanimous in the belief 
that larval therapy was best suited to cleaning 
‘dirty’ or ‘sloughy’ wounds to achieve a speedy 
debridement, and a dramatic, visible improvement 
in the condition of an ulcer, providing a morale 
booster for both patients and the staff caring for 
them:
I mean you can see the improvement…the area that 
they have cleaned up, it’s been dramatic really in 
most of them, it’s so good. (N12)
it was quick, it was extremely quick, say if we put 
them on a Monday, by the time we got back, two to 
three days later, maybe 60–70% of the slough was 
gone, so fast, so quick fast….it did us all good, we 
thought, ahhh, right, we are getting somewhere after 
all these weeks and months something has inally 
happened…so from that point of view, the speed 
with which they can make a difference is signiicant 
I would say… (N13, community nurse with 27 
years’ experience of wound care)
you put them on and you can see instant results…
all the slough is gone when you take them off, it is so 
good because it is so visual. (N14)
The role of larval therapy in the ‘palliative’ care of 
wounds that were malodorous and offensive, and 
deeply unpleasant for patients and their families 
was valued:
if you’ve got an ulcer that full of slough, it smells, 
and the quickest way to get rid of that is to use 
maggots. (N11)
The use of larval therapy following, or instead 
of, surgical debridement was described as a cost-
effective and safe means of cleaning a ‘dirty’ wound 
quickly:
I’ll get them to come in and sharp debride the 
worse of it and then we’ll use maggots to inish 
off, and that’s probably my favourite way of using 
them, because otherwise I’ve got to use two or three 
applications and that’s expensive. (N11, Tissue 
Viability Specialist Nurse)
sometimes the other option is the surgeon will say, 
we’ll debride it, and people don’t want to go and 
have surgery…and they [the patient] said, I don’t 
want it, and I say, well, let’s try maggots…it’s got 
to be cost-effective, and we don’t want MRSA, that’s 
another thing… (N14)
The major perceived drawback of using larval 
therapy was that the results achieved in a short 
space of time were not maintained. Nurses 
described wounds as ‘going in a backwards direction’ 
(N3) soon after the removal of larvae; ‘after you take 
them off, the wound tends to go back to being sloughy’ 
(N1).
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we’re not keeping it clean with an NA dressing, it 
is not enough…10 days down the line they’ve got a 
sloughy wound again. (N2, clinic nurse)
I think they are right for the job that they do, but 
there is always a need once you take the larvae off, 
to have a different dressing that will keep the wound 
clean, because putting nothing on, just an NA 
Ultra, does not keep the wound clean. (N1, Tissue 
Viability Nurse)
A further perceived limitation of larval therapy 
was that certain wounds, or certain types of 
patient, were deemed not suitable for treatment. 
Wounds with a thick eschar, or where the bottom 
of the wound bed could not be viewed clearly, and 
patients with vascular impairment, or those taking 
warfarin, were viewed as unsuitable for larval 
therapy:
I wouldn’t use it if I couldn’t see the bottom of the 
wound bed…if they’ve got a cavity…where that 
cavity was tracking…I would make sure that I 
would know where the base of the wound was, so you 
know what is going in and what is coming out…or 
is it a big thick eschar that you wouldn’t use maggots 
on because they can’t chew away at that… (NP1)
if you put them on a leg that’s got vascular problems, 
they’re only going to reslough, so there is no point. 
(N9)
I checked their drugs and they were on warfarin, and 
it’s a contraindication you see… (N9)
Amongst the nurses, opinion was divided as to 
whether debridement with larval therapy promoted 
the healing of leg ulcers:
I don’t know whether they heal faster, I have no idea 
about that. (N11)
they have, in my experience, enhanced the wound-
care healing rates of wounds once they’ve been 
cleaned. (N10)
they did a good job, but not completely, it was only 
partial, so I think expectation was a bit too high 
then, and the patient was pleased, but a little bit 
disappointed because they hoped that everything 
would be clean and ready for the healing process to 
take place. (N13)
For a majority of nurses, larval therapy was 
considered a treatment to try when all else had 
failed, as a last resort:
traditionally, it has always been a last resort…if 
we’ve come up against a brick wall, then we try the 
larval therapy… (N13)
A number of nurses appeared to work within a 
personal ‘hierarchy’ of tried and tested approaches 
to ulcer care, and larval therapy seemed to sit 
between irst-line treatments, such as dressings and 
gels, and surgical debridement:
I would go for the simple choice irst, and then move 
on to that [larval therapy], I wouldn’t use it as the 
irst choice to debride, but I would deinitely put it on 
a par instead of allowing the surgeon to come and 
play with a scalpel. (N19)
Cost-effectiveness of larval therapy emerged as an 
important consideration in some nurses’ thinking 
about the value of the treatment. The current lack 
of evidence regarding its effectiveness meant that 
nurses were unsure whether or not it represented a 
cost-effective option:
the only reason I hesitate is the cost. If you’re using 
maggots because you believe that debriding a wound 
faster makes it heal faster, that’s one economic 
argument. If you’re using them as a palliative 
measure to reduce smell, that is a different argument. 
I ind it much easier to justify the palliative one 
because I know they work, I don’t even need a trial, 
I know they work… (N11)
sixty odd pounds per application, but then some 
dressings are very dear, desloughing can take so 
long…in the long run I think it is a matter of 
writing down how much you spent on using say a gel 
or some other method and gave it to a GP…it’s taken 
X weeks at that cost…and compare it, I am sure that 
in the long run it is cost-effective. (N17)
Concerns were raised by two senior, experienced 
nurses, working in the community, that larval 
therapy was currently being overused, as the latest 
‘fad’ in wound care:
we seem to have maggots fans [laugh]…there are 
some nurses will always leap on the latest idea…I 
have nurses who will want to use maggots on nearly 
everything, and I’ve got doubts about that frankly…
if there is a bit of slough, and we must debride it, 
I’m saying, why don’t you put them into compression 
and see what happens, because in my experience that 
usually gives a satisfactory result… (N11)
4XDOLWDWLYHVWXG\UHVXOWV
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I have concerns that there’s people thinking ‘I’ll put 
maggots on’, that haven’t got enough knowledge or 
have had any training. (N9)
1XUVHV·SHUFHSWLRQVRISDWLHQWV·
ZLOOLQJQHVVWRWU\ODUYDOWKHUDS\
In general, nurses believed that patients were open 
to the idea of trying larval therapy, as long as they 
could be reassured that the larvae could not escape 
from the dressing:
I am quite amazed at how accepting patients are of 
them. (N17)
most of them are ine about maggots as long as they 
feel conident that they are not going to get out. 
(N11)
Some patients were perceived as particularly 
enthusiastic about trying larval therapy as an 
innovative form of treatment, and likely to be 
disappointed if their request to try ‘maggots’ was 
not met:
I think they are keen to try things that are so called 
‘new’ because they are cutting edge…they feel special 
when they are having them. (NP2)
patients might approach you and say, ‘Can I have 
maggots?’ and then you have to say to them your 
ulcer does not meet the requirements for it, and 
they say, ‘what do you mean?’ and you say, ‘well 
if you put the maggots on they will die, there will 
be nothing for them to suck’, and they will be right 
disappointed, you know. [patients, not maggots] (N4, 
clinic nurse)
Of the patients who appeared initially reluctant to 
try larvae, nurses believed that some might be open 
to persuasion, but not all:
some of them ‘Oh no, I couldn’t possibly have that,’ 
but you know, you talk to some of them and they 
could change their mind, and they’ll have them, but 
others are adamant… (N3)
One group of patients considered highly likely to 
try larval therapy were those described as ‘willing 
to try anything’ because of their desperation to try 
any form of treatment that might offer hope of 
improvement for their ulcer, even one as ‘extreme’ as 
larval therapy. Nurses believed that these patients 
could, or would, overcome any feelings of fear or 
distaste in their desire to ind a cure:
a lot of our patients have got to the point where they 
will try anything because they are absolutely fed up of 
having a chronic wound because it has such a great 
impact on their life. (N6)
I think by the time they get to the stage of needing 
some fairly extreme therapy like that, they just don’t 
care, they just want to try anything and they will 
agree to it. (N3)
ones that have had them have come to the end of the 
road…it’s sort of like desperation and so I think they 
would try anything, even if they had some sort of fear 
about them. (N9)
Patients considered extremely unlikely to accept 
larval therapy were a small minority characterised 
as exhibiting strong feelings of fear or revulsion. 
Nurses attributed these feelings to: a lack of 
knowledge about larvae and how they function; 
associations of larvae with ishing maggots, dirt 
and death; worries about larvae emerging from 
the wound as full-blown lies; anxiety about 
experiencing an unpleasant ‘wiggling’ sensation; 
and the notion of ‘maggots’ being able to escape 
from the dressing to crawl over their leg, burrow 
into their lesh, or escape into their bedding.
you ask them why they are squeamish, and they say, 
can you imagine putting those things on to me, 
nibbling, and then you say, well, they don’t nibble, 
they suck…because I think they think it is something 
that is going to do more damage than good, because 
they don’t understand how they work. (N4)
I think it is before they see them, because I think they 
think they are going to be big, like ishing maggots… 
(N7)
occasionally, people say to me, they won’t turn into 
lies will they? (N11)
what the patients worry about is, can they escape, 
can they get out? (N18)
what they worry about is them escaping, or that they 
are going to eat into the skin and track through. 
(N14)
others are just adamant, ‘Oh, the thought of it’…
lies and maggots and things they think they are dirty 
although they are specially bred for it.’ (N12)
The fear identiied by nurses as lying uppermost in 
patients’ minds, that larvae might escape, seemed 
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to lead to an assumption that patients would prefer 
to have bagged rather than loose larvae:
they get it into their head that they are going to 
escape, so it constantly plays on their mind, whereas I 
think if you put bagged maggots on they would feel a 
lot safer… (N5)
Referring to a patient recruited into VenUS II, N18 
commented:
luckily, she got teabag maggots…I am sure we would 
have had a lot more discussion if she had got the 
loose ones, which she really didn’t want…it was the 
thought of them escaping, which they shouldn’t have 
done, because I would have taped them in well… 
(N18)
Other factors which nurses believed might affect 
the likelihood of patients accepting to try larval 
therapy were the views of partners and other family 
members, and the approach nurses take when they 
initially raise the possibility of using larval therapy. 
Data relating to these factors are summarised in 
Boxes 4 and 5.
$FFHSWDELOLW\RIODUYDOWKHUDS\
Overall, nurse participants expressed the general 
view that larval therapy was a beneicial form 
of treatment (in terms of debridement) for the 
treatment of leg ulcers, and one that was acceptable 
to the majority of nurses and patients.
Nurse participants classiied themselves and nurses 
that they knew into three groups with regard to 
acceptability of larval therapy: ‘real converts’ (NP2) 
who thought ‘maggots are marvellous’ (N4); nurses 
who attempted to overcome their own feelings 
of squeamishness to beneit patients (see N17 
below); and a minority of nurses who would not 
‘entertain the idea’ of using larval therapy under any 
circumstances (N14).
At the point in time when they were interviewed, 
19 of the 22 study participants had had experience 
of applying larval therapy, either in a clinic or 
community setting. Two participants (N8 and N16) 
had chosen not to apply larval therapy, because of 
their dislike of ‘creepy-crawlies’. A further nurse 
(N12) said that the relatively ‘junior’ position that 
she occupied on the community nursing team 
meant that she was not required to apply larval 
therapy as ‘the Sisters do them…’.
During interview, nurses discussed acceptability of 
larval therapy with reference to:
• feelings of squeamishness, distaste or disgust
• perceived potential side effects of larval 
therapy: pain and bleeding
• practical issues.
,QQDWHVTXHDPLVKQHVV
Half of the nurses interviewed said that they had 
‘no qualms’ about using larval therapy, or that it 
‘never bothered’ them (NP1, NP2, N1, N2, N3, N5, 
N6, N9, N10, N13, N14).
The remainder expressed varying degrees of 
squeamishness, linked to anxieties that larvae 
might escape from dressings, a general dislike of 
creepy-crawly creatures, and particular distaste for 
the wriggly movements of larvae.
Two (N8 and N16) of the three nurse participants 
who had never applied larval therapy 
attributed their reluctance to use it to their own 
squeamishness:
3DWLHQWV·UHODWLYHVLQSDUWLFXODUWKHLUSDUWQHURUVSRXVHZHUHWKRXJKWE\QXUVHVWRSOD\DQLQÁXHQWLDOUROHLQWKHGHFLVLRQ
PDNLQJSURFHVVDERXWZKHWKHURUQRWDSDWLHQWPLJKWEHZLOOLQJWRWU\ODUYDOWKHUDS\1DFRPPXQLW\QXUVHZLWK
\HDUV·H[SHULHQFHRIORRNLQJDIWHUSDWLHQWVZLWKOHJXOFHUVYLHZHGDFKURQLFXOFHUDVDIDPLO\UDWKHUWKDQLQGLYLGXDO
DIÁLFWLRQDQGVXJJHVWHGWKDWSDWLHQWVPLJKWEHSHUVXDGHGE\IDPLO\PHPEHUVWR¶JRIRU·ODUYDOWKHUDS\
 3DWLHQWVDUHFRQFHUQHG\RXNQRZ¶,·OOKDYHWRDVNP\KXVEDQG·RU¶,·OOKDYHWRDVNP\ZLIHEHFDXVH,DPQRWVXUHWKH\ZLOO
ZDQWWKDW·EXW,WKLQNE\WKHWLPH\RXKDYHDFKURQLFXOFHULWDIIHFWVWKHZKROHIDPLO\LWDIIHFWVWKHSHRSOHDURXQGWKHPVR
WKH\DUHTXLWHSOHDVHGWRKDYHDJR,KDGRQHODG\DQGKHUKXVEDQGSHUVXDGHGKHUJRRQKDYHDJREHFDXVHVKHZDVQ·W
NHHQDQG,WKLQNLWKHOSHGKHUWRKDYHVRPHERG\LQWKHIDPLO\VD\LQJJRRQJRIRULW,ZLOOVXSSRUW\RXZH·OOJHWWKURXJKLW
WRJHWKHUUHDOO\1
%2; 1XUVHV·SHUFHSWLRQVRIWKHLQÁXHQFHRIIDPLO\PHPEHUVLQSDWLHQWGHFLVLRQPDNLQJFRQFHUQLQJDFFHSWDQFHRIODUYDOWKHUDS\
4XDOLWDWLYHVWXG\UHVXOWV

1XUVHVEHOLHYHGWKHZD\LQZKLFKWKH\EURDFKHGWKHVXEMHFWRIODUYDOWKHUDS\ZLWKSDWLHQWVFRXOGLQÁXHQFHWKHLUGHFLVLRQ
DVWRZKHWKHUWRDFFHSWRUUHMHFWLWDVFRXOGWKHLUHQGRUVHPHQWRIWKHWUHDWPHQW
 +RZ\RXUDLVHWKHVXEMHFWZLWKWKHSDWLHQW«\RX·UHDZDUHWKDW\RXDUHVXJJHVWLQJVRPHWKLQJWKDWVRPHSHRSOHZRXOGÀQG
GHHSO\GLVWDVWHIXO1
 \RX·YHJRWWRDSSURDFKSDWLHQWVLQWKHULJKWZD\$VVRRQDV\RXVD\PDJJRWVWKH\DUHOLNH¶2RRRRRRKKKKKK·EXW\RX·YHJRW
WRH[SODLQVRUWRISUHHPSWWKHPDQGVRUWRIVD\\RXNQRZ¶,NQRZDORYHO\WUHDWPHQWWKDWZH·YHWULHG·DQG\RX·YHJRWWR
UHDVVXUHWKHPWKDWWKH\DUHQRWJRLQJWRHVFDSH1
 ,·YHJRWDQLQIRUPDWLRQERRNOHW«WKDWH[SODLQVZK\ZHXVHWKHPZKHQLWVWDUWHG\RXNQRZIURPWKH)LUVW:RUOG:DUWLPHV
DQGSDWLHQWVJHQHUDOO\JHWYHU\H[FLWHGDQGFDQ·WZDLW«,·YHQHYHUKDGRQHUHVLVWHG1
%2; 1XUVHV·SHUFHSWLRQVRIWKHLUUROHLQSURPRWLQJSDWLHQWV·DFFHSWDQFHRIODUYDOWKHUDS\
my concern was that they would get out of the 
dressing, would you wake up the next morning and 
ind them in the bed and things… (N8)
I come from the Philippines, for me you see they 
are dirty, even though I know it is clean…I never 
like any worm at all, and to think about maggots, 
putting maggots onto the skin of a client, it just make 
my head big. (N16)
Several nurses indicated that they would try 
to set aside or overcome their innate feelings 
of squeamishness in order to offer patients a 
potentially beneicial treatment for their ulcer.
I mean we do a lot of things in nursing that you 
don’t particularly like doing, but you do them, you 
just get on… (N15)
Actual ‘hands-on’ experience of applying larval 
therapy, and observing beneits for patients, 
resulted in some nurses reporting that their 
feelings of squeamishness diminished and their 
conidence in using larval therapy increased:
I was wondering how would I cope with these little 
live creatures…I was a bit apprehensive…I was 
hoping not to show any disdain, or you know, cock 
this up in front of the patient…I was pleasantly 
surprised to ind that actually I had no concern 
about using them, usually I don’t like creepy-crawly 
things, and then it just becomes another treatment, 
I have no qualms now I have had a go at them… 
(N17)
I remember the irst time I saw maggots I were like, 
Oooohhhhh, but I saw the condition of the patient’s 
ulcer prior to the maggots being used, and obviously 
when they went on I was a little squeamish, and 
when they came out, I were like ‘WOW’, because they 
were so big and juicy and the ulcer was so clean! 
(N4)
A minority of nurses reported that the 
transformation undergone by the larvae during 
the time they had been applied to the wound had 
shocked or disturbed them; an extreme case was 
N20, who described having a nightmare after 
applying larvae for the irst time.
I did have nightmares subsequent [to using larval 
therapy]. I dreamt one night that I was in a room…
and the maggots were falling down from the 
ceiling…it’s a bit like, you’re using it and you know 
you are using it, you’re blocking out everything else, 
and then I suppose you have no control over when 
you might have a lashback about it… (N20)
In two cases, (N11, N19) feelings of squeamishness 
were only experienced when the nurses came 
to remove larvae, after the wound had been 
debrided. At this stage, the larvae could no longer 
be considered clean or sterile, though they could 
potentially escape from the wound area to their 
surroundings, and the nurse would have to retrieve 
them:
it’s not something that I feel completely comfortable 
with maggots, because when you put them on, they 
are very clean, and it’s not until you come to take 
them off, and I suppose that is with any dressing you 
take off, you want to put them in the bin as soon as 
possible… (N19)
sterile maggots and the maggots that have been on 
a ilthy loor or rotting leg, you know, there is a 
difference, and I think once you start using them 
clinically, you start to differentiate between the two 
types…and some used maggots I still ind repulsive. 
(N11)
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Four of the study participants (NP1, N1, N3, N5) 
attributed their lack of squeamishness to the fact 
that they had seen or handled ishing maggots 
at some stage in their lives. N10 believed she 
was not squeamish about maggots because of her 
upbringing on a farm, where maggots would have 
been a common sight. The three nurses who had 
not applied larval therapy prior to their interview 
reported that they had neither seen nor handled 
maggots.
3HUFHLYHGSRWHQWLDOVLGHHIIHFWVRI
ODUYDOWKHUDS\SDLQDQGEOHHGLQJ
Pain and bleeding in association with larval 
therapy were reported by nurses as leading to 
the early removal of larvae on occasion, but these 
occurrences did not seem to lead the nurses 
involved to question its acceptability. Only N15 
mentioned that she might ‘think twice’ about 
using larval therapy after a patient bled profusely 
subsequent to application of larvae. Of the 22 
nurses interviewed, nine reported that patients had 
complained of pain, sometimes severe, during the 
period that they had received larval therapy. Pain 
did not seem to be considered by the nurses as an 
untoward event during larval therapy, particularly 
where an ulcer had been judged to be small, or 
not very ‘sloughy’. Patients were usually advised by 
nurses to carry on with larval therapy, while taking 
analgesia.
A minority of patients were said to suffer pain 
so severe that nurses had had to remove larvae 
prematurely. In these cases, the cause of patients’ 
pain was not necessarily linked by nurses directly 
to their having larval therapy. Nurses’ suggested 
explanations for these patients’ pain included the 
possibility of different pain thresholds amongst 
patients; the presence of arterial disease; and one 
suggestion that pain was psychosomatic in origin.
I wonder if the slough has gone and what the 
maggots are excreting is irritating the wound bed, 
sort of like a stinging pain…one gentleman asked 
for them to be taken off, it [his ulcer] was about 5 cm 
square…he couldn’t tolerate the pain. (N9)
two out of four patients I have looked after said it 
was quite painful, and they asked to come in a little 
bit earlier and have them taken off, and the other two 
were OK with it, and said it wasn’t that bad, and just 
dealt with it. (N5)
we had one lady had larvae put on during the day, 
actually admitted [to hospital] that night because 
she couldn’t stand the pain…but she did have some 
arterial disease in the end… (N6)
I went to see her and she said, just take them off, just 
take them off…I don’t know if it whether it was a 
psychological pain because…she said she could feel 
them [the larvae] digging into her leg, you know, like 
a pin prick sort of thing… (N7)
Bleeding in association with larval therapy was 
not considered unusual either, unless profuse, and 
did not appear to be a reason for considering the 
rejection of the use of larval therapy. A commonly 
suggested cause of bleeding was that the larvae had 
eaten their way down to the wound bed:
a little bit of bleeding, but nothing excessive, nothing 
that I haven’t dealt with with other dressings… (N5)
I think there wasn’t much slough left for them to 
eat, so they were just having a chomp, but it wasn’t 
a massive bleed, so we took the larvae off because it 
was clean. (N1)
Two of the most experienced nurses interviewed, 
(N15 and N17), mentioned instances where 
patients who had received larvae had bled through 
their dressings so as to cause concern, but only 
(N15) commented that she might be less willing to 
consider using larval therapy in future.
she had an ulcer developing at the back of her leg 
that was beginning to get quite sloughy and we put 
maggots on that, when we took the dressing down, 
not the irst time, but the second time, it actually bled, 
it haemorrhaged, we sent her up to A&E, she came 
back with a pressure bandage on…whether it was 
related to the maggots I don’t know, but it has made 
me think twice about using maggots, and when I 
would use them…I know they are only supposed to 
eat the necrotic lesh… (N15)
3UDFWLFDOLVVXHV
Practical issues linked to nurses’ views of 
acceptability of larval therapy included the form of 
larvae available to them (bagged or loose); nurses’ 
inability to prescribe larval therapy despite holding 
a nurse independent-prescribing qualiication 
(larvae are currently an unlicensed medicinal 
product); training issues; cost of larvae; and 
occasional problems in the supply or delivery of 
larvae.
Where nurses expressed a preference for bagged 
or loose larvae, they were more likely to favour 
4XDOLWDWLYHVWXG\UHVXOWV
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bagged larvae, partly because they believed they 
were easier to apply, and less time consuming for 
senior nurses who would be expected to apply 
the larvae themselves, or supervise others. Nurses 
also deemed bagged larvae more acceptable to 
themselves and patients because the larvae were 
contained in the bag, which might provoke less 
anxiety about them escaping:
the majority of the ones I have treated have expressed 
a preference for bagged, just simply because they are 
contained. (N17)
it’s time-consuming when you’ve got free-range ones 
on because of putting them on. Putting the bagged 
ones on is far easier…bagged it’s literally just a 
couple of seconds. Free-range you’ve got to make a 
framework and then I would say about 5–10 minutes 
putting them on. It’s just an added complication and 
a iddle… (N9)
Lacking prescribing powers to prescribe larval 
therapy themselves meant that nurses were forced 
to rely on GPs and other doctors to generate the 
prescription necessary to obtain larval therapy. This 
was perceived as potentially problematic because 
doctors were said to lack interest in wound care, 
and to retain a tight control on the prescribing 
budget, and the cost of larval therapy could seem 
high in comparison with usual dressings.
GPs are very tight with the purse strings, so it’s 
getting them on board as well I think actually. (N17)
I don’t think that doctors get as involved as they 
should do… (N14)
Increased training for nurses was highlighted 
by many respondents as a means of promoting 
acceptability of larval therapy more widely. Clinic-
based nurses believed that nurses working in 
general hospital wards and community nurses 
would beneit from a systematic approach to 
training and education aimed at increasing 
awareness and use of larval therapy by nurses other 
than those directly involved in tissue viability. NP2, 
a Tissue Viability Advisor, commented on some 
of the components of a pack she was using for 
training purposes.
I just think it would be a good idea for people to 
be taught on a more widespread basis, out on the 
wards…so they are not so concerned about using 
maggots… (N6, Bradford clinic)
[they] watch and go through a systematic process of 
what they need and we have a pack, an information 
pack with patient information about maggots, and 
there is also a maggot care plan as well, so it is very 
systematic and easy to follow. (NP2)
Generally, supply and delivery of larval therapy 
were considered good, though nurses highlighted 
a number of teething problems or hiccups that had 
occurred in the service:
we had some that were delivered elsewhere and went 
to the wrong depot, so we had to cancel a treatment 
and then reorder… (N13)
the bagged ones from Germany hadn’t arrived 
because of fog which is fair enough. (N1)
I got to the patient’s house, opened the pack, there 
was no maggots…they had sent everything but 
the maggots, I couldn’t believe it, I was looking 
everywhere! (NP2)
Not being able to able to obtain larval therapy on 
a Monday was not usually viewed as a problem 
because nurses could plan around that restriction:
we know we are not supposed to get them delivered 
on a Monday...as long as we plan ahead that is not 
a problem. (N5)
However, for clinic nurses, inding community 
nurses to look after patients having larval therapy, 
for instance to carry out rehydration, over 
weekends posed a substantial problem:
on the ward it is different, they can put them on any 
day…because there is always somebody to take them 
off, but we are not here at weekends… (N6)
6XPPDU\RIPDLQÀQGLQJV
IURPQXUVHLQWHUYLHZV
• The majority of the nurses interviewed 
considered larval therapy an eficient treatment 
for the debridement of dirty or ‘sloughy’ 
leg ulcers, which achieved visible results in a 
short period of time. The main drawback of 
larval therapy was perceived as the tendency 
of wounds to ‘reslough’, often quite quickly. 
Nurses believed that most patients were willing 
to accept the option of having larvae applied 
to their ulcer, though a small minority would 
always be resistant.
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• Acceptability of larval therapy amongst the 
nurse participants was high. Nurses who 
imagined they would ind the application 
of larvae dificult because of feelings of 
squeamishness on their part, found that they 
were able to carry out the procedure without 
becoming overly anxious.
• Pain was commonly, and bleeding less 
commonly, reported among patients receiving 
larval therapy, sometimes necessitating the 
removal of larvae.
• There was general satisfaction with the 
supply and delivery of larval therapy, despite 
occasional shortfalls. Nurses were less satisied 
with having to rely on doctors to obtain 
prescriptions for larvae, and with the level of 
education and training available for hospital 
and community nurses about larval therapy.
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This is the irst randomised trial of larval therapy as a leg ulcer treatment that follows 
patients to healing and currently the only RCT 
of larval therapy that measures impact on MRSA. 
The indings of this RCT are therefore important 
and hugely relevant for decision-makers. This 
discussion will consider the clinical, cost and 
qualitative indings in turn, followed by an 
objective overview of the internal and external 
validity of the trial.
&OLQLFDOHIIHFWLYHQHVV
8OFHUKHDOLQJ
We did not ind any evidence that a phase of 
treatment with either loose or bagged larvae 
reduced the time to leg ulcer healing compared 
with hydrogel. Loose and bagged larvae showed 
very similar results for healing and were considered 
as one group in the main analysis. The hazard ratio 
for healing for leg ulcers treated with larval therapy 
relative to hydrogel was 1.13 (95% CI 0.76 to 1.68) 
indicating that whilst larvae-treated participants 
were 13% more likely to heal, this difference was 
not statistically signiicant (p = 0.54). The CI 
around the hazard ratio means that the true value 
may range between a 68% increase in the chance 
of healing with larvae and a 24% reduction in the 
chance of healing with larvae.
The median healing times (236 days for the 
participants receiving larvae and 245 days for the 
hydrogel group) were longer than in our previous 
trial where the median healing time with 4LB was 
92 days and 126 days with SSB.12 The most likely 
explanation for the increased healing time in 
VenUS II is that inclusion was restricted to sloughy 
and necrotic leg ulcers and those associated with 
more arterial disease than in the previous study.
As previously,12,85,86 we found that baseline ulcer 
area and ulcer duration were statistically signiicant 
predictors of time to healing (p < 0.0001) with 
larger ulcers and those of a longer duration taking 
longer to heal.
8OFHUGHEULGHPHQW
We found good evidence that larval therapy does 
debride leg ulcers more quickly than hydrogel. The 
hazard ratio for debridement of 2.56 (95% CI 1.76 
to 3.71) indicates that the ulcers of participants 
receiving loose larvae were more than twice as 
likely to debride at any time during the trial than 
those of participants receiving hydrogel. The 
hazard ratio for bagged larvae relative to hydrogel 
was 2.05 (95% CI 1.39 to 3.03), again suggesting 
that this treatment was a more effective debriding 
agent than hydrogel. Whereas a previous RCT57 
and a number of non-RCT studies53,54,56,134 have 
concluded that larval therapy is an effective 
debriding agent; these are the irst data from a 
large, robust RCT to conirm these indings.
Although the median time to debridement was 
longer in the bagged larvae group than the 
loose larvae group (28 days versus 14 days) this 
difference was not statistically signiicant in the 
adjusted analysis. Hence, although there was a 
trend for loose larvae to debride more quickly than 
bagged larvae, this difference may have occurred 
by chance and our trial was not powered to detect 
a difference in debridement between the two larvae 
formulations, only a difference in time to healing 
between larvae and hydrogel.
In this trial there was a delay of approximately 5 
days between randomisation and irst application 
of larval therapy, because larvae had to be ordered 
from either Wales or Germany, and delivered for 
use (as is the case in normal clinical practice). 
After this initial delay, debridement in the larval 
therapy groups was rapid up to day 20. At day 20 
approximately 10% of those treated with hydrogel 
were debrided compared with approximately 
58% of people receiving larval therapy. After 
day 20 the rate of debridement seemed to slow 
in the larval therapy group and then plateau at 
approximately day 80, whereas in the hydrogel 
group debridement occurred at a steady rate 
between days 0 and 80. Although larval therapy 
was observed to be an effective debriding agent, 
data suggest that not all ulcers receiving this 
treatment will debride (20% of reference ulcers did 
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not debride in the loose larvae group, 23% did not 
debride in the bagged larvae group). Reasons for 
this could include participant intolerance of larval 
therapy because of pain. Ulcer-related pain scores 
at the removal of the irst debridement treatment 
were signiicantly higher for both loose and bagged 
larvae compared with hydrogel.
This trial did not investigate debridement as a 
longer term outcome so we do not know how many 
ulcers that did debride remained debrided. We do 
know that a number of participants were withdrawn 
from trial treatment in the larval therapy and 
hydrogel arms (trial treatment being debridement 
treatment in Phase 1 and knitted viscose dressings 
plus bandage in Phase 2) because of increased 
slough, suggesting that some ulcers resloughed 
after initial debridement. This is also supported by 
data from the qualitative interviews.
%DFWHULDOORDG
Larval therapy has been proposed as an 
antimicrobial treatment for chronic wounds. 
Suggested mechanisms for its action are via 
secretions and digestive processes,37–40,135 and 
via debridement of bacteria-rich tissue which 
is thought to be important in controlling 
infection.35,37,38
Data from VenUS II did not ind evidence of an 
impact of larval therapy on the bacterial load of leg 
ulcers. Although bacterial load decreased over the 
duration of the trial – this decrease was not related 
to treatment group. Our aim was to investigate 
the antimicrobial action of larval therapy, so we 
have not yet conducted analyses to investigate 
the association between bacterial load and ulcer 
healing. These analyses will be reported separately.
Most previous research investigating the 
antimicrobial activity of larvae has been in 
vitro, using whole body extraction and isolated 
secretions.37,38,44 Whereas this work is important, 
in VenUS II we assessed the impact of larvae on 
leg ulcers in vivo where the environment is very 
different to that of the Petri dish. Previously, 
Steenvoorde and Jukema81 investigated the 
antimicrobial action of bagged larvae in 16 
patients, the majority with osteomyelitis, fasciitis 
necroticans or gangrene. A varying number of 
wound swabs were taken from patients one month 
before larval treatment, during the treatment and 
after the larval treatment. The swabs were cultured 
to assess the growth of Gram-positive or Gram-
negative bacteria. Bacterial load was not quantiied 
further. The study concluded that larvae may have 
an impact on Gram positive bacteria but have less 
effect on Gram-negative bacteria. However, as this 
study had no comparison control group, attributing 
microbiological changes to larvae is dificult. 
Additionally, because a number of swabs were taken 
from each individual during the study, special 
analysis is required to account for correlation 
within participants.
VenUS II is the irst RCT we have identiied to 
investigate and publish data on the antimicrobial 
action of larval therapy but we also recognise the 
limitations of the methodology employed. We only 
investigated an association between larval therapy 
and total bacterial load. Beyond identiication of 
MRSA we did not have the resources to conduct 
qualitative investigation of bacterial wound lora so 
cannot draw any conclusions about the impact of 
larval therapy on other species.
We assessed bacterial load using quantitative 
surface swabs, where the sample was taken from 
viable tissue at the wound surface with light 
pressure to extract wound luid. Nurses were 
instructed to use a standardised protocol for 
sample collection (Appendix 7). We did not collect 
wound biopsies, which are commonly cited as the 
gold standard for measurement of bacterial load 
because they remove deeper tissue for analyses.68,136 
However, the collection of wound biopsies 
requires specialist skills and is more painful for 
the patient: their use could only be justiied if 
they offered signiicantly better bacterial load data 
than swabs and we found this dificult to justify 
based on existing data. Studies have compared 
swab techniques with wound biopsies in terms 
of quantifying bacterial load, however the focus 
has typically been on identifying wound infection 
(deined as at least 1 × 106 CFUs/g tissue).62,63 
Bill et al.136 took surface swabs using Levine’s 
technique – swabbing a small area of the wound 
free from slough/necrotic tissue for ive seconds 
with enough pressure applied to obtain luid from 
the wound tissue – and wound biopsies from 38 
patients with diabetic foot ulcers, venous leg ulcers 
and arterial leg ulcers. Wound biopsies identiied 
74% of wounds as having a bacterial load > 105 
organisms/g tissue, compared with 58% of swabs. 
Sensitivity was reported as 79% and speciicity 
60%. Gardener et al.137 compared the measurement 
of bacterial load in non-arterial chronic wounds 
using (1) swabbing wound exudate from the wound 
surface, (2) zigzagging a rotating swab over the 
whole wound area, and (3) Levine’s technique (the 
swabbing approach used in VenUS II was a hybrid 
'2,KWD +HDOWK7HFKQRORJ\$VVHVVPHQW9RO1R
4XHHQ·V3ULQWHUDQG&RQWUROOHURI+062$OOULJKWVUHVHUYHG

of the Levine and the zigzagging approaches). The 
diagnostic value of each swabbing technique was 
assessed by comparing values with the result of 
a tissue biopsy (reference standard) where ulcers 
were classed as being either infected (≥ 1 × 106) or 
non-infected (1 × 106). All samples were cultured. 
The Levine technique performed best – at 90% 
sensitivity, speciicity was 57% (critical threshold 
3.7 × 104 organisms per swab) and the authors 
conclude that the Levine swabbing technique is an 
acceptable alternative to tissue biopsy in identifying 
clinical infection. Davies et al.68 investigated 
the microbiology of venous leg ulcers again by 
culturing quantitative surface swabs and biopsies 
taken from the same 66 patients. The authors 
report an association between increased bacterial 
load and delayed healing whether bacterial load 
was measured by swab or biopsy, with no difference 
in prognostic value.
Existing data suggest therefore that swabs are a 
viable alternative to biopsies in clinical practice 
when diagnosing infection. Unfortunately, there 
are no published data reporting the agreement 
of bacterial load estimates from tissue biopsies 
and swabs, for example using the Bland–Altman 
method.138 It is possible that swabbing could have 
underestimated the bacterial load assessment in 
VenUS II, although there should be no systematic 
differences between the trial arms. Arguably, if 
larval therapy did impact on bacterial load we 
would have expected to see this with the use of 
swabs.
A more serious limitation which offers an 
alternative explanation as to why no difference in 
bacterial load was observed between trial groups 
is that, unlike most studies investigating bacterial 
load and chronic wounds, the samples in VenUS 
II were analysed using molecular techniques.139 
These measured the presence of bacterial DNA 
in samples, rather than culturing samples or 
employing luid microscopy or luorescent live–
dead staining (the cost of and practicalities of 
using these techniques were prohibitive in this 
study, which collected thousands of samples from 
mainly community-dwelling people across the 
UK). Molecular techniques have the advantage 
that bacterial load can be quantiied from a 
single sample, though they do not differentiate 
between live and dead organisms. For this reason, 
the measure of bacterial load may not have been 
sensitive to treatment-related changes if bacterial 
DNA from dead organisms was detected. Despite 
this limitation, however, if larval therapy has a 
clinically important impact on bacterial load we 
would have expected to see an impact of this over 
time using the molecular techniques and we did 
not.
056$
To determine the approximate prevalence of 
MRSA in venous and mixed venous/arterial leg 
ulcers, a pilot study was conducted on the irst 
75 baseline swabs collected for VenUS II. MRSA 
was present in 16% of participants. We obtained 
funds to analyse all swabs at baseline and to follow-
up all MRSA-positive participants. However, 
data for our pilot were obtained using molecular 
techniques that detected S. aureus and the gene 
for methicillin resistance in two separate tests (the 
duplex assay) so the methicillin-resistance gene 
could be detected in the absence of S. aureus. This 
method potentially overestimated the prevalence 
of MRSA. Following the pilot we employed a new 
method that detected methicillin resistance in S. 
aureus only (the single primer set or SPS assay; all 
previous sample were reanalysed). Using this new, 
more accurate approach to measure MRSA for all 
baseline samples, only 6.7% of participants had 
MRSA present in their leg ulcer at baseline. We are 
not aware of any other igures for community leg 
ulcer patients in the UK. This igure is lower than 
previously reported igures for a UK diabetic foot 
clinic (13%)79 (a study in which MRSA was assessed 
using MRSA-speciic cultures). Other prevalence 
estimates of MRSA in ulcer patients are 31% 
for diabetic foot ulcers in patients admitted to a 
specialised diabetic foot unit in France80 and 30% 
in a retrospective analysis of the medical records of 
patients with chronic ulcers admitted to secondary 
care;140 in both cases it is unclear how MRSA was 
assessed.
Concern has been expressed over an apparent 
increase in the presence of MRSA in the 
community, and it has been suggested that 
larval therapy may remove localised MRSA from 
chronic wounds. We assessed the impact of larval 
therapy on MRSA after the debridement phase. 
Of the 18 participants with MRSA at baseline, 12 
(66.7%) were MRSA-free following debridement; 
however, the small numbers involved mean that 
no conclusions can be made regarding difference 
between the treatment arms. One previous study 
conducted in vivo also investigated the impact 
of loose larvae on the presence of MRSA in 13 
patients with diabetic foot ulcers where MRSA 
was detected using MRSA-speciic culturing 
techniques.82 The study reports that MRSA was 
eliminated in 12 of the 13 wounds (92%) treated 
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with loose larvae. However, the conclusions drawn 
from this study are limited because there was no 
control group. We therefore do not know what 
would have happened to similar wounds over the 
same period had they received standard care. 
The VenUS II data highlight the importance of 
a comparison group since MRSA was eradicated 
in nine of 12 cases (75%) in the combined larvae 
group. However, MRSA was also eradicated in three 
of six (50%) of the hydrogel group.
+HDOWKUHODWHGTXDOLW\RIOLIH
Changes in HRQoL from baseline were 
investigated using the SF-12. The poor physical 
health of people with leg ulcers is, as in other 
studies,12 emphasised by the low PCS. There was 
little change in the PCS score during the trial in 
both larvae and hydrogel groups. The MCS scores 
were higher than the PCS but again there was no 
evidence of a statistically signiicant change over 
time. We cannot conclude that larval therapy has 
any impact on participant HRQoL even though 
it increases the likelihood of debridement. The 
HRQoL measures in this study were generic 
rather than disease speciic and so arguably may 
have missed changes in ulcer-speciic dimensions. 
However, our previous work demonstrated that the 
SF-12 and EQ-5D are sensitive to, and thus able to 
measure, change in venous leg ulcer patients.96
$GYHUVHHYHQWV
Overall there were no signiicant differences in 
the numbers and types of adverse events between 
trial treatments. Interestingly, however, more of 
the adverse events reported for patients receiving 
larval therapy were classiied by the treating nurse 
as possibly, probably or deinitely related to the 
treatment (though the actual numbers were small). 
It must be emphasised that this was an open 
trial and therefore nurses were probably more 
likely to attribute adverse events (such as ulcer 
deterioration) to a treatment with which they were 
relatively unfamiliar.
Analysis of ulcer-related pain scores suggests 
that participants had more pain when treated 
with larvae compared with hydrogel. This is the 
irst report of pain associated with larval therapy 
in a large number of leg ulcer patients, with a 
control group for comparison. Previous reports 
regarding the association between pain and larval 
therapy have come from small qualitative studies 
suggesting that some patients have a reduction 
in pain when treated with larval therapy83 while 
some have increased pain.54 As with the reporting 
of adverse events because participants were not 
blinded to treatment there is the possibility of 
some bias against the larvae. However, because 
this is a pragmatic trial and if larval therapy causes 
a perception of increased pain this remains an 
important inding. These data combined with data 
from the qualitative interviews (discussed below) 
suggest that there are some participants for whom 
larval therapy may lead to a substantial increase in 
pain which they attribute to the treatment. Reasons 
suggested in the literature as to why larval therapy 
may increase ulcer pain include a change in wound 
pH and participants with neuropathy having 
increased sensitivity to the movement of the larvae 
or to chemicals secreted by the larvae.41,42
Ulcer deterioration was deined as either an 
increase in ulcer area, malodour, apparent allergy 
and ulcer bleeding. Some ulcer deterioration in 
the larval therapy arms was reported. It is not clear 
if this was related to ulcer bleeding, which has 
been discussed as a side effect of larval therapy. 
Deterioration in the hydrogel group may have been 
related to a lack of response to the treatment and 
subsequent withdrawal from trial treatment.
&RVWHIIHFWLYHQHVV
In a ield where there is a plethora of treatment 
options available to treat leg ulcers it is important 
that, in addition to clinical effectiveness, the value 
for money a treatment offers in terms of cost versus 
beneits is explored. In VenUS II this was assessed 
in both a cost–utility and a cost-effectiveness 
analysis. In both cases trial data suggest that 
larval therapy and hydrogel have similar costs 
and effects. In the base-case analysis the mean 
cost of larval therapy was £97 greater than the 
hydrogel treatment per participant per year and 
slightly more effective (mean difference in time 
to healing 2.4 days, mean difference in QALYs 
0.01 both favouring larval therapy). Yet, there was 
a signiicant amount of uncertainty around the 
parameter point estimates and the corresponding 
ICERs, to the extent that the spread of points on 
the cost-effectiveness plane was almost uniform 
over the four quadrants. The decision uncertainty 
associated with the cost-effectiveness of larval 
therapy when compared with hydrogel indicated 
that there was approximately 50% probability 
of the larval therapy being cost-effective. The 
uncertainty associated with the distribution of 
differential cost and health beneits suggests that 
the costs and effects of larval therapy and hydrogel 
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are likely to be similar in the treatment of sloughy 
leg ulcers. Based on this result it could be argued 
that health care decision-makers should then 
be indifferent when choosing between these two 
therapies; however, given the higher levels of pain 
associated with larval therapy and the requirement 
for advance ordering and appropriate storage, 
decisions about whether to use larval therapy are 
likely to be greatly inluenced by speciic treatment 
goals (e.g. where rapid debridement is required) 
and patient wishes.
A number of sensitivity analyses were conducted 
to assess the impact of altering the base-case 
analysis. Although the use of nurse-reported visits 
(rather than participant-reported) suggested 
that larval therapy was a dominant therapy when 
compared with hydrogel, the decision uncertainty 
associated with the dominance of larval therapy 
was considerable. The probability of larval therapy 
being cost-saving (i.e. dominant) was 50%. There 
was a small number of amputations recorded in 
the trial and twice as many in the hydrogel group 
(n = 2) than the larval therapy groups (n = 1) but 
given that amputations were not reported in a 
systematic way we cannot discard the possibility 
of this difference being the result of chance. The 
number of events is small but the costs associated 
with amputations are high and unsurprisingly 
their inclusion had a signiicant effect on both 
our base-case estimate of mean difference in cost 
and the associated uncertainty. In this scenario 
larval therapy is associated with a 75% chance of 
being cost-saving (i.e. dominant). These data must 
be interpreted with caution, however, because 
a priori there is no reason to believe that rates 
of amputation would differ between trial arms, 
rather what we are observing is likely to be a 
chance imbalance (amputation is relatively rare 
even in this population). What this sensitivity 
analysis highlights is the importance of assessing 
amputation as an outcome in future wound-care 
trials.
Carrying out one-way sensitivity analyses where 
the setting and duration of nurse visits were both 
decreased and increased to assess the impact on 
cost-effectiveness did not impact on the cost-
effectiveness conclusions.
It is important to note that the economic evaluation 
in VenUS II has only compared larval therapy with 
hydrogel and found them likely to have similar 
cost and health beneits, i.e. indistinguishable cost-
effectiveness. In practice there are several other 
methods available for debriding wounds, so when 
making debridement treatment choices decision-
makers are faced with a more complex decision 
than that represented by this trial. In terms of 
assessing cost-effectiveness, RCTs are limited by 
the number of comparisons they can make.141 In 
this case we do not know how larval therapy or 
hydrogel relate to other debridement treatments in 
terms of cost-effectiveness. To make an informed 
decision from this wide selection of treatment 
options to ensure the most cost-effective treatments 
are used, data from this RCT and other studies 
should be incorporated into further decision 
analytic modelling work. This approach allows 
the synthesis of data on the costs and effects from 
relevant studies in a suitably structured model. The 
value of this approach is that, data permitting, the 
cost-effectiveness of several treatment options can 
be compared simultaneously.
4XDOLWDWLYHVWXG\SDWLHQW
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People with leg ulcers who had not received larval 
therapy were interviewed to assess their views 
about the acceptability of larval therapy with most 
stating that they would accept larval therapy as 
a treatment. Most of the participants had strong 
beliefs about the effectiveness of the treatment that 
stemmed from the media or anecdotal report. What 
was perhaps surprising is how generally acceptable 
larval therapy is to the relevant patient population; 
there were only two cases where interviewees 
would not consider larval therapy under any 
circumstance. In one case where a participant 
found the idea of larval therapy unacceptable 
the news that a bagged larvae formulation was 
available made larvae more acceptable; however, 
overall strong preferences were not expressed for 
bagged larvae. In one case a participant required 
effectiveness information to make an informed 
decision about whether to have loose of bagged 
larvae.
The indings from these patient interviews agree 
with previous work in which 35 UK patients with 
leg ulcers were asked about their preference 
for different types of larval therapy and their 
thoughts regarding the treatment.142 In this study, 
larval therapy was acceptable to a majority (77%) 
of interviewees. As with data from our study, 
patients expressed a strong desire to heal their 
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ulcers – expressed as a willingness to try different 
treatments. In this previous study 23% (8/35) of 
participants would not consider larvae to treat their 
leg ulcer – of these eight, seven were women.142 In 
VenUS II, two participants who stated initially that 
they would not accept larvae were also women.
The nurse data mirrored the participant data. 
Most nurses were happy to use larval therapy, 
especially after seeing positive debridement results 
in practice. Some nurses had previously successfully 
overcome some squeamishness. However, there 
were a small number of nurses who would not 
consider the use of larval therapy at all because 
of the nature of the therapy. Although there 
have been previous studies on the acceptability 
of larval therapy to participants, this is the irst 
that highlights how important it is that nurses are 
happy to deliver the treatment.
The role of the nurse seems important in 
reassuring the patient about the treatment, 
especially explaining how the larvae were secured 
into place so that they could not escape. The 
importance of the treating health professional 
in helping to inform patients to make a decision 
about having larval therapy have also been 
highlighted elsewhere.83,142 The nurses interviewed 
for VenUS II recognised that there are a number 
of leg ulcer patients who would try anything in 
the treatment of their ulcer, whereas there are 
others who would never consider larval therapy. 
Unlike patient participants, nurses appeared to 
have a preference for bagged larvae because they 
were viewed as easier and quicker to apply. The 
nurses believed that the bagged larvae would be 
more acceptable to participants, but this was not 
borne out in the participant interviews. It remains 
possible that some nurse antipathy to larval 
therapy partly explains our poor recruitment to the 
trial.
It is interesting to note that several of the nurses 
interviewed anticipated the results of VenUS II in 
that their clinical experience was of larvae leading 
to rapid debridement, although they did note that 
this debridement was often only temporary. There 
was less certainty expressed about the impact of 
larval therapy on healing.
3DWLHQWH[SHULHQFH
Of the ive interviewees who had received larval 
therapy two reported associated pain, which 
was severe in one case. Nurses also recognised 
that larval therapy may be associated with pain, 
although the nature and severity of this pain may 
have been underestimated. When nurses had 
treated patients who had reported extreme pain 
resulting in early termination of larval therapy, the 
nurses outlined potential underlying reasons for 
the pain, including arterial disease.
Interestingly, participants who had received larval 
therapy and nurses who had used it seemed to 
recognise that the treatment cleaned wounds – 
there was little discussion about healing, apart from 
the uncertainty about the impact of larval therapy 
on healing by nurses. The anecdotal reports of 
both the patients and the nurses suggest that 
debrided wounds are liable to reslough after the 
removal of larval therapy.
&RQVLGHUDWLRQRI
WKHPHFKDQLVPVDQG
H[SORUDWLRQRINH\ÀQGLQJV
Although VenUS II demonstrates convincingly 
that larval therapy is a more effective debriding 
agent than hydrogel, healing and debridement 
are not linked in a straightforward manner as is 
often suggested.23,143 In fact there are no high-
quality data demonstrating a causal link between 
debridement and increased healing2,24,144 and 
although there appears to be a strong clinical belief 
in the importance of debridement. For example, 
the most widely cited evidence that debridement is 
directly linked to faster healing is a trial of a growth 
factor in diabetic foot ulcers145 in which a post hoc 
analysis of centre effects identiied a correlation 
between ‘high debriding’ centres and better 
healing. Clearly this is circumstantial evidence 
that requires further experimental investigation; 
however, we have been unable to identify an RCT 
of sharp or surgical debridement (because such 
a trial would be the most direct evaluation of 
debridement per se without the extraneous effects 
of dressings and other procedures). A more recent 
study in non-healing chronic venous leg ulcers 
compared sharp debridement of sloughy ulcers 
with the usual care of non-sloughy, non-healing 
ulcers because the authors claimed it was not 
ethical to randomise.144 This small evaluation 
(n = 55), although showing greater rates of healing 
in the debrided group, suffers from huge selection 
bias and never compared ulcers with similar 
prognosis (and there are few or no data available 
on the value of slough as a prognostic variable).
'2,KWD +HDOWK7HFKQRORJ\$VVHVVPHQW9RO1R
4XHHQ·V3ULQWHUDQG&RQWUROOHURI+062$OOULJKWVUHVHUYHG

We cannot claim that VenUS II is a trial of 
debridement; it is a trial of larval therapy, which 
has been claimed to have wide and varying effects 
from debridement through antibacterial to direct 
healing effects. Nevertheless, our trial analysis has 
found no impact of larvae on healing even with the 
effective early debridement obtained using larvae. 
We plan a more detailed analysis of the relationship 
between debridement and healing using the trial 
data, but such a piece of work was outside the 
scope of this inal report. Finally, it may be that 
successful debridement (i.e. a clean wound) has 
value to patients irrespective of any perceived link 
with healing; however, we have been unable to ind 
any data in the literature regarding this and our 
HRQoL data showed no such effect. Additionally 
the importance patients place on debridement is 
likely to be inluenced by nurses’ attitudes.
We anticipate some criticism from strong advocates 
of larval therapy that time to complete healing was 
an inappropriate end point for the evaluation of a 
debridement treatment. They may feel that because 
larval therapy (and its comparator treatment) 
ceased often months before healing, then an effect 
on healing should not be investigated. There are 
important reasons, however, why it was essential to 
examine healing; irst larval therapy is promoted 
as having an effect on healing and second there 
is no evidence (see above) of the link between 
debridement and healing. Our trial was pragmatic 
and relects routine leg ulcer care in the UK in 
which patients have short bursts of debridement 
treatments in the hope of preparing the wound 
bed for healing.143 For such an intervention to 
be worthwhile from a clinical and economic 
perspective one would expect to see an impact on 
the most important outcome, namely healing.
&RQWULEXWLRQRIWKLV
WULDOWRWKHHYLGHQFH
This is the irst RCT that we have identiied to 
investigate the effectiveness of larval therapy on 
the healing of venous and mixed venous/arterial 
ulcers. The only other published RCT of larval 
therapy was small and had debridement as a 
main outcome measure, hence a limited follow-
up period. Although RCT evidence is limited, 
there are several non-RCT studies that advocate 
the use of larval therapy as a clinically effective 
treatment26,30,31,34,146 – with ‘effective’ variously 
deined as: the promotion of healing,41,44–46,147 
promotion of debridement,33 reduction of micro-
organisms in the wound37–39 and reduction of 
MRSA speciically.39
VenUS II supports the view that larval therapy 
is an effective debriding agent. However, it also 
raises an important question regarding the role 
of debridement in leg ulcer care. Further research 
is required to explore the relationship between 
debridement and healing and debridement and 
wound microbiology. Some of this we plan to 
undertake with the data collected in this trial 
but more clinical research in conjunction with 
laboratory studies is probably merited. It is clear 
that healing can (and did in this study) occur in 
the presence of what experienced clinical nurses 
regarded as ‘slough’. It may be that clinicians 
are currently unable to discriminate between 
slough and other forms of exudate which may 
be conducive to healing. If this is the case then a 
debridement strategy could be beneicial in some 
situations and harmful to healing in others.
A piece of good news arising from this trial is 
the relatively low rate of MRSA identiied in leg 
ulcers in community-dwelling individuals. This 
inding contrasts with other reports79,80 but used 
the latest, more sensitive, molecular techniques for 
identifying MRSA. We have also demonstrated that 
MRSA can disappear from leg ulcers irrespective of 
whether or not patients received larval therapy.
6WUHQJWKDQGOLPLWDWLRQV
RIWKHVWXG\
6WXG\VL]H
Recruitment of suficient numbers of eligible 
patients was a huge challenge for this trial and 
we did not reach our initial sample size despite 
an extension in time and funding. The reasons 
for this are probably complex. Anecdotally, 
nurses reported that there were fewer leg ulcer 
patients ‘on their books’ than 5 years previously, 
attributing this to increased use of compression 
bandaging. Second, fewer ulcers than we originally 
anticipated were ‘sloughy’. Indeed the main single 
reason for participant exclusion was ulcers not 
containing suficient slough to be eligible. Because 
this is a prerequisite for using larval therapy, our 
experience in VenUS II suggests that performing 
a larger trial in the UK would be challenging. 
Information on these recruitment issues before 
the conduct of this full study would have been 
invaluable. This highlights the value of conducting 
pilot trials where feasibility data can be used to 
'LVFXVVLRQ

assess recruitment rates and issues and plan in 
advance for these when designing a full trial.
%OLQGHGRXWFRPHDVVHVVPHQW
Like most trials of wound treatment in a 
community setting, we were unable to conduct in 
person, blinded outcome assessment for reasons 
of logistics and resourcing. Although blinded 
outcome assessment is fairly easy to achieve in a 
clinic or hospital setting, most of our participants 
were seen in their own homes. To conduct blinded 
outcome assessment for people treated at home 
we would need blinded assessors to lurk outside 
patients’ homes while the treating nurse took away 
all evidence of current treatment, cleaned up the 
ulcer and then called the assessor in. Given the 
dispersed nature of leg ulcer patients through the 
community and the many nurses involved this was 
not logistically possible and would have doubled 
the cost of the trial. We are satisied that our 
approach of remote, blinded assessment of serial 
photographs is robust and we would emphasise 
the importance of clinically active nurses making 
the assessments because ultimately whether a 
wound is regarded as clean, or healed, is a clinical 
judgement.
Although we did not ind a difference in our 
primary outcome whether we used blinded or 
unblinded healing data, other wound trials have 
observed such as difference.148 In a study of a 
dressing to treat exuding wounds the statistically 
signiicant effect in favour of the intervention 
seen using non-blinded data disappeared when 
blinded outcome assessment was used.147 It is 
important to note that this study’s outcome was 
wound improvement rather than healing, which is 
arguably a more objective outcome.
The use of blinded outcome assessment means that 
we have more conidence in our primary outcome 
but it is important to note that undertaking such 
assessment is not easy. In some cases we did not 
receive photographs (e.g. where a camera was 
stolen or camera data cards were lost) and we 
had to fall back on unblinded data. Using real-
time assessment of photographs would also help 
to ensure as complete a data set as possible was 
available for blinded assessment. In future trials 
we would investigate the e-mailing or texting 
of images to allow closer, contemporaneous 
monitoring of images. During our pilot phase of 
the blinded outcome assessment process we noted 
that the clinical deinition of healing that nurses 
had used was slightly different from the deinition 
that was in the protocol. Nurses were classifying 
ulcers as healed in the presence of small amounts 
of dry skin and eschar, and this did not agree with 
our protocol. Had we not undertaken the blinded 
outcome assessment we would not have detected 
this discrepancy. It is unclear if the interpretation 
of healing is an issue for other studies. If we had 
followed the protocol deinition we may have 
underestimated healing and compromised the 
pragmatic nature of the trial. We consulted with 
senior tissue viability nurses who agreed with 
the trial nurses in that an ulcer could be classed 
as healed in the presence of small amounts of 
eschar as long as a dressing was not required. 
As a consequence we changed our deinition for 
the assessment process. We did not change our 
protocol because the assessment occurred after all 
data had been collected. This change represents 
a limitation of the study. However, we do not 
anticipate that this change will have inluenced our 
results.
$WWULWLRQ
As with VenUS I, we observed a marked reduction 
in the patient questionnaire response rate over 
time. At 12 months from baseline almost 50% of 
HRQoL data were missing. This was in spite of 
our efforts to ensure the return of questionnaires 
(reminders and a inancial incentive). Preliminary 
analysis suggests that those participants who healed 
were more likely to return data so we may have 
overestimated HRQoL scores. It is important to 
highlight that, overall, there was no evidence of 
differential attrition within trial group.
*HQHUDOLVDELOLW\
RIWKHUHVXOWV
The data from VenUS II were collected from 18 
centres across England and Northern Ireland. 
However, Figure 2 highlights that most recruitment 
took place in clinical sites in the North of England. 
Different sites had different models of practice 
including outpatient clinics, community tissue 
viability services and district nursing teams, 
encompassing the different practices common to 
the UK and enhancing the generalisability of the 
study.
&RQFOXVLRQV
Larval therapy signiicantly reduced the time to 
debridement of slough and/or necrotic, chronic 
venous and mixed venous/arterial leg ulcers, 
compared with hydrogel. However, larval therapy 
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did not increase the rate of healing of the ulcers 
nor did it reduce bacterial load and larval therapy 
was associated with signiicantly more pain in the 
24 hours before removal of the irst application 
than hydrogel. Larval therapy was broadly 
acceptable to both patients who had and had not 
received it previously. It was impossible on the 
basis of this evidence to distinguish between larval 
therapy and hydrogel in terms of cost-effectiveness.
,PSOLFDWLRQVIRUKHDOWKFDUH
There is no evidence from this trial that larval 
therapy should be used routinely on sloughy or 
necrotic leg ulcers with the aim of speeding healing 
or reducing bacterial load. If debridement per se is 
a treatment goal, e.g. before skin grafting or other 
surgery, then larval therapy should be considered; 
however, it is associated with signiicantly more 
pain than hydrogel. Most patients we interviewed 
were happy to consider larval therapy. However, 
future treatment decisions should be fully informed 
by the inding that there is no evidence of an 
impact on healing time.
5HFRPPHQGDWLRQV
IRUIXWXUHUHVHDUFK
Although this study did not ind any evidence that 
the use of an active debriding agent such as larval 
therapy results in more rapid healing of venous 
and mixed aetiology leg ulcers compared with a 
more passive debriding agent such as hydrogel, 
this trial does not directly answer the question of 
whether debriding sloughy and necrotic wounds 
speeds their healing. There is a variety of ways 
by which the bigger debridement question could 
be tackled; one could compare sharp (surgical) 
debridement with no active debridement for 
example, or, more pragmatically, one could 
compare the effect of having a policy of active 
debridement with a policy of no debridement. Such 
studies are likely to be focused on speciic wound 
types, because the advantages of debridement may 
vary for different aetiologies. In reality it may be 
very dificult to garner suficient enthusiasm for a 
debridement trial among clinicians, many of whom 
are unlikely to be in equipoise regarding the value 
of debridement.
Relatively little is known about the nature of the 
outcomes that matter most to the people with 
chronic wounds themselves and more research is 
needed on this topic, including an exploration of 
the value of debridement to patients and clinicians. 
It may be that a clean wound is perceived as having 
a value beyond that accruing from the association 
with a shorter healing time.
To inform health care professionals’ selection 
of debriding agents where debridement is the 
treatment goal, decision analytic modelling of all 
alternative debridement treatments is required.
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3OHDVHUHDGWKLV
GRFXPHQWFDUHIXOO\
We would like to invite you to take part in a 
research study. Before you decide whether to take 
part it is important for you to understand why the 
research is being done and what it will involve. 
Please take time to read the following information 
carefully. Feel free to discuss this with anyone else 
you wish to, for example, friend/nurse/doctor or 
relative. Ask us if there is anything that is not clear. 
We are happy to provide more information. Take as 
much time as you need to decide whether you want 
to take part.
Thank you for reading this.
:KDWLVWKHSXUSRVH
RIWKLVVWXG\"
This is a study of larval therapy for the treatment of 
leg ulcers. Larval therapy involves the application 
of small, sterile maggots to a skin ulcer or wound. 
It is thought that larval therapy helps with healing 
but we need to ind out if this really is the case.
Leg ulcers are common and can be very distressing 
for patients. Leg ulcers may contain dead skin cells 
and this dead tissue (called slough) is thought to 
delay healing. The removal of the dead tissue is 
undertaken in an attempt to speed up the healing 
process. Several different treatments can be used 
to clean a leg ulcer including different wound 
dressings and larval therapy. The use of hydrogel 
wound dressings is very common and simply 
involves applying a watery jelly to the ulcer. This 
treatment can work quite slowly, and it is thought 
that larval therapy may be a quicker way to clean 
up the ulcer and to help healing.
:KDWLVWKHWUHDWPHQW
EHLQJVWXGLHG"
We are looking at larval therapy (also called 
maggots). Larval therapy involves the use of 
larvae (sterile maggots). The larvae may be put 
onto the wound in a sealed bag or placed directly 
onto the wound and kept in place with a sealed 
dressing system. The main dressings containing the 
larvae are left in place for up to 5 days. The outer 
padding is changed as often as required. Most 
people only need one or two applications of larvae 
to clean up their ulcer (over 1 or 2 weeks), and can 
then have regular wound dressings until their ulcer 
heals.
:K\KDYH,EHHQFKRVHQ"
Your nurse and/or doctor think that you might 
beneit from treatment to remove dead tissue from 
your leg ulcer. Across the UK about 300 people 
with leg ulcers will be asked to take part in this 
study.
'R,KDYHWRWDNHSDUW"
Participation in this study is entirely voluntary. It 
is up to you to decide whether or not to take part. 
If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a 
consent form. If you do decide to take part you 
can still change your mind at any time. Your future 
care and treatment will not be inluenced by your 
decision to take part or not. If you do agree to 
take part in this study and decide at a later time 
to withdraw then you are free to do so at any time 
without inluencing your future care or treatment.
$SSHQGL[
3DWLHQWLQIRUPDWLRQVKHHW
Site heading
$SSHQGL[

:KDWZLOOKDSSHQWRPH
LI,DJUHHWRWDNHSDUW"
We are interested in how quickly the ulcers heal, 
and also in your opinion about the treatment you 
receive. In order to compare the treatments we 
need to treat approximately 100 patients with the 
larval therapy in bags, 100 patients with loose 
larval therapy and another 100 with hydrogel 
wound dressings. If you agree to take part in 
this study you will be allocated to one of these 
three treatments. The decision regarding which 
treatment you will receive will be made after you 
agree to take part. The choice of treatment will be 
determined at random, that is we cannot predict 
which treatment you will receive. You will have an 
equal chance of receiving each treatment, in the 
same way that tossing a coin gives an equal chance 
of getting ‘heads’ or ‘tails’. Two people out of every 
three in the trial will receive larval therapy.
:KDWGR,KDYHWRGR"
You will continue seeing your community nurse or 
clinic staff for the leg ulcer dressings to be carried 
out. The ulcer will be traced and photographed 
at the start of the study and then regularly to 
see if the ulcer is reducing in size. The study will 
last for 12 months. You will be asked to complete 
several questionnaires, at entry into the study, and 
at 3, 6 and 12 months after that. We will send you 
questionnaires about your leg and how it affects 
you, even if your ulcer has completely healed. We 
do not anticipate that you will have to see the nurse 
or attend your clinic more frequently than would 
normally be required. For this reason we will not be 
able to pay any travel expenses incurred.
There are no restrictions on your activity when 
you are in the study. You will continue with any 
other medical treatment, such as taking regular 
medication.
:K\GRWKHVWXG\"
Larval therapy may be more effective than using 
hydrogel wound dressings. It is therefore important 
to carry out this study so that patients with leg 
ulcers can be provided with the most appropriate 
and effective care. We are also interested in how 
you feel while you have the leg ulcer treatment so 
that nurses, doctors and patients can make future 
decisions about which treatments are comfortable. 
Without this information patients may receive 
ineficient care, and precious NHS money may be 
wasted.
$UHWKHUHDQ\DOWHUQDWLYHVWR
WKHWUHDWPHQWVEHLQJVWXGLHG"
There are a number of treatments for removing 
dead tissue from leg ulcers. Wound dressings to 
keep the ulcer moist can be used. The body can 
remove dead tissue beneath moist dressings. Less 
commonly, the nurse or doctor can sometimes 
remove dead tissue using forceps.
$UHWKHUHDQ\VLGHHIIHFWV
IURPWKHODUYDOWKHUDS\"
There may be an increase in the amount of luid 
coming from your wound. This is perfectly normal. 
The colour of the liquid will also change and will 
be slightly pink. There may also be a change in the 
smell of the wound – this is caused by the maggots 
and is perfectly normal. The smell is usually 
masked by the layers of bandages on top and will 
go as soon as the outer dressing is changed. It is 
sometimes possible to feel a different sensation in 
the wound after the maggots have been applied. If 
you wish to have the maggot therapy discontinued 
for any reason then you can have it removed.
$UHWKHUHSRVVLEOH
GLVDGYDQWDJHVWRWDNLQJSDUW"
We do not anticipate that being in this trial will 
harm you. Should this occur, however, normal NHS 
negligence procedures will apply.
In an emergency you should contact your 
community nurse or clinic nurse. The name of a 
contact nurse and telephone number where they 
can be reached is provided below.
:KDWDUHWKHSRVVLEOH
DGYDQWDJHVRIWDNLQJSDUW"
We hope that your ulcer will improve with either 
treatment (larvae or gel). We cannot guarantee that 
your ulcer will improve by your being in the trial. 
The information we get from this study may help 
us to treat people with leg ulcers better.
:KDWLIQHZLQIRUPDWLRQ
EHFRPHVDYDLODEOH"
Sometimes during a research project, new 
information becomes available. If this happens, 
your nurse/doctor will tell you about it. They will 
discuss with you whether you want to continue in 
the study. If you decide to withdraw from the study 
your care will continue without the trial treatments. 
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If you decide to continue, then you will be asked to 
sign an updated consent form.
If new information means that your nurse or doctor 
decides to take you out of the study, then she/he 
will discuss this with you. He/she will explain the 
reasons for this and arrange for your leg ulcer care 
to continue without the trial treatment.
:KDWKDSSHQVZKHQWKH
UHVHDUFKVWXG\VWRSV"
Larval therapy is only available in some clinics. 
Gel wound dressings are available to every nurse/
doctor in the UK. After the research stops the gel 
treatment will continue to be available throughout 
the UK. Larval therapy may not be available in 
your area once the trial stops.
:KDWLIVRPHWKLQJJRHVZURQJ"
If taking part in this research project harms you, 
there are no special compensation arrangements. 
If you are harmed due to someone’s negligence, 
then you may have grounds for a legal action but 
you may have to pay for it. Regardless of this, if 
you wish to complain, or have any concerns about 
any aspect of the way you have been approached or 
treated during the course of this study, the normal 
NHS complaints mechanisms should be available 
to you.
:LOOP\WDNLQJSDUWLQWKLV
VWXG\EHNHSWFRQÀGHQWLDO"
All information that is collected about you during 
the course of the research will be kept strictly 
conidential. Any information about you that leaves 
the hospital/surgery will have your name and 
address removed so that you cannot be recognised 
from it.
If you consent to take part in the research, the 
University of York (for purposes of analysing the 
results) may inspect any of your medical records. 
People from regulatory authorities may also look 
at them to check that the study is being carried out 
correctly. Your name, however, will not be disclosed 
outside the hospital/GP surgery.
Your GP will be notiied of your participation in the 
trial.
:KDWZLOOKDSSHQWRWKH
UHVXOWVRIWKHVWXG\"
The results of the study will be published in 
medical and nursing journals. This is likely to 
happen in 2008. You will be able to obtain a copy 
of the results from the University of York. You will 
not be identiied in any publication arising from 
this study.
:KRLVRUJDQLVLQJDQG
IXQGLQJWKHUHVHDUFK"
The study is being funded by part of the UK NHS 
(the Health Technology Assessment Programme). 
They have provided funds to pay for the larval 
therapy, for research nurses, and for the tests to 
monitor your wound (e.g. camera, wound tracing). 
The research nurses will work with your regular 
nurse/doctor to collect all the information needed. 
Your nurse or doctor is not receiving any money for 
including you in the trial.
The study is being organised by researchers from 
the University of York.
:KRKDVUHYLHZHGWKHVWXG\"
The West Midlands Research Ethics Committee 
has reviewed the study. Your Local Research Ethics 
Committee has also been involved in reviewing the 
study.
:KDWGR,GRQRZ"
If you are interested in taking part please complete 
the enclosed questionnaire and sign the consent 
form, returning it to your study nurse in the 
envelope provided.
:KHUHFDQ,JHWPRUH
LQIRUPDWLRQDERXWWKHVWXG\"
If you do not understand anything on this 
information sheet or would like further information 
please contact your local research nurse on the 
telephone number below.
Local nurse: Telephone number:
 Address:
Research coordinator:  Telephone number:
 Address:
Thank you for taking the time to read this 
information sheet
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3LFNWKHQHDUHVWVL]HIURPWKHPHDVXUHPHQWVRQWKHOHIWRIWKHFKDUW
0RYHVLGHZD\VWRWKHDSSURSULDWHSHUFHQWDJHRIZRXQGFRYHUDJH
6WDWHWKHQXPEHURISRWVUHTXLUHGIURPZLWKLQWKHFHOO
0D[LPXP
ZRXQGVL]HFP
3HUFHQWDJHRIZRXQGFRYHUHGZLWKVORXJKQHFURWLFWLVVXH
    
XSWRð     
ð     
ð     
ð     
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ð     
ð     
ð     
ð     
ð     
ð     
ð     
1RWHWKDWWKHFDOFXODWRURQO\PHDVXUHVWKHVXUIDFHDUHDRIWKHZRXQG,IWKHZRXQGKDVVLJQLÀFDQWGHSWKPRUHODUYDHPD\
EHUHTXLUHG
$SSHQGL[

$SSHQGL[
7$%/( /DUYDOFDOFXODWRUVIRUORRVHDQGEDJJHGODUYDH
$SSUR[LPDWH
ZRXQGVL]HFP
3HUFHQWDJHRIZRXQGDUHDFRYHUHGZLWKQHFURWLFWLVVXH
    
ð
ð
ð
ð
ð
ð
ð
ð
ð
ð
ð
$SSUR[LPDWHQXPEHURIIUHHUDQJHVWHULOHODUYDHUHTXLUHG
     
%LREDJVDUHDYDLODEOHLQWKHIROORZLQJVL]HV
%LR%DJ0LQL ODUYDH ðFP
%LR%DJ6PDOO ODUYDH ðFP
%LR%DJ0HGLXP ODUYDH ðFP
%LR%DJ/DUJH ODUYDH ðFP
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$SSHQGL[
)ORZFKDUWRI9HQ86,,
Pre-trial screening
Patient not eligible Patient eligible
Patient
consents
Nurse Participant
Complete: Patient Record Form
Collect: tracing(s), photograph(s),
wound swab
Completes: Baseline Patient
Questionnaire
Patient gives completed
questionnaire to nurse
Complete: Phase 1 Application Booklets
until reference ulcer debrided
Collect: Wound swab + checklist after
each application until debridement, if
debrided before 1 month, weekly up to
1 month, then monthly
Digital image weekly until 6 months then
monthly until reference ulcer healed/
trial exit
When reference ulcer debrided/withdrawn
from treatment phase 2, complete
Dressing Log Booklet UNTIL
Reference ulcer heals
Complete: Reference
Ulcer Healed Form
Reference ulcer is unhealed
at trial end
Complete: Trial Exit Form
If no unhealed ulcers
on reference leg, 
complete Trial Exit
Form
If unhealed (non-reference
ulcers), continue to complete
Dressing Log Booklet until
12 months have elapsed/
trial end (whichever first)
then complete Trial Exit Form
Fills in 3-monthly
questionnaires to trial end
Responds to nurse's
questions about pain
Patient does
not consent
Give Patient Information Sheet
If participant withdrawn
from trial treatment
complete Withdrawal
from Treatment form
and move to phase 2
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Every digital photograph must include the colour reference target card, which includes 
a centimetre measuring scale and colour targets. 
The patient’s trial number and date must ALWAYS 
be clearly written on the colour target card. Please 
make sure that the colour target card is included in 
the photograph otherwise the photograph cannot 
be used as data collected.
Please take two photographs at baseline and at 
healing.
1. reference leg toe to knee (colour target card 
placed near to toe end of leg)
2. reference Ulcer Only – ** See ‘Taking the 
Weekly Photographs’ overleaf.
Please always try to take a photograph of the 
reference leg ulcer from directly above the wound, 
if it is photographed at an angle it may be dificult 
to assess the wound accurately.
In the case of circumferential wounds additional 
adjacent photographs may be required.
Every reasonable effort must be made to take all 
consecutive photographs from the same viewpoint 
and distance using the same camera and same 
zoom facility.
Please ensure that the ulcer and surrounding 
area are cleaned thoroughly before taking the 
photograph. This is to reduce the possibility 
of blinded assessors being able to predict the 
treatment received by the patient (e.g. zinc paste 
around the wound might indicate the patient had 
received loose larval treatment).
All consecutive views of the reference ulcer area to 
be photographed using the trial camera.
All cameras have been calibrated so they are 
standardised to the same speciication – please do 
not change any of these settings at any time.
All digital photographs to be kept conidential 
and secure for the duration of the trial. Patient 
conidentiality will be maintained throughout trial 
by the use of unique trial numbers.
No ilm, recording media or data to be 
manipulated or changed in any way with the 
intention of affecting the results of the trial.
Copies of all photographs taken during the trial 
will be:
• saved on a Compact lash card
• stored on the Local Research Nurse’s computer
• sent on the Compact lash card to the Trials 
Unit, University of York.
The photographs will then be transferred from 
the Compact lash card onto a trial database at the 
Trials Unit in York and then be deleted from the 
Compact lash card and the card returned to the 
Local Research Nurse to be used again.
All cameras have been calibrated to the same 
speciication as follows:
• automatic mode – the camera responds to the 
shooting conditions at the time and controls 
the majority of camera settings
• white balance is automatically set and used to 
preserve the natural colours under types of 
lighting
• the lash is set to automatic
• image quality/size – set to 3M (normal – 
2048 × 1536)
All cameras are supplied with a guide and it might 
be helpful to read this before you start to use the 
camera.
7DNLQJSKRWRJUDSKV²
IUDPLQJWKHSLFWXUH
Hold the camera steadily in both hands about 18 
inches to 2 feet (45–60 cm) away from the patient. 
$SSHQGL[
'LJLWDOLPDJHSURWRFRO
$SSHQGL[

Zoom in using the optical zoom facility on the 
camera (PRESS T) ensuring that the whole of the 
wound area and the colour reference target card 
are included in the picture (see page 18 in your 
camera guide book).
When you press the ‘T’ button a white oblong box 
will appear in the top of the viewinder and a bar 
will move towards the line (two-thirds along the 
box) until it stops. Stop pressing the ‘T’ button at 
this stage and take your photograph. Press the ‘W’ 
button to zoom out.
),*85( 1LNRQ&RROSL[
W T
W T
Press T to operate
the optical zoom
Press W to take
this facility off
Play button
Press this to view the
latest picture taken
Delete button
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6SHFLPHQFROOHFWLRQ
Explain to the participant that you are about to 
take a wound swab from their leg ulcer.
Please DO NOT clean the wound before taking the 
swab to ensure the maximum numbers of bacteria 
are present.
Take the swab from an area of the wound 
containing viable tissue if possible (e.g. granulating 
tissue).
Avoid taking the sample from areas of the wound 
covered with slough or necrotic tissue.
&ROOHFWLRQPHWKRG
SWAB: rotate the swab, moving across the area in a 
zigzag fashion, applying light pressure with the aim 
of saturating the swab.
$SSHQGL[
:RXQGVZDESURWRFRO
If the wound is very dry you may moisten the swab 
with sterile water or sterile saline to aid in the 
collection of the specimen.
:KHQ\RXKDYHFROOHFWHGWKHVSHFLPHQ
• place the swab in the swab container
• write the patient’s trial number and date of 
birth on the sticky label provided and seal the 
container with this label
• write the same information on the pathology 
specimen form
• THE INFORMATION ON THE SWAB 
LABEL AND THE FORM MUST MATCH 
OTHERWISE THE SPECIMEN WILL NOT 
BE VALID
• place the sealed swab inside the plastic bag 
provided, fold the form and place it in the 
outer pocket of the polythene bag then place in 
the prepaid, addressed, padded envelope.
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3DWLHQWLQIRUPDWLRQVKHHW
3DWLHQWV·EHOLHIVDQGH[SHULHQFHVRIODUYDO
WKHUDS\LQWKHWUHDWPHQWRIOHJXOFHUV
You are being invited to take part in a research 
study. Before you decide it is important for you to 
understand why this research is being done and 
what it will involve. Please take time to read the 
following information carefully and discuss it with 
your relatives and the nurse if you wish. Ask if there 
is anything that is not clear or if you would like 
more information. Take time to decide whether 
or not you wish to take part. Your involvement is 
entirely voluntary.
The information gathered from this study will 
provide information about how people with leg 
ulcers view larval therapy (sterile medical maggots) 
and will not inluence the treatment of your leg 
ulcer in any way. If you do decide to take part you 
will be asked to sign a consent form, and will be 
given a copy of this to take away. You will be able 
to leave the study at any time, without giving a 
reason. This will not affect any aspect of your care. 
If you decide not to take part this will not affect any 
aspect of your care.
Background to the study
Larval therapy is another name for the use of 
maggots in wound care. A large clinical study is 
being undertaken to ind out if leg ulcers heal more 
quickly by using maggots. The maggots used are 
small, sterile maggots. The maggots are placed 
on the ulcer and covered by a bandage. As part 
of this study, we are interested in knowing your 
views about the use of maggots in the treatment of 
wounds.
What would the study involve?
A nurse researcher will ask patients with a leg ulcer 
to agree to be interviewed on one occasion. This 
can be done in a place of your choosing: in the 
setting you usually receive care for your leg ulcer, in 
your home or at the leg ulcer clinic. The interview 
would be tape recorded and then typed out in 
full. During the interview you will be asked about 
treatments you have received for your leg ulcer and 
how you feel about the use of maggots.
All information that is collected about you during 
the course of this study will be strictly conidential. 
Your name and personal details will be removed so 
that you cannot be recognised.
What will happen to the 
results of this study?
This study will lead to a better understanding 
of how acceptable the use of larval therapy is to 
people with leg ulcers. This information will be 
used in the large study of larval therapy to help us 
identify the reasons people agree to this form of 
therapy or why they might not want this form of 
therapy.
Administrative information
This study has been commissioned by the 
Department of Health Research and Development 
Health Technology Assessment Programme. The 
funding has enabled a researcher to be employed 
to interview patients who is not involved in your 
care in any way and is not employed by the hospital 
or community.
$SSHQGL[
4XDOLWDWLYHLQWHUYLHZVSDUWLFLSDQW
DQGQXUVHLQIRUPDWLRQVKHHWV
Site heading
$SSHQGL[

This study has been reviewed and approved by a 
multicentre research ethics committee.
Thank you for considering this study. If you have 
any questions about the study at any time, please 
contact:
Dorothy McCaughan
Department of Health Sciences
University of York, YO10 5DD
Tel: 01904 000000
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Site heading
1XUVHLQIRUPDWLRQVKHHW
1XUVHV·EHOLHIVDQGH[SHULHQFHVRIODUYDO
WKHUDS\LQWKHWUHDWPHQWRIOHJXOFHUV
You are being invited to take part in a research 
study. Before you decide it is important for you to 
understand why this research is being done and 
what it will involve. Please take time to read the 
following information carefully. Please contact the 
researcher if there is anything that is not clear or if 
you would like more information. Your involvement 
is entirely voluntary. If you do decide to take part 
you will be asked to sign a consent form. You will be 
able to leave the study at any time, without giving a 
reason.
Background to the study
A large clinical study is being undertaken to ind 
out if leg ulcers heal more quickly by using larval 
therapy (sterile medical maggots). As part of this 
study, we are interested in knowing your views 
about the use of maggots in the treatment of 
wounds.
What would the study involve?
A researcher is interested in talking to nurses who 
are involved in caring for people with leg ulcers 
to ind out your views about the use of maggots in 
clinical care. You will be asked to participate in one 
interview which can be done in a setting convenient 
to you. The interview would be tape recorded and 
then typed out in full.
All information that is collected about you during 
the course of this study will be strictly conidential. 
Your name and personal details will be removed so 
that you cannot be recognised.
What will happen to the 
results of this study?
This study will lead to a better understanding 
of how acceptable the use of larval therapy is to 
nurses involved in caring with people who have leg 
ulcers.
Administrative information
This study has been commissioned by the 
Department of Health Research and Development 
Health Technology Assessment Programme. The 
funding has enabled a researcher to be employed 
to interview nurses who is not employed by the 
hospital or community.
This study has been reviewed and approved by a 
multicentre research ethics committee.
Thank you for considering this study. If you have 
any questions about the study at any time, please 
contact:
Dorothy McCaughan
Department of Health Sciences
University of York, YO10 5DD
Tel: 01904 000000
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3DWLHQWLQWHUYLHZVFKHGXOH
This schedule includes generic questions for all 
participants. The participant will be asked speciic 
questions dependent on their experience of larval therapy.
Introduction to the study
Explain about conidentiality and tape recording
1. Background
a. age
b. ethnic origin
c. household composition
2. How long have you had a leg ulcer?
3. What impact has the leg ulcer had on you?
4. What treatments have you had on your leg 
ulcer?
The following questions will be posed to those 
participants who HAVE NOT had experience of 
maggots.
5. What do you think about ‘natural treatments’ 
for leg ulcers (such as maggots)?
6. How do you feel about maggots being used in 
the treatment of your leg ulcer?
7. Why do you think you feel this way?
8. Have you had any previous experience of 
maggots (e.g. ishing)?
9. Have you talked to any members of your family 
about your leg ulcer/treatment of your leg 
ulcer?
10. How do you think they would view the use of 
maggots in the treatment of leg ulcers?
The following questions will be posed to those 
participants who HAVE had experience of 
maggots.
5. How did you feel when larval therapy was 
suggested for the treatment of your leg ulcer?
6. Have you had any previous experience of 
maggots (e.g. ishing)?
7. What is the maggot treatment like (e.g. do you 
have any pain)?
8. How do you think the maggots are helping 
your wound?
9. Have you talked to members of your family 
about the treatment of your ulcer?
10. How do you think they view the use of maggots 
in the treatment of leg ulcers?
Is there anything else you would like to tell me 
about your leg ulcer and its treatment?
Reiterate about conidentiality
Thank you
1XUVHLQWHUYLHZVFKHGXOH
This schedule includes generic questions for all 
participants. The participant will be asked speciic 
questions dependent on their experience of larval therapy.
Introduction to the study
Explain about conidentiality and tape recording
1. Background
a. age
b. ethnic origin
c. employment details – position/grade and 
where based
2. How long have you been involved in caring for 
patients with leg ulcers?
3. What treatments have you used on leg ulcers?
4. Have you been involved in using larval therapy 
before?
The following questions will be posed to those 
participants who have NOT HAD experience of 
maggots.
5. How do you feel about maggots being used in 
the treatment of leg ulcers?
6. Why do you think you feel this way?
7. If a patient were prescribed larval therapy for 
the treatment of their leg ulcer, would this 
concern you?
8. Have you had any previous experience of 
maggots (e.g. ishing)?
9. Have you talked to colleagues about the use of 
maggots in the treatment of leg ulcers? If so, 
what were their views?
$SSHQGL[
4XDOLWDWLYHLQWHUYLHZVSDWLHQWDQG
QXUVHLQWHUYLHZVFKHGXOHV
$SSHQGL[

The following questions will be posed to those 
participants who HAVE had experience of 
maggots.
5. Tell me about your experiences of using larval 
therapy. Were these loose or bagged?
6. Did anything concern you about using 
maggots?
7. Did you encounter any problems in the 
ordering or supply of the maggots?
8. What did the patients say about the use of 
maggots on their wounds?
9. Have you had any previous experience of 
maggots (e.g. ishing)?
10. Have you talked to colleagues about the use of 
maggots in the treatment of leg ulcers? If so, 
what were their views?
Is there anything else you would like to tell me 
about the use of larval therapy?
Reiterate about conidentiality and anonymity
Thank you
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No. 1
Home parenteral nutrition: a systematic 
review.
By Richards DM, Deeks JJ, Sheldon 
TA, Shaffer JL.
No. 2
Diagnosis, management and screening 
of early localised prostate cancer.
A review by Selley S, Donovan J, 
Faulkner A, Coast J, Gillatt D.
No. 3
The diagnosis, management, treatment 
and costs of prostate cancer in England 
and Wales.
A review by Chamberlain J, Melia J, 
Moss S, Brown J.
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Screening for fragile X syndrome.
A review by Murray J, Cuckle H, 
Taylor G, Hewison J.
No. 5
A review of near patient testing in 
primary care.
By Hobbs FDR, Delaney BC, 
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Thorpe GH, et al.
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Systematic review of outpatient services 
for chronic pain control.
By McQuay HJ, Moore RA, Eccleston 
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Neonatal screening for inborn errors of 
metabolism: cost, yield and outcome.
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Preschool vision screening.
A review by Snowdon SK, 
Stewart-Brown SL.
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for the ethics of clinical trials.
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A critical review of the role of neonatal 
hearing screening in the detection of 
congenital hearing impairment.
By Davis A, Bamford J, Wilson I, 
Ramkalawan T, Forshaw M, Wright S.
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Newborn screening for inborn errors of 
metabolism: a systematic review.
By Seymour CA, Thomason MJ, 
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Cockburn F, et al.
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Routine preoperative testing: a 
systematic review of the evidence.
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No. 13
Systematic review of the effectiveness of 
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By Petticrew M, Watt I, Sheldon T.
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When and how to assess fast-changing 
technologies: a comparative study of 
medical applications of four generic 
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A review by Mowatt G, Bower DJ, 
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McKee L.
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Antenatal screening for Down’s 
syndrome.
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Screening for ovarian cancer: a 
systematic review.
By Bell R, Petticrew M, Luengo S, 
Sheldon TA.
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and their use in clinical guideline 
development.
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A cost–utility analysis of interferon beta 
for multiple sclerosis.
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Miller P, Thomas S, Bates D.
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Effectiveness and eficiency of methods 
of dialysis therapy for end-stage renal 
disease: systematic reviews.
By MacLeod A, Grant A, Donaldson 
C, Khan I, Campbell M, Daly C, et al.
No. 6
Effectiveness of hip prostheses in 
primary total hip replacement: a critical 
review of evidence and an economic 
model.
By Faulkner A, Kennedy LG, Baxter 
K, Donovan J, Wilkinson M, Bevan G.
No. 7
Antimicrobial prophylaxis in colorectal 
surgery: a systematic review of 
randomised controlled trials.
By Song F, Glenny AM.
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Bone marrow and peripheral 
blood stem cell transplantation for 
malignancy.
A review by Johnson PWM, 
Simnett SJ, Sweetenham JW, Morgan GJ, 
Stewart LA.
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Screening for speech and language 
delay: a systematic review of the 
literature.
By Law J, Boyle J, Harris F, 
Harkness A, Nye C.
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Resource allocation for chronic 
stable angina: a systematic 
review of effectiveness, costs and 
cost-effectiveness of alternative 
interventions.
By Sculpher MJ, Petticrew M, 
Kelland JL, Elliott RA, Holdright DR, 
Buxton MJ.
No. 11
Detection, adherence and control of 
hypertension for the prevention of 
stroke: a systematic review.
By Ebrahim S.
No. 12
Postoperative analgesia and vomiting, 
with special reference to day-case 
surgery: a systematic review.
By McQuay HJ, Moore RA.
No. 13
Choosing between randomised and 
nonrandomised studies: a systematic 
review.
By Britton A, McKee M, Black N, 
McPherson K, Sanderson C, Bain C.
No. 14
Evaluating patient-based outcome 
measures for use in clinical trials.
A review by Fitzpatrick R, Davey C, 
Buxton MJ, Jones DR.
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No. 15
Ethical issues in the design and conduct 
of randomised controlled trials.
A review by Edwards SJL, Lilford RJ, 
Braunholtz DA, Jackson JC, Hewison J, 
Thornton J.
No. 16
Qualitative research methods in health 
technology assessment: a review of the 
literature.
By Murphy E, Dingwall R, 
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The costs and beneits of paramedic 
skills in pre-hospital trauma care.
By Nicholl J, Hughes S, Dixon S, 
Turner J, Yates D.
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Systematic review of endoscopic 
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By Harris KM, Kelly S, Berry E, 
Hutton J, Roderick P, Cullingworth J, 
et al.
No. 19
Systematic reviews of trials and other 
studies.
By Sutton AJ, Abrams KR, Jones DR, 
Sheldon TA, Song F.
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Primary total hip replacement surgery: 
a systematic review of outcomes 
and modelling of cost-effectiveness 
associated with different prostheses.
A review by Fitzpatrick R, Shortall 
E, Sculpher M, Murray D, Morris R, 
Lodge M, et al.
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Informed decision making: an 
annotated bibliography and systematic 
review.
By Bekker H, Thornton JG, 
Airey CM, Connelly JB, Hewison J, 
Robinson MB, et al.
No. 2
Handling uncertainty when performing 
economic evaluation of healthcare 
interventions.
A review by Briggs AH, Gray AM.
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The role of expectancies in the placebo 
effect and their use in the delivery of 
health care: a systematic review.
By Crow R, Gage H, Hampson S, 
Hart J, Kimber A, Thomas H.
No. 4
A randomised controlled trial of 
different approaches to universal 
antenatal HIV testing: uptake and 
acceptability. Annex: Antenatal HIV 
testing – assessment of a routine 
voluntary approach.
By Simpson WM, Johnstone FD, 
Boyd FM, Goldberg DJ, Hart GJ, 
Gormley SM, et al.
No. 5
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